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Type 2 diabetes is an established risk factor for non-alcoholic fatty liver disease (NAFLD).
Despite this, there are few data investigating NAFLD within large populations of people with
Type 2 diabetes. In the initial chapters of this thesis NAFLD is defined and the pathological
processes linking it to Type 2 diabetes are described. The epidemiological evidence that
underpins current understanding of prevalence, risk factors and progression of the condition
is reviewed in detail. Subsequent chapters describe research undertaken within the
Edinburgh Type 2 Diabetes Study on the epidemiology of NAFLD in this population.
The prevalence of NAFLD was determined within 939 subjects, aged 61 - 76 years, with
well-characterised Type 2 diabetes. NAFLD was defined by the presence of ultrasound-
diagnosed steatosis with detailed exclusion of secondary causes for liver disease.
Ultrasound gradings were validated in a subgroup of 58 participants using 1Fi magnetic
resonance spectroscopy, the non-invasive gold-standard method for hepatic lipid
quantification, and intra- and inter-observer variability in ultrasound grading was calculated.
The final prevalence of NAFLD, 42.6%, was higher than in the general population, but lower
than in the few studies that have been performed in populations with Type 2 diabetes. It is
likely that this was due to comprehensive screening for secondary causes of liver disease
and validation of the ultrasound measure which resulted in re-categorisation as "normal"
subjects initially graded as having mild steatosis. Independent predictors of NAFLD were
diabetes variables or components of the metabolic syndrome.
The utility of conventional "liver function tests" in detecting hepatic steatosis and NAFLD was
examined. Although liver enzyme levels (alanine aminotransferase, aspartate
aminotransferase and gamma-glutamyltransferase) were significantly higher in participants
with hepatic steatosis compared with those with normal liver on ultrasound, values remained
within the normal range in the majority of cases. The negative predictive values of normal
levels were therefore low, calling into question their utility as screening tests for liver disease
in the diabetic population.
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The prevalence of advanced liver disease had not previously been studied in a population
with Type 2 diabetes, and was investigated in our population using surrogate markers of
hepatic fibrosis. Hyaluronic acid (HA) levels were significantly elevated in 5.7% of subjects
and 0.4% had ultrasound-diagnosed cirrhosis. Hepatocellular carcinoma was detected in
0.2% of participants. Liver enzyme markers were poorly predictive of high HA levels. Clinical
risk scores identified a large proportion of subjects as potentially having severe fibrosis, but
these scores have not previously been validated in populations with Type 2 diabetes and
therefore have to be interpreted with caution.
NAFLD has previously been shown to be predictive of cardiovascular disease in the context
of Type 2 diabetes, but mechanisms underlying this have not been fully elucidated. In the
current study the association of hepatic steatosis and NAFLD with non-classical
cardiovascular risk factors - clot formation and lysis dynamics, prothrombotic mediators and
markers of inflammation - was investigated. NAFLD was significantly associated with a
longer clot lysis time and higher levels of complement C3 and plasminogen activator inhibitor
type 1. Following adjustment for these prothrombotic compounds, the association of NAFLD
and clot lysis time was lost, and it is therefore hypothesised that NAFLD may influence clot
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Chapter 1
Diagnosis and pathophysiology of non-alcoholic fatty liver
disease (NAFLD)
1.1 Introduction
Liver disease is a significant health and economic problem both in the United Kingdom
(UK), where it is the fifth most common cause of death, and worldwide(l). Historically, two
aetiologies - alcoholic liver disease and chronic viral hepatitis - have been recognised as
making the largest contribution to this burden. In the last three decades, however, a third
aetiology has been increasingly recognised in the form of the obesity-related non-alcoholic
fatty liver disease (NAFLD)(2).
Since its initial description in 1980 by Ludwig and colleagues(3), NAFLD has been
acknowledged as the most common liver-related medical condition in Westernised countries,
affecting as much as one third of the general population(4;5). Its close relationship with
central obesity, insulin resistance and Type 2 diabetes has fostered the proposal that it is the
hepatic component of the metabolic syndrome(6), and studies have suggested that it is an
independent risk factor for cardiovascular disease(7). Furthermore, NAFLD is a documented
cause of cirrhosis and hepatocellular carcinoma (HCC), and accounts for over 10% of
patients on the waiting list for liver transplantation in the UK(8).
Despite the body of research on the long-term outcome of NAFLD and the persuasive
evidence that the combination of NAFLD and diabetes can be associated with a relatively
poor prognosis there is no consensus on screening for or managing this condition within the
context of Type 2 diabetes. Neither the National Institute for Clinical Excellence guidelines
for the management of Type 2 diabetes, nor guidelines with a similar scope produced by the
Scottish Intercollegiate Guidelines Network, give guidance on liver disease within the
context of Type 2 diabetes. Moreover, there is evidence of variation between clinicians from
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different specialties in their response to markers of liver disease in such patients(9). This is
likely to reflect a number of features of the evidence available, in particular the relative
paucity of data from otherwise unselected populations of patients with Type 2 diabetes, the
absence of an accurate and simple test for use within the diabetes clinic room to diagnose
and stage NAFLD, and the shortage of effective and available treatments. In keeping with
this, the American Association for the Study of Liver Diseases has identified as necessary
further research into NAFLD in the context of Type 2 diabetes(lO).
In this and following chapters the body of literature on the pathogenesis and epidemiology of
NAFLD, with particular respect to its incontrovertible link with Type 2 diabetes, will be
explored and discussed.
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1.2 Definition of NAFLD
NAFLD encompasses a spectrum of disease, from simple steatosis ("fatty" change) to
steatohepatitis (an inflammatory state), fibrosis and cirrhosis. The pathological appearances
on histological examination are identical to those found in alcoholic liver disease, a factor
that may have contributed to delay in the recognition ofNAFLD as a specific disease entity.
The original paper to describe NAFLD actually defined non-alcoholic steatohepatitis
(NASH) in a group of 20 patients who had biopsy findings mimicking alcoholic hepatitis,
but in the absence of an alcohol precipitant(3). Over time, the definition of the condition has
broadened to include people with hepatic steatosis alone without a significant inflammatory
or fibrotic component (also termed non-alcoholic fatty liver (NAFL)). Furthermore, the
previously termed "cryptogenic cirrhosis" has been recognised in many cases to represent
the most severe end of the NAFLD spectrum(l 1; 12). Liver fat accumulation accounting for
over 5-10% of liver weight in the absence of alcohol excess or other causes of liver disease is
characteristic of both simple steatosis and NASH(IO). Practically, this has been interpreted
as over 5% of parenchymal involvement by steatosis on liver biopsy(13). It is however well
recognised that steatosis can regress as fibrosis and cirrhosis develop(14).
It is recognised that a number of conditions, over and above alcohol excess, can be
associated with pathological findings suggestive ofNAFLD. These have been classified into
primary and secondary NAFLD, and for the purposes of this review I will focus on
"primary" NAFLD, i.e. that which is associated with insulin resistance and features of the
metabolic syndrome, as outlined below. "Secondary" causes of NAFLD are varied, and
include particular medications, disorders of lipid metabolism (including
abetalipoproteinaemia), mitochondrialopathies, severe weight loss following bariatric
surgery (particularly jejunoileal bypass), total parenteral nutrition and exposure to industrial
solvents(10;15-17).
Although the initial description of NAFLD was based on clinicopathological findings, the
majority of diagnoses, particularly in population-based studies, are now made by non¬
invasive means(5). A working definition of NAFLD as being the presence of hepatic
steatosis on imaging in the absence of a secondary cause for this has been adopted and used
in a number of studies(l8-20), although limitations of this approach have been
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recognised(16;21). In particular, this classification has designated NAFLD as a disease of
exclusion, rather than a condition that is defined according to its aetiology. Aside from
intellectual considerations, this has practical implications in that NAFLD can technically
only be diagnosed in the absence of other hepatic diseases despite indications that NAFLD
may co-exist with other liver disease and indeed that the presence ofNAFLD may influence
the natural history of other liver pathology(22).
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1.3 Pathophysiology of NAFLD
1.3.1 Lipid metabolism in health
The liver plays a significant role in normal lipid metabolism and an understanding of this is
helpful in elucidating the pathophysiological processes ofNAFLD. The body's fat stores are
in the form of triglyceride, each molecule of which comprises a "spine" of glycerol esterified
to three fatty acids(23). Although most triglyceride is stored within adipose tissue, there can
also be deposition in organs such as the liver and muscle. Hepatic triglyceride originates both
from dietary sources and from synthesis within hepatocytes. Dietary lipid is transported via
peripheral tissues such as muscle and adipose tissue and arrives at the liver within a
chylomicron remnant containing triglyceride and cholesterol ester. Synthesis of triglyceride
within the liver utilises both fatty acids that are made de novo, and non-esterified (free) fatty
acids (NEFA) removed from the circulating pool. Export of triglyceride from hepatocytes
occurs within very low density lipoprotein (VLDL), a complex of protein, lipids and
phospholipids that contains apolipoprotein BlOO (apoBlOO). These pathways are
summarised below in Figure 1.1.
It is clear that the maintenance of a normal liver depends on a complex balance between
hepatic triglyceride synthesis and storage on the one hand, and utilization and export on the
other. This balance can be disturbed by factors both intrinsic and extrinsic to the liver,
resulting in triglyceride accumulation and hepatic steatosis. Such perturbations will be
considered in the next section.
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Figure 1.1
Role of the liver in triglyceride metabolism. The main factors governing triglyceride
content of the liver are shown.
ApoB, apolipoprotein B100; CH, chylomicron remnant containing triglyceride; FFA,
free fatty acids; NEFA, non-esterified fatty acids; TG, triglycerides; VLDL, very low
density lipoprotein
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1.3.2 Pathophysiology of NAFLD
There is no single unifying model to describe the events in the establishment ofNAFLD and
its progression to inflammatory and fibrotic liver disease. Nevertheless, the "two-hit
hypothesis", proposed by Day & James in 1998(24), has been the most influential and
prevailing framework in explaining the pathogenesis. Summarised in Figure 1.2, this model
suggests that hepatic steatosis (the "first hit") is the initial event and a necessary component
in the development of NASH, but is not itself sufficient to promote this advancement. A
"second hit" is then required to stimulate the progression to more advanced liver disease.
This theory is attractive as it goes some way towards explaining why only a subgroup of
people with NAFLD go on to develop NASH, fibrosis and cirrhosis.
Figure 1.2




Although the pathophysiology of NAFLD is incompletely understood, it is accepted that
excess triglyceride accumulation within hepatocytes is a central event. Three pathways, as
demonstrated above in Figure 1.2, have been described as promoting this state: (1) increased
free fatty acid (FFA) influx into the liver; (2) de novo lipogenesis within the liver; and (3)
impaired export of lipid from the liver. A fourth possible mechanism, reduced FFA
oxidation, has not been shown to play a role(25). Differing degrees of insulin resistance in
different tissues appear to play an important role in increasing the burden of hepatic fat.
(1) Increased FFA influx into the liver
Insulin resistance in peripheral tissues has been postulated to be the initial event in the
pathogenesis of hepatic steatosis(26). Physiologically, insulin acts to suppress lipolysis in
adipose tissue and when its actions there are inhibited, as can occur in the context of
excessive fat accumulation, there is dysregulation of lipolysis that increases the supply of
FFA to the liver. One study which used isotope methodology to quantify relative
contributions to hepatic triglyceride accumulation in nine patients with NAFLD who
underwent a medically-indicated liver biopsy, found that over half (59%) of hepatic
triglyceride arose from NEFA from adipose tissue(27). The role of FFA flux from adipose
tissue to liver is further supported by a study of 18 individuals (6 NASH, 6 steatosis alone, 6
controls) in which the percentage suppression in appearance of FFA and glycerol in the
circulation (a measure of lipolysis) in response to insulin infusion was significantly less in
the steatosis and NASH groups compared with controls(28). This finding of a reduction in
insulin-mediated suppression of lipolysis in people with NAFLD has been mirrored
elsewhere(6;29). There is significant, albeit indirect, evidence that visceral adiposity (rather
than peripheral adipose tissue) may have particular significance in the development of
hepatic steatosis. It has been shown that people with NAFLD may have an increased
waistihip ratio (WHR) and waist circumference (WC, measures of abdominal adiposity),
relative to body mass index (BMI)(6;29), and the relative preponderance of visceral fat and
its independent role in predicting liver fat has been confirmed on magnetic resonance
imaging (MRI) studies that have quantified adiposity directly(29-31). It has also been
proposed that visceral adipose tissue is more insulin resistant and prone to lipolysis than
subcutaneous adipose tissue(32). From an anatomical perspective there is a direct link
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between abdominal fat and the liver and any FFA released from central adipose stores are
delivered directly to the liver via portal venous drainage.
(2) de novo lipogenesis within the liver
Hepatic production of fatty acids appears to contribute to a relatively minor proportion of the
triglyceride that is synthesised within and secreted from the liver in health, but its
contribution may increase in NAFLD. Evidence originates from two isotope studies, one of
which is outlined above(27). In this study of patients with NAFLD, 26% of triglyceride on
liver biopsy had been produced by de novo lipogenesis. This was a smaller proportion than
that produced from NEFAs from adipose tissue, but a higher percentage than that produced
from dietary fatty acids. In a second study, hepatic lipogenesis was measured using the stable
isotope deuterated water, which is incorporated into newly synthesised fatty acids but is not
present in fatty acids or triglyceride from other sources(33;34). The calculated contribution
of lipogenesis to hepatic triglyceride secretion was three times higher in the five NAFLD
subjects than in controls (14.9% vs 4.6% respectively); it is expected that there would be a
similar contribution to hepatic triglyceride content. It has been hypothesised that the increase
in lipogenesis is driven by high insulin levels and mediated via the transcription factor sterol
regulatory element binding protein (SREBP-lc)(35); this theory assumes that this hepatic
pathway remains sensitive to the effects of insulin, in the presence of peripheral resistance.
(3) Impaired export of lipid from the liver
The assembly of VLDL, in the process of triglyceride export from the liver, is a complex
process and there several points in the pathway that are susceptible to impairment. One area
of interest is the synthesis of apoBlOO, a rate-limiting step in VLDL formation. Rate of
synthesis has been shown to be significantly lower in one study of patients with NASH (31.5
mg/kg/day) compared to BMI-matched (115.2 mg/kg/day) and lean (82.3 mg/kg/day)
controls, and this appeared to be an effect specifically on apoBlOO rather than a generalised
effect on all protein synthesis(36). It is, however, impossible to be sure in this cross-sectional
study that the results seen are not a consequence rather than a cause ofNASH. Furthermore,
results from another report(37) have suggested that there is a significant difference in
apoBlOO synthesis rates between simple steatosis and NASH and this calls into question the
theory that impaired export of VLDL by this mechanism is the primary event in the
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pathogenesis ofNAFLD (as opposed to a step in its progression to NASH). In an additional
study hepatic steatosis was associated with an increase in apoBlOO secretion within
VLDL(38). Assuming that inhibition of apoBlOO formation does play a role, it seems likely
that hyperinsulinaemia is once again a key step in this pathway(39), but results from studies
examining this have been mixed(40).
Second hit
The steatotic liver is vulnerable to further insults which promote hepatocyte injury,
inflammation and fibrosis. It has been proposed that triglyceride storage (rather than being
hepatotoxic in itself) is a marker of increased exposure to potentially-toxic FFA, and that
simple steatosis progresses to NASH when mechanisms that protect hepatocytes from FFA-
mediated lipotoxicity are exhausted(14). Both oxidative stress and increased cytokine
production have been proposed as mediators in the pathogenesis of NASH and subsequent
fibrosis.
(1) Lipid peroxidation
Lipid peroxidation induced by reactive oxygen species (ROS) has previously been shown to
be capable of causing the pathological features typical of NASH-associated inflammation
and fibrosis - including stimulation of neutrophil chemotaxis, formation of Mallory bodies,
activation of hepatic stellate cells (which are key players in fibrogenesis), and hepatocyte
necrosis and apoptosis(41). One possible mechanism of ROS generation is mitochondrial
dysfunction. A study comparing liver biopsy specimens from patients with NASH, simple
steatosis and controls found abnormal mitochondrial morphology on electron microscopy in
the samples from those with NASH(28); such abnormalities have previously been associated
with an uncoupling of oxidation and phosphorylation, ROS production and subsequent lipid
peroxidation. Mitochondrial abnormalities in the same study were paralleled by a higher
level of mitochondrial fatty acid P-oxidation in these patients. Although the cross-sectional
nature of this study precluded assessment of whether the mitochondrial abnormalities were a
cause or an effect of NASH, it was hypothesised that clinically silent mitochondrial
abnormalities present in a proportion of the normal population can be "unmasked" by the
increase in FFA P-oxidation seen in hepatic steatosis, predisposing to inflammation.
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A further proposed source of ROS in NAFLD is enhanced hepatic expression of cytochrome
P450 2E1 (CYP2E1). This pathway was initially considered to be of possible relevance as
hepatic CYP2E1 expression is increased in the context of alcoholic liver disease, and is
associated with increased production of ROS in this patient group. A study examining
biopsies from patients with NASH revealed a significant increase in CYP2E1 compared to
controls, and a similar pattern of immunostaining to patients with alcoholic liver disease(42);
this appeared to be an increase that was specific to CYP2E1 rather than a generalised
increase in cytochrome P450 enzymes. As the visual pattern of increased CYP2E1 followed
that of fat accumulation within hepatocytes, it can be hypothesised that the increase in
CYP2E1 is driven by the lipid accumulation. Further support for a role of this pathway
comes from a study that examined the activity of CYP2E1, as measured using the
hydroxylation of chloroxazone, in patients with NASH versus age-, gender- and BMI-
matched controls(43). In this study there was an increased activity of the enzyme in the
context of NASH (with an increased rate of clearance of serum chloroxazone and an
increased rate of appearance of urinary 6-hydroxy chloroxazone in this group). Although this
pathway is clearly of interest, both of the above studies were of cross-sectional design and
therefore not sufficient to imply a definite causal role of CYP2E1 in the pathogenesis of
NASH.
(2) Cytokines
The cross-sectional associations between NAFLD and inflammatory mediators are well-
established but causal relationships have been more difficult to define. As roles in cytokine
production have been ascertained for both visceral adipose tissue and the liver, one area of
complexity is determining the source of circulating inflammatory molecules and establishing
the pathological sequence of events. The evidence supporting a causal role for the pro¬
inflammatory cytokines tumour necrosis factor-a (TNFa) and interleukin-6 (IL-6) in the
pathogenesis of NAFLD and its progression to NASH, along with evidence for their
production in both adipose and hepatic tissue, is explored below. Adiponectin, a
hepatoprotective cytokine, has also been shown to be significantly, but inversely, related to
NAFLD and its progression, but will not be considered further here.
Attempts to confirm whether TNFa has a causative role in promoting progression ofNAFLD
have involved both animal and human studies. One approach has been to use mouse models
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of NAFLD (including NAFLD-inducing diets or ob/ob mice) and examine the effect of
TNFa inhibition with anti-TNFa antibodies on liver histology(44;45). In contrast to the
controls, the liver biopsies of mice receiving anti-TNF antibodies showed markedly
improved histology including reduced hepatic steatosis, inflammation and fibrosis. A further
study compared mice genetically deficient in both TNFa receptors (TNFR knockout mice)
with their wild-type counterparts after ingestion of NASH-inducing diet(46). Both TNFR-
knockout and wild-type mice showed a significant increase in hepatic triglyceride levels
after administration of the diet (compared to control mice fed an isocaloric diet), but this
increase was significantly lower, and there was a markedly reduced amount of hepatic
fibrosis, in the TNFR-knockout mice. The supportive evidence for a causative role of TNFa
in NAFLD disease progression from animal studies has been mirrored by studies in humans
that have examined the effect of TNFa inhibition and different TNFa polymorphisms on
liver disease. Two small studies of patients with biopsy-proven NASFI have examined the
effects of a 6-12 month trial of pentoxifylline (a phosphodiesterase inhibitor that inhibits
TNFa production)(47;48). In one case aminotransferase levels fell over the study period, but
repeat biopsies were not performed, there was no control group and it was unclear if the
effect on transaminases was independent of the significant reduction in BMI observed(47).
In the second study, which again had no control group, 55% had a reduction in steatosis or
lobular inflammation and 67% showed reduction in fibrosis on repeat biopsy(48). In genetic
studies, attention has focussed on the relationship of biopsy findings within NAFLD to
single nucleotide polymorphisms in the promotor region of the TNFa gene, whose
polymorphic variant leads to a higher rate of transcription compared to the wild allele.
Results have been variable, with some variant alleles associated with significantly higher
rates of moderate/severe (vs mild) inflammation, NASH and presence of fibrosis than those
with the wild allele(49;50), while in other cases trends failed to reach statistical
significance^ 1). Although perhaps not as conclusive as the results from animal models, the
above human studies also broadly support a causative role for TNFa in promoting NAFLD
disease progression. Evidence for a role of IL-6 is less direct and there are no studies that
have formally assessed the effect of IL-6 on liver histology. There is, however, evidence
from murine studies that chronic exposure to IL-6 induces hepatic insulin resistance(52).
The role of different tissues, specifically adipose tissue and the liver, in producing TNFa and
IL-6 has been explored in other studies. Significantly higher levels of TNFa secretion, and a
trend towards higher levels of IL-6 secretion, from adipose tissue biopsy samples have been
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observed in obese human subjects compared with lean controls(53;54). Following weight
loss in obese subjects, significantly lower levels of TNFa-and 1L-6 mRNA and protein
expression within fat biopsy specimens was observed, compared with levels pre-weight
loss(55;56). The increased production of cytokines from the expanded fat mass in humans
with obesity has been postulated to be a consequence of relative adipose tissue hypoxia,
caused by expansion of adipose tissue. It has been proposed that this is the initial event in a
necroinflammatory process that promotes an increasing number of cytokine-producing
resident macrophages that in turn perpetuate the cycle of inflammation(57).
A higher production of TNFa and IL-6 in liver tissue in patients with NASF1 has also been
described. In patients undergoing bariatric surgery for obesity, the mRNA expression of
TNFa and its receptor was significantly higher in the liver biopsy samples of patients with
NASH compared to those with normal liver histology or simple steatosis(58). When patients
with NASH were further subdivided according to the presence or absence of fibrosis, there
was a grade-dependent increase in TNFa mRNA expression through the fibrosis groups; a
close correlation between mRNA expression in liver and adipose tissue was also observed.
In a study performed on liver tissue from humans with biopsy-proven NASH, simple
steatosis or normal liver, hepatic IL-6 expression, as assessed by immunohistochemistry
using a monoclonal antibody, was significantly higher in NASH patients compared with
simple steatosis patients with a further significant difference between steatosis patients and
controls(59). Furthermore, IL-6 expression was significantly correlated with stage of
fibrosis, and was higher in patients with fibrosis compared to those without. These findings
have been mirrored in animal studies(60). Interestingly, in a study examining the effect of
anti-TNFa antibodies on liver pathology in mice, the hepatocyte expression of TNFa-mRNA
was reduced in those mice receiving the antibody, providing evidence for the circular
relationship of TNFa expression and inflammation(44).
To outline the cellular mechanisms of TNFa and IL-6 production and action in detail is
beyond the scope of this review. A couple of points, however, deserve mention with the
particular aim of relating cytokine pathophysiology to the other pathogenic processes
outlined above. There is evidence that lipid accumulation within hepatocytes, along with
oxidative stress, is a stimulus for hepatic cytokine production via activation of the nuclear
factor kappa-light-chain enhancer of activated B cells (NF-kB) pathway (the inflammatory
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"master-switch") which in turn promotes production of cytokines including TNFa and IL-
6(61). In this way hepatic steatosis per se can predispose to the more inflammatory NASH.
Downstream, molecular pathways of action of cytokines have been shown to enhance insulin
resistance (via Jun N-terminal kinase activity, a TNFa-dependent enzyme that causes insulin
resistance by increasing the serine phosphorylation of insulin receptor substrate (IRS)-l and
-2) and activate Kupffer cells (liver-specific macrophages) that in turn contribute to the
inflammatory milieu(62). Thus, inflammatory cytokines contribute to hepatic insulin
resistance that in turn exacerbates whole body insulin resistance.
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1.4 Diagnostic tools for NAFLD
Although symptoms of NAFLD (in particular right upper quadrant discomfort and fatigue)
are recognised, the majority of patients are asymptomatic until advanced liver disease
develops(15). As a result, most ascertained cases are discovered incidentally or as a result of
biochemical screening investigations. There is legitimate concern regarding the accuracy of
liver enzymes in this role, and it is clear that the majority of cases are unrecognised(63;64).
Definitive diagnosis involves biopsy but in reality this is undertaken in a minority of cases,
with the remainder of diagnoses, particularly in population-based research studies, being
made on imaging. The evidence underpinning the use of these investigative tools is explored
in this chapter.
1.4.1 Biopsy
Histological examination of liver tissue, in combination with careful ascertainment for
secondary causes of hepatic damage, is acknowledged as the gold standard method of
diagnosing and staging NAFLD. An understanding of the functional anatomy of the liver is
important in understanding the terminology used. On a microscopic level, the liver is made
up of multiple small lobules at the mid-point of which is the central vein(65). Radiating out
from the central vein are sinusoids separated from each other by hepatocytes and peripheral
portal tracts. Hepatocytes are divided functionally into zones. Zone 1 refers to the peri-portal
area, which is closest to the hepatic artery (and portal vein) and therefore receives the most
oxygenated blood. Zone 3 is located around the central vein and therefore receives the
poorest oxygenation and is most sensitive to ischaemic injury. Zone 2 is intermediate
between zones 1 and 3.




• Steatosis graded 1 - 3
o Steatosis < 33% parenchymal involvement
o Steatosis 33 - 66% parenchymal involvement
o Steatosis > 66% parenchymal involvement
• Necroinflammatory activity graded 0-3
o 0 - none
o 1 - mild, occasional ballooned (dead) hepatocytes, mild lobular
inflammation, no or mild portal inflammation
o 2 - moderate, obvious hepatocyte ballooning, mild lobular inflammation,
mild to moderate portal inflammation
o 3 - severe, marked hepatocyte ballooning, scattered lobular inflammation,
mild to moderate portal inflammation
• Fibrosis staged 0-4
o 0 - none
o 1 - zone 3 perisinusoidal fibrosis
o 2 - as 1 plus portal fibrosis
o 3 - as 2 with bridging (central to portal or central to central) fibrosis
o 4 - cirrhosis
Matleoni et al. (67)
• NAFLD Type 1 - steatosis alone
• NAFLD Type 2 - steatosis with lobular inflammation only
• NAFLD Type 3 - steatosis with hepatocellular ballooning (NASF1)
• NAFLD Type 4 - steatosis with Mallory hyaline (a protein inclusion found in the
cytoplasm of hepatocytes) or fibrosis (NASH)
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NASH Clinical Research Network Scoring System(l3)
• Steatosis scored 0 - 3 on the basis of percentage of parenchymal involvement (< 5%,
5 - 33%, 33 - 66%, > 66%), location and presence ofmicrovesicular steatosis
• Inflammation and liver cell injury scored on the basis of features including lobular
and portal inflammation and hepatocyte ballooning
• Fibrosis staged 0 - 4 (0, no fibrosis; 1, perisinusoidal or periportal; 2 perisinusoidal
and portal/periportal; 3, bridging fibrosis; 4, cirrhosis)
Examples of biopsy specimens demonstrating simple steatosis and NASH are shown below
(Figure 1.3)
Figure 1.3






Although there have been encouraging results from studies that have attempted to non-
invasively identify more advanced NAFLD, biopsy continues to play an important role in
cross-sectional and longitudinal studies. Self-evident limitations include its invasive nature
and the, albeit small, risk of side-effects including haemorrhage. Furthermore, a
percutaneous biopsy sample is representative of 1/50000 of the total mass of the liver and
there is evidence that sampling error can lead to misclassification, particularly in staging of
NASH and fibrosis(68;69). Studies also suggest that intra- and inter-observer agreement in
grading is imperfect. Inter-observer agreement has been as high as 0.85 and 0.84 respectively
for stage of fibrosis, and 0.83 and 0.79 for steatosis, but much lower for some features of
inflammation, such as lobular and portal inflammation (0.60 and 0.45, and 0.55 and 0.45
respectively), and in one study the agreement on the diagnosis ofNASH was only 0.61(13).
1.4.2 Imaging modalities - magnetic resonance spectroscopy
'H magnetic resonance spectroscopy (MRS), widely recognised as the non-invasive gold
standard for measurement of hepatic fat, has a high correlation with liver fat concentration
on biopsy, of the order of 0.7 - 0.9(70-72). MRS produces a spectrum of the different
resonances of protons that are embedded in different chemical bonds, relying on the fact that
protons within different bonds are exposed to differing patterns of nuclei and electrons that
in turn cause small magnetic field perturbations which affect received frequencies of protons.
Hepatic MRS uses the ratio of the proton peak from fat to the proton peak from water to
determine the fat fraction (FF). Examples of the spectra seen are shown in Figure 1.4.
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Figure 1.4
MRS spectra from (a) a normal liver and (b) a liver with significant steatosis (FF






Different "normal" values for hepatic FF on magnetic resonance imaging have been reported
previously(63;73;74). In an early study, 28 healthy volunteers underwent MR scanning by a
modified Dixon gradient echo technique. All had a MR hepatic FF under 9% and this was
later considered as being the upper limit of normal(73;74). In the same study seven subjects
with cystic fibrosis underwent both MRI scanning and liver biopsy: two subjects with no
steatosis on biopsy had a FF on MRI of < 9%; five subjects with mild to severe steatosis had
a FF of > 9%. Later studies, however, have suggested that a lower cut-off of FF is a more
realistic indication of normality, and the Dallas Heart Study was a significant study in this
regard(63). In this population, normal hepatic FF was defined as the 95th percentile of
hepatic triglyceride content in a group of 345 participants who were selected to be low risk
for hepatic steatosis (normal BMI, glucose tolerance and liver enzymes, and non-excessive
alcohol use). The value corresponding to the 95th percentile (expressed as grams triglyceride
per 100 grams wet liver tissue) was 5.5%, which in turn corresponded to an MRS FF of
6.1%(70). A prospective study of 161 subjects, with a rate of hepatic steatosis > 5% on
biopsy of 44%, found sensitivity, specificity, positive predictive value (PPV) and negative
predictive value (NPV) of MRS (hepatic triglyceride content cut-off of 5.7%) to be 80%,
80%, 71% and 87% respectively(75). These results were mirrored or bettered in other
smaller studies(72;76;77), and in a meta-analysis which found values for sensitivity and
specificity to be 88.5% and 92% respectively(78).
MRS has been used in one large scale study of over 2000 participants but, in general, studies
have been small, presumably limited by expense. Advantages that might promote its use in
future (longitudinal) studies are that it allows accurate quantification of steatosis while
avoiding serial liver biopsies. Weaknesses include "within liver" variability in results(79)
and the fact that it has no role in grading more advanced liver disease such as NASH.
1.4.3 Imaging modalities - ultrasound
Ultrasound imaging is an established imaging modality in the diagnosis of hepatic steatosis,
both clinically and in large-scale studies. Although several grading systems have been
proposed for the assessment of hepatic steatosis using ultrasound, no consensus has been
achieved(l6;80-83). Detection of hepatic fat is based on well-established characteristics
including an echogenic parenchyma (especially in relation to the right kidney), posterior
attenuation (posterior darkness and loss of definition of the diaphragm) of the ultrasound
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beam as it passes through the liver, and areas of focal fatty sparing(l 6;82-85). Examples of
ultrasound images from normal and steatotic livers are shown in Figure 1.5.
Figure 1.5
Ultrasound images of (a) a normal liver and (b) a liver with significant steatosis. In
(a) the liver parenchyma and right kidney are iso-echogenic. In (b) the liver
parenchyma is echogenic compared to right kidney, and there is evidence of



















The diagnostic accuracy of ultrasound in the diagnosis of hepatic steatosis has been the
subject of a number of studies. In a large meta-analysis sensitivity of ultrasound in diagnosis
of any degree of hepatic steatosis was 73.3% and corresponding specificity was 84.4%(78).
However, diagnostic accuracy has varied between studies, with sensitivity reported as 53.3 -
100% and specificity as 77 - 100%(75;76;80;82;84;86). There are several plausible reasons
for the differing results. Firstly, studies varied considerably in the population examined, with
examples ranging from participants suspected of having chronic liver disease to those at low
risk such as prospective liver transplant donors. Thus the control participants who were free
of steatosis comprised people with truly normal livers in some studies(75), and patients with
another form of liver pathology in others(82;84;86). Secondly, ultrasound has been shown to
be less sensitive in the diagnosis of steatosis in patients with significant obesity(87), but BM1
was poorly documented in the studies performed. Thirdly, there was no unifying grading
system between reports for the definition of ultrasound-detected steatosis. Furthermore,
studies have been disparate in terms of the year in which they were performed (with a gap of
twenty years separating the oldest and youngest publications included above) and therefore
presumably in terms of the scanning technology utilised. This has not, however, always
translated into better diagnostic accuracy in recent years, with sensitivity towards the lower












of steatosis on liver biopsy has been inconsistent between studies, and indeed that in some
(often earlier) reports further definition is not given. One recent prospective study of 161
prospective liver donors illustrates the potential effect of differing steatosis definitions within
the biopsy comparator on the utility of ultrasound: when a cut-off of > 5% was used,
sensitivity and specificity of ultrasound were 61.7% and 81.2%; corresponding figures for a
cut-off of 30% were 81.8% and 98.0% respectively. This suggests that ultrasound is more
sensitive in the detection of more severe hepatic steatosis, a finding mirrored in a meta¬
analysis in which the sensitivity of ultrasound rose from 73.3% for detecting even minimal
steatosis to 85.7% for detection of steatosis > 25-33%(78).
Although a degree of subjectivity is recognised when diagnosing hepatic steatosis by
ultrasound examination, few studies have formally examined intra- and inter-observer
variability in making this diagnosis. One study of 25 patients with biopsy-proven NAFLD
(less than a quarter of whom had diabetes) reported that the inter-observer correlation
between two radiologists in determining severity of steatosis was 0.40 (representing fair
agreement), and the intra-observer correlation was 0.63 (suggesting more substantial
agreement)(80). A different study - of 168 patients - who had undergone abdominal
ultrasonography for a variety of abdominal disorders, demonstrated inter-observer agreement
between three radiologists on the presence and severity of hepatic steatosis, of 0.40-0.51 and
intra-observer agreement of 0.58 (moderate agreement)(88). In both studies, the assessment
of the severity of steatosis was based on the presence and severity of increased echogenicity
of the hepatic parenchyma and attenuation of the ultrasound beam.
1.4.4 Liver enzymes
Screening for liver disease clinically usually involves performing (inappropriately named)
"liver function tests" (LFTs), including a combination of alanine aminotransferase (ALT),
aspartate aminotransferase (AST), alkaline phosphatase (AlkP) and gamma
glutamyltransferase (GGT). These enzymes are released from damaged hepatocytes into the
circulation and are therefore used as indicators of liver injury. ALT and, to a lesser extent,
GGT have been used as a surrogate markers ofNAFLD(89;90). Laboratory reference ranges
for liver enzymes rely upon historical data generated from general populations that may have
included people with covert liver disease (particularly undiagnosed NAFLD). Thus, the
upper part of the traditional ALT reference range may reflect values that are more typical of
liver disorder than of normality. As a result, new reference ranges have been derived that are
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based on data from an Italian population at low risk for liver disease (no medication use and
normal BMI, lipid profile and glucose); the upper limit of normal (95th percentile) of ALT in
this group was 30 units/I in men and 19 units/1 in women(91). These more stringent cut-offs
have not, however, been widely adopted.
The diagnostic utility of LFTs in detecting NAFLD-related hepatic steatosis has been
examined in a number of studies. On the one hand, ALT levels have been shown to be
related to the presence and severity of hepatic steatosis in the context ofNAFLD. There is a
documented stepwise increase in ALT through groups with increasing severity of ultrasound-
diagnosed steatosis(92), and the prevalence of elevated ALT has been shown to be higher in
people with hepatic steatosis(63;93). On the other hand, within population-based studies, the
significant majority of people with hepatic steatosis have been shown to have an ALT level
within the normal range(63) and mean levels have also been normal(92). There are few
analyses that have formally examined the diagnostic accuracy of ALT. In one study, using
the laboratory cut-off of 39 units/1 to denote an abnormal ALT level, and comparing with
ultrasound findings of steatosis, the sensitivity and specificity were found to be 8.2% and
98% respectively(93). The use of a lower ALT cut-off of 19.5 units/1, derived from a
receiver operating characteristic (ROC) curve, gave sensitivity of 72% and specificity of
60%. In another study, in which the estimated prevalence of hepatic steatosis was estimated
to be around 60%, the PPV of a high ALT level in predicting the presence of steatosis on
ultrasonography was calculated to be 78%(94).
Several studies have examined the ability of LFTs, particularly ALT, to detect more
advanced liver disease. ALT has been shown to be independently predictive of NASH(95)
and, in a number of studies, levels have been found to be significantly higher in patients with
hepatic fibrosis compared to those with less severe liver disease(96-98). However, such rises
appear to be of statistical rather than clinical significance with mean values often remaining
within the normal range. Certainly, the full spectrum of NAFLD has been described in
people with normal ALT levels. Two studies have compared histological findings in patients
with biopsy-proven NAFLD, subdivided on the basis of normal versus high ALT levels, and
found no difference in the prevalence of severe fibrosis between the groups(64;96). In one of
these, 6 of 51 participants with a normal ALT level had evidence of cirrhosis(64).
Furthermore, in a longitudinal study comparing serial liver biopsies, mean ALT improved
over time and this was associated with improvement in inflammatory grade but was
independent of fibrosis progression(99).
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It is noteworthy that the patients with normal ALT levels in the above studies had been
referred for biopsy on the basis of clinical or radiological evidence of liver disease, and
therefore represent a biased sample that may not be typical of the large proportion of
NAFLD that is subclinical. This limitation is only partly addressed by a further study of
routine liver biopsies from obese women undergoing bariatric surgery, over 70% of whom
had a normal ALT(97). Using their laboratory cut-off of 30 units/I to denote a normal ALT,
57.9% of patients with NASH, and 31.9% of those with significant (bridging fibrosis or
cirrhosis) fibrosis had a normal level. Using the same cut-off, sensitivity of ALT for
diagnosis of NASH or portal fibrosis (vs. simple steatosis alone) was 32%, specificity 81%,
PPV 75% and NPV 40%: corresponding figures for a cut-off of 19 units/1, as has been
proposed as a more realistic upper limit of normal(91), were 65%, 40%, 66% and 40%, and
this lower cut-off did not therefore appear to add diagnostic value. Again, this was a highly
selected population, with a low prevalence of normal liver biopsies, and results may not be
generalizable to the general population of patients with NAFLD.
In summary, it has been repeatedly demonstrated that the full spectrum of histological
abnormalities is possible in people with normal ALT levels. Although there is an association
between ALT levels and severity of steatosis and inflammation, this is not adequate to be
able to predict individual biopsy results, and in particular stage of fibrosis appears to be
relatively independent of ALT levels.
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1.5 Detection of hepatic fibrosis and cirrhosis - non-invasive
markers
The poor performance of liver enzymes in detecting advanced liver disease has been
described in Chapter 1.4. Although these remain the first line screening tool for hepatic
pathology, other methods for identifying these patients have been explored.
1.5.1 Hyaluronic acid - a biochemical marker of fibrosis
Extensive research has gone into the pursuit of specialised biochemical markers that reliably
distinguish patients with NAFLD-related fibrosis from those with less severe forms of the
condition. Hyaluronic acid (HA) is a component of the extracellular matrix, whose
production is increased, and degradation by hepatic sinusoidal endothelial cells decreased, in
hepatic fibrosis. Several reports have confirmed significantly higher levels of HA in patients
with severe fibrosis due to a variety of causes of liver disease) 100-102).
Studies have examined the use of HA as an isolated measurement in predicting severe
fibrosis in NAFLD, and cut-off values of 42-50 ng/ml have been shown to give optimal
sensitivity and specificity in this regard) 102-105). One study of 79 patients with
histologically-confirmed NAFLD, 25% of whom had severe (stage 3 - 4 on Brunt's staging
system) fibrosis, a cut-off of HA of 46.1 ng/ml was associated with a sensitivity of 85% and
specificity of 80% in diagnosis of severe fibrosis) 102). PPV and NPV were calculated, on
the basis of a 20% fibrosis rate, to be 51% and 95.5% respectively. Similar, if variable,
results were obtained from the other studies with quoted sensitivity 65 - 100%, specificity 80
- 90%, PPV 51 - 92% and NPV 61 - 96%. The variation in results may be at least in part
due to the prevalence of fibrosis within the cohorts studied, with the highest PPV and lowest
NPV originating from the study with the highest prevalence of severe fibrosis) 105). Of note,
one further study has found excellent sensitivity, specificity, PPV and NPV each of over
90% using a much higher cut-off of HA (149 ng/ml) to detect any level of fibrosis) 106). The
reason for the discrepancy between this and the other studies is unclear, but may relate to
differences in population composition or assay methodology, the latter possibly being more
likely.
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Higher levels of HA may be associated with increasing severity of liver disease and
increased specificity in diagnosing fibrosis and cirrhosis. One study, performed in a Scottish
population of patients with a variety of underlying diagnoses suggested that a level > 100
ng/ml had a 78% specificity and 83% sensitivity for predicting cirrhosis, with specificity
being raised to 96% if a cut-off of 300 ng/ml was used( 107).
1.5.2 Alternative biochemical markers of fibrosis and NASH
In addition to the studies outlined above, the use of HA has been well documented within the
European Liver Fibrosis (ELF) panel that combines three markers of matrix turnover
(including tissue inhibitor of matrix metalloproteinase l (T1MP 1) and aminoterminal
peptide of pro-collagen 111 (P3NP)). Together these markers have a high accuracy for severe
liver fibrosis in the populations studied including patients with NAFLD(108;109). In a
multicentre cross-sectional study of 1021 participants, 61 of whom had "fatty liver" and 19
cryptogenic cirrhosis (with the majority of the remaining diagnoses comprising chronic
hepatitis C), the area under the ROC curve (AUC) for an algorithm containing these
measures along with age was 0.862 for the test group and 0.804 for the validation
group(109). For the subgroup with NAFLD the AUC was 0.870, and using the optimal cut¬
off, stage 3 and 4 fibrosis could be distinguished from more minimal fibrosis with sensitivity
96% and specificity 89%. It is unclear from this study what the added value of TIMP 1 and
P3NP was, over and above HA. In a follow-on study undertaken in a population of people
with NAFLD, ofwhom 23% had stage 3-4 fibrosis, the use of the ELF panel (without an age
parameter) was associated with a sensitivity of 80%, specificity 90%, PPV 71% and NPV
94% in the detection of this level of fibrosis( 108). It is worthwhile emphasising that these
PPV and NPV are based on prevalence of fibrosis in the population studied and will be
inaccurate in a population in which rates of fibrosis differ significantly. This is particularly
relevant as the scores were developed in patients in whom liver enzymes were elevated and
there was clinical justification for liver biopsy; in the general population PPV will be
significantly lower and NPV significantly higher than in a tertiary referral centre.
Other panels of biochemical markers (including extracellular matrix molecules and enzymes)
that were originally developed to stage hepatitis C have been studied in NAFLD(110). AUC
for each of the following batteries of biomarkers was between 0.7 and 0.8: the Fibrotest
panel contains age, sex, bilirubin, GGT, a2-macroglobulin (a2M, a protease inhibitor),
39
Iiaptoglobulin and apolipoprotein A1 (AUC 0.78); the Hepascore contains age, sex, bilirubin,
GGT, a2M and HA (AUC 0.75); the Fibrospectll panel contains a2M, HA and TIMP1
(AUC 0.70; and, finally, Fib-4 contains age, AST, ALT and platelets (AUC 0.80).
Additional to biomarkers of fibrosis, an accurate non-invasive diagnostic test for NASH
would clearly be valuable in the earlier identification of people that are at increased risk of
disease progression to fibrosis and cirrhosis. Cytokeratin-18 fragments (a product of
hepatocyte apoptosis) hold promise in this regard. Their level has been shown to be
significantly higher in patients with definite NASH compared to simple steatosis alone or
healthy controls, with an AUC of 0.93(111). The exclusion of patients with "borderline
NASH" from analysis represents a limitation of this study, and indeed the AUC was lower
(although still indicative of good diagnostic ability) in a subsequent validation study(l 12).
1.5.3 Imaging studies in the diagnosis of hepatic fibrosis and cirrhosis
Novel techniques in the detection of hepatic fibrosis
Transient elastography, a method of measuring tissue elasticity based on ultrasound
technology, has been used in the non-invasive detection of hepatic fibrosis. Initially
developed in the field of hepatitis C, it has been shown to have good accuracy in detecting
severe fibrosis (stage 3-4) in that patient group, with an AUC of 0.90(113). Its utility is
reduced in obese patients and one study showed a BMI of over 28 kg/nr to be the only
independent risk factor for failure of the procedure, with an odds ratio for procedural failure
of 10(114). A recent meta-analysis has suggested that an unreliable reading or failure rate
might be expected in up to 25% of the obese population, even using technology such as the
extra-large probe(115). Nonetheless, AUC for diagnosis of stage 3-4 fibrosis in the
NAFLD population was high at between 0.9 and 1.0 in each of five studies examined.
In the last six years magnetic resonance elastography, a further technique by which liver
stiffness can be measured, has shown promise in the detection of hepatic fibrosis. An AUC
as high as 0.997 in the detection of severe fibrosis has been quoted and there are indications
that it may also have a role in the detection ofNASH(1 16; 1 17). Its use at present, however,
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is confined to research and it seems likely that cost will remain a barrier to its widespread
adoption for the foreseeable future.
Ultrasound imaging in detection of cirrhosis
The diagnostic accuracy of ultrasound, as compared with histological findings, in detecting
cirrhosis has been investigated in a number of previous studies. Results have been variable,
with sensitivity ranging from 55% to 100% and specificity 88 to 100%(82;84; 118).
Diagnostic accuracy has been estimated to be 84% in one study, with PPV 79% and NPV
86%(119). The variation is likely to reflect improvements in scanning technology over time,
with the poorer results being from earlier studies) 118; 120). When considering the
discrepancies in specificity, it is important to consider the possibility of sampling error with
liver biopsy - i.e. these may not be false positives, but rather true positives that have been
missed by biopsy.
1.5.4 Indirect measures of portal hypertension
Both splenomegaly and thrombocytopenia are established consequences of cirrhosis.
Splenomegaly arises as a result of portal hypertension. The aetiology of thrombocytopenia is
multifactorial with contributors including pooling of platelets within an enlarged spleen and
decreased activity of the haematopoietic growth factor thrombopoetin(121). Using a cut-off
of 150 x l O'/mm, platelet count has been shown to have a sensitivity of 53 - 68%, specificity
76 - 78%, PPV 52 - 54% and NPV 77 - 87% in detecting cirrhosis in a population of
patients with chronic viral hepatitis)122). Ability to generalise these results to other forms of
chronic liver disease is limited by the ability of viral hepatitis to cause thrombocytopenia by
different mechanisms including direct effects on the bone marrow. The platelet count/spleen
diameter ratio (PSR) is a parameter that has been established to link thrombocytopenia to
spleen size, thus taking into consideration the decrease in platelet count that depends on
hypersplenism rather than other factors associated with chronic liver disease) 123). Its use has
been developed in people with cirrhosis of varying aetiologies as a surrogate marker of
portal hypertension and a means of predicting presence of oesophageal varices. Taking into
account the original population of patients with documented cirrhosis and a subsequent
validation study, the optimal cut-off gave sensitivity 91.5 - 100%, specificity 67 - 93%, PPV
77 - 96% and NPV 87 - 100% in the detection of varices and diagnostic accuracy was
41
superior to either variable alone(123;124). When patients with compensated cirrhosis were




2.1 Prevalence of NAFLD
2.1.1 Prevalence of NAFLD
The prevalence of NAFLD has been determined in a number of studies which have been
diverse in terms of populations examined and mechanism of diagnosis. These are
summarised in Table 2.1.
43
Table 2.1
Summary of studies that have examined the prevalence of NAFLD in non-diabetic populations, I









Spain Obese patients undergoing bariatric
surgery (46)
13% Biopsy











USA General population, weighted to











Israel People over the age of 80 years










Italy General population, with participants
with an elevated ALT or GGT (311)
paired with participants with normal
ALT and GGT (287; total 598)
ND USS
Fan et al, 2005(130) China General population (3175) 16.1% USS
Hamaguchi et al,
2005(19)


















Jimba et al, 2005(134) Japan People screened as part of a health
check program (1950)
5.7% USS
Wolf et al, 2005(135) Germany Morbidly obese patients undergoing
bariatric surgery (179)
15.6% Biopsy
Chen et al, 2006(136) Taiwan General population (3245) ND USS
Halon et al, 2006(137) Poland Cadaveric liver donors (70) 70 Biopsy




Israel General population sampled from




India General population (1168) 4% USS
Yamamoto et al,
2007(140)
Japan Living liver donors (263) ND Biopsy
Williams et al,
2011(95)





ALT, alanine aminotransferase; GGT, gamma-glutamyltransferase; LFT, liver function test; Ml
NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; ND, n(
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Ill the above studies, the estimated prevalence of NAFLD in the general population ranged
between 3.1% and 46.2%. The lowest estimates originated from two large population studies
which used LFTs as surrogate markers of hepatic steatosis(89;133), and found 3.1% and
5.5% respectively to have evidence of biochemical abnormalities without a secondary cause.
As has been discussed above, LFTs are poorly sensitive markers of liver injury and these
figures are almost certainly underestimates of the true prevalence ofNAFLD.
The majority of studies used imaging to detect hepatic steatosis and clinical and biochemical
assessment to exclude secondary causes for this. Reported prevalence of NAFLD in these
studies ranged between 11.5% and 46.2%. The lowest prevalence in this group was in a large
population-based study in Taiwan, with exclusion of alcohol excess, hepatotoxic medication
and chronic viral hepatitis from the diagnosis of NAFLD after ultrasound scanning (USS)
had been performed(136). Asian countries displayed prevalences of NAFLD of under 20%,
generally lower than in "Western" countries. Highest prevalences were seen in a small
population of hospitalised octogenarian patients in Israel( 128) and in a moderately large
general population in the USA(95). In both of these studies people were excluded prior to
study commencement if a secondary cause of liver disease was detected.
One further large population study merits further discussion. Browning et al examined the
prevalence of hepatic steatosis in a large American population of over 2000 people taking
part in the Dallas Fleart Study(63). MRS, the non-invasive gold standard method of
quantifying hepatic fat, was used and detailed analysis was performed to determine the
normal range for hepatic fat as outlined above. The prevalence of hepatic steatosis reported,
31%, is therefore possibly the most accurate that has been reported at a population level.
However, the study population was biased to include 50% black and 50% nonblack subjects
and is therefore not fully representative of the Dallas population as a whole (after statistical
correction for this, the prevalence of hepatic steatosis in Dallas was calculated to be 34%). In
addition, due to the weight limit of the scanner, the most obese participants (n = 58) were
excluded and it is therefore likely that the rate of steatosis noted is an underestimate. Formal
exclusion of secondary causes for hepatic steatosis was not performed, but it was commented
that the prevalence of hepatic steatosis was not different in participants who abstained from
alcohol (32%) compared to those with modest alcohol intake (< 30 g/day men, < 20 g/day
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women; 30%). Alcohol intake above modest levels was seen in a tiny proportion of the
overall study population (< 1%).
Histological studies within the general population have included one autopsy study, one
study of dead potential liver donors and two studies of living potential liver donors. The
autopsy study(125) comprised people who had died in a car accident, and the prevalence of
hepatic steatosis (23.9%) may therefore be fairly representative of the general population at
that time. Secondary causes were not excluded, but of note, there was no correlation between
the presence of steatosis with any of information on drinking habits, blood alcohol
concentration at the time of the accident or circumstances of the accident, and the prevalence
of "chronic alcoholism" in this sample was in the order of 2%. It should be noted that this is
now an historic study and lifestyle changes since that time may have rendered this figure less
applicable to today's population. In the reports of potential liver donors, studies were often
small (137; 138). Furthermore, there was no systematic attempt to describe exclusions for
secondary causes for liver disease, but one wonders if this process was inherent in the
selection of potential donors (particularly liver donors) for biopsy.
There are a number of general points to be made about the limitations inherent in many of
the studies examined. Incomplete exclusion of secondary causes of hepatic steatosis was
common, and often only high alcohol intake or high alcohol intake plus chronic viral
hepatitis were sought. Studies varied in the timing of such exclusions (with some studies
excluding these patients altogether(19;93;131;139), and others excluding them after
screening from the diagnosis ofNAFLD(20;89;127;133)), and this affects the overall quoted
prevalence ofNAFLD. Finally, a relatively small number of countries (Italy, USA and Japan
in particular) have contributed a large proportion of the data available, and it is unclear how
widely the results attained can be generalised to other countries. This is particularly
important as rates of excess alcohol intake and chronic viral hepatitis vary significantly
between countries thus affecting exclusions from, and quoted prevalence of, NAFLD. It is
also clear that the prevalence will depend considerably on rates of obesity which differ
between and within countries.
49
2.1.2 Prevalence of NAFLD in the obese population
A number of studies have examined the prevalence of NAFLD in morbidly obese
populations, often by means of liver biopsy at the time of bariatric surgery. Results have
been variable but prevalence of NAFLD has been reported to be over 90% in high risk
populations in USA, France and Spain(l26;l27;131). The largest study in this field( 129), of
over 2600 patients, in contrast, reported a much lower rate of hepatic steatosis (26%;
secondary causes were not excluded), but had used a higher cut-off of hepatic fat content to
define severe hepatic steatosis (> 70% hepatocytes affected). Results are therefore not
directly comparable with other studies with a similar scope, and should be regarded as
prevalence of very severe steatosis. One further drawback of this study was its retrospective
nature, and specifically that the pathology slides were not assessed by a blinded member of
the research team according to established histological scoring systems, and rather relied on
historical pathology reports.
Common procedure prior to bariatric surgery is the commencement of a hypocaloric diet, but
this was not commented upon in the papers quoted above. If participants were on a pre-
surgery diet then it is possible that this influenced the results observed: weight loss has been
associated with a reduction in hepatic steatosis(141) and may account in part for why the
prevalence of hepatic steatosis in this very high risk group was not 100%; conversely, rapid
severe weight loss itself has been shown to be a risk factor for NAFLD(10).
2.1.3 Incidence of NAFLD
Whilst prevalence ofNAFLD has been extensively studied, its incidence has been less well
characterised. One study, performed in a Japanese government office population from which
people with an alcohol intake > 140 g/week, hepatitis B or C or prevalent liver disease were
excluded, found a cumulative incidence of ALT or AST abnormalities of 14.7% over 60
months in the 20 - 39 year age group and 8.1% in the 40 - 69 year age group(142). The
inherent limitations of the use of hypertransaminasaemia as a marker of NAFLD pertain to
this study. A more robust study examined 4401 Japanese participants (mean age 48 years,
mean BMI 22.6 kg/m2) who were enrolled in a medical check-up program, and in whom
liver disease at baseline and secondary causes of liver disease had been excluded(l 9). The
determined incidence of ultrasound-diagnosed NAFLD over a mean time period of 414 days
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was 10% in this population. It is, however, unclear how generalizable the results would be to
a non-Japanese population, and there is a possible selection bias inherent in using potentially
health-conscious people who have signed up for a health check.
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2.2 Clinical and biochemical correlates of NAFLD
2.2.1 Insulin resistance and features of the metabolic syndrome
The now-irrefutable association between NAFLD and hepatic insulin resistance has been the
subject of many studies. Studies that have examined this directly and in depth have used
labelled glucose and a hyperinsulinaemic euglycaemic clamp to examine insulin-mediated
suppression of glucose production (from the liver), thus separating the effects of hepatic
insulin resistance from insulin resistance elsewhere. In one such report, comparing 12 non-
obese, non-diabetic patients with NAFLD with 6 control subjects, the rate of glucose
production for any given concentration of insulin was higher in subjects with NAFLD,
although this did not reach statistical significance(29). In another similar study, insulin-
mediated suppression of hepatic glucose production was significantly reduced in the NAFLD
group vs controls(6). These reports have substantiated conjecture that there is a causal link
between NAFLD and insulin resistance as postulated by previous studies that have shown a
higher level of insulin resistance in NAFLD compared to controls, independent of
BMI( 143; 144). At a cellular level, it has been shown that triglyceride accumulation within
hepatocytes interferes with tyrosine phosphorylation of IRS-1 and -2 to cause insulin
resistance(145). Insulin resistance at the level of the liver exacerbates whole-body insulin
resistance and thus contributes to the pathogenesis of Type 2 diabetes(26); factors associated
with the progression of NAFLD, particularly inflammatory cytokines as outlined in Chapter
1.3, may also promote this sequence of events.
Several studies have examined the relationship of NAFLD with clinical features that have
tended to cluster with insulin resistance, together known as the metabolic syndrome. Such is
the strength of the associations that NAFLD has been proposed as the hepatic component of
this syndrome(6). There are several definitions of the metabolic syndrome, but all include the
components of central obesity, hypertension, dyslipidaemia and glucose intolerance(26). As
reported above, the prevalence of NAFLD in subgroups of people with components of the
metabolic syndrome such as obesity is higher than in the general population. Both cross-
sectional and (to a lesser extent) longitudinal studies have examined the relationship of
NAFLD with these individual elements, and with the metabolic syndrome as a whole, in
more detail. These are outlined below, and the relationship ofNAFLD with Type 2 diabetes
is dealt with in depth in later chapters.
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Obesity
Obesity has been consistently associated with the presence of hepatic steatosis and
NAFLD(19;20;63;94;95;146). A number of studies have examined the prevalence of
NAFLD, or surrogate markers of the same, in people grouped according to BM1, as a marker
of generalised obesity. In a large study population in which alcohol excess and chronic viral
hepatitis as secondary causes of steatosis had been excluded, prevalence of a raised ALT
level increased in a stepwise fashion through four groups subdivided according to BMI (< 25
kg/m2, 1.0%; 25 - 30 kg/m2, 3.3%; 30 - 35 kg/m2, 5.5%; > 40 kg/m2, 6.6%)(146). Another
study which examined prevalence of NAFLD as defined using ultrasound and exclusion of
people on the basis of alcohol excess and viral hepatitis found a prevalence of 16.4% in
people with a BMI < 25 kg/m2 compared with a prevalence of 75.8% in those with BMI > 30
kg/m2, a 4.6-fold difference(94). One of the first papers to examine the relationship between
obesity and hepatic steatosis on autopsy specimens from patients without a known secondary
cause for fatty liver showed an increase in prevalence of steatosis and in the proportion of
more significant steatosis (>25% of hepatocytes involved) in a stepwise fashion though
increasing grades of obesity( 147).
Conversely, other studies have compared BMI between people with a normal liver and those
with NAFLD, and have found significantly higher BMI levels and rates of obesity in
participants with presumed NAFLD (20;63;95). In a study of over 2000 members of the
general population of the USA, the prevalence of obesity of 67% in those with hepatic
steatosis, compared with 33% in the subgroup without steatosis(63). Another large study
carried out in Japan showed a similar trend, with a prevalence of high BMI (>25 kg/m2) of
54% in the group with NAFLD versus 15% in the group with a normal !iver(19). Biopsy
studies have consistently demonstrated a positive correlation of hepatic steatosis (quantified
according to percentage of hepatocytes affected) and BMI(129;148).
The link between abdominal/visceral adiposity is particularly strong and has been
investigated in studies that have used both indirect and direct measures of abdominal obesity.
In parallel with BMI, both WC and WHR have been shown to be associated with
NAFLD(20;146). In one multivariate analysis, looking at predictors of a raised ALT level,
the association of BMI with NAFLD was ameliorated by the addition ofWHR to the model,
and WHR was the variable most consistently associated with NAFLD even after addition of
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insulin concentration to the model(146). Similar conclusions were drawn from a second
study in which WC, but not BMI, was an independent predictor of the presence of NAFLD
as diagnosed using ultrasound(93). Other studies have used cross-sectional imaging to
directly measure visceral adiposity. One such study showed that the relationship between
BMI (and indeed WC) and NAFLD, was eliminated after adjustment for visceral adiposity
quantified on computerised tomography (CT) imaging, whereas abdominal subcutaneous fat
values did not modify the association - suggesting that fat deposition around the intra¬
abdominal organs is the more important determinant of NAFLD(149). Of note, this study
used a definition ofNAFLD that required both hepatic steatosis on CT scan and an elevated
ALT level and it is not possible to clarify the relative importance of hepatic steatosis per se,
as opposed to the inflammatory process that may possibly be inferred by high ALT levels, on
this relationship
Triglycerides
Triglyceride concentrations have been associated with NAFLD independently of obesity in
some studies(20;93; 130; 134) but not in others(146). Triglyceride levels and the presence of
abdominal obesity are intrinsically interlinked, as described in Chapter 1.3, and in
multivariate models the effect of one can be at least partly offset by the other. The specific
association between hepatic steatosis and triglyceride levels, rather than between steatosis
and hyperlipidaemia generally, has been demonstrated in a study of patients referred to a
lipid clinic. The prevalence of ultrasound-diagnosed fatty liver was 72.4% in the sub-group
with hypertriglyceridaemia, compared to 32.7% in the sub-group with hypercholesterolaemia
and normal triglyceride levels. Triglyceride was a predictor for hepatic steatosis
independently of obesity (BMI > 28) and the presence of diabetes. Limitations were the
failure to exclude participants with excessive alcohol intake which can be associated with
both hypertriglyceridaemia (although alcohol was not significantly associated with hepatic
steatosis in this study) and the lack of a measure of abdominal adiposity.
Metabolic Syndrome
The prevalence of NAFLD has been shown to be significantly higher in people with the
metabolic syndrome than in those for whom the criteria are not met. In one study, the
prevalence of an elevated ALT level was 6.3% in people with the metabolic syndrome and
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2.0% in those without (p = 0.005)(146). Another study examined the prevalence of features
of the metabolic syndrome in 304 patients with NAFLD, and found that a diagnosis of
metabolic syndrome could be made in 36% of cases (this rose to 67% of patients in the obese
category)(l 50). In a study of the prevalence and incidence of NAFLD in a large Japanese
population, NAFLD at baseline was associated with a higher prevalence of each of the five
components of the metabolic syndrome, and a significantly (5 - 9 x) higher prevalence of the
metabolic syndrome overall when compared to those with a normal liver on ultrasound(19).
Furthermore, in participants without NAFLD at baseline, the presence of the metabolic
syndrome was associated with an adjusted odds ratio of developing NAFLD of 4.00 (2.63 -
6.08) in men and 11.20 (4.85 - 25.87) in women, independent of weight gain.
2.2.2 Demographics
Age
Results from studies that have analysed the association between age and NAFLD have not
been uniform. Some have found an association of younger age with NAFLD both on
univariate analysis and after adjusting for confounders(20;146). Pathophysiologically it is
difficult to explain age as a protective factor, and it is instead more likely that results are
skewed due to morbidity and mortality secondary to NAFLD or other medical conditions
associated with NAFLD or obesity such as cardiovascular disease or cancer. Thus survival
bias may be playing a role in the association. Another possible explanation is that more
severe fibrotic liver disease is being missed in these older individuals, as steatosis regresses
with increasing fibrosis. Other studies within the general population have found no
association or a positive relationship (63;95) of age with NAFLD.
Of interest, the one study that has specifically looked at an older population (octogenarians
undergoing rehabilitation in hospital) found a high prevalence of ultrasound-diagnosed
NAFLD overall (46%, after appropriate exclusions), but did not find any additional effect of
age within the cohort(128). When this group was compared with another group with mean
age 54 years, also diagnosed with NAFLD, the prevalence of obesity (as measured by BMI),
glucose intolerance, hypertriglyceridaemia and metabolic syndrome was significantly less in
the older cohort. The prevalence of a raised WC, however, was not different. One might
conjecture that age is associated with a weakened association between the metabolic
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syndrome and NAFLD, perhaps due to a different, age-related, mechanism for hepatic
steatosis. The conclusions that can be drawn are, however, weakened by the study design,
whereby the older and younger groups with NAFLD were not comparable in terms of
selection (with the older group picked up by population screening, and the younger group
diagnosed in the process of investigation for abnormal LFTs).
Gender
In contrast to early, biased data that suggested that NAFLD was a disease more prevalent in
women, male gender has been shown to be associated with the condition in a number of
more representative studies(63;93;95;146). One possible reason for this is the higher rate of
abdominal/visceral obesity in men (compared with a higher rate of subcutaneous adiposity in
women), and in one of these studies the association was lost after adjustment for WC or
WHR(146). In other studies, however, correction for obesity and insulin resistance
differences between the sexes has not abolished the relationship of male gender with
NAFLD(63;93;95). One study which examined the effect of gender on the presence of
hepatic steatosis as quantified using MRS found an almost two-fold higher prevalence of
hepatic steatosis in white men compared to white women(63). This significantly higher
prevalence remained even when a non-obese (BMI < 30) and relatively more insulin
sensitive (HOMA IR < 4.04) subgroup was examined. Although their obesity measure did
not take into consideration the differential effects of a greater degree of visceral adiposity in
men, the results within the insulin-sensitive subgroup suggest that another factor is involved.
One possible explanation is different rates of alcohol consumption between the genders. In
this study men who reported a moderate intake of alcohol (< 30 g/day) had a higher
prevalence of hepatic steatosis than their non-drinking male counterparts: the converse was
true in women (alcohol < 20 g/day). Although the hepatic metabolism of ethanol is known to
be sexually dimorphic, it is unclear why the prevalence of hepatic steatosis was raised in
men and not women with moderate alcohol intake. In this study obesity was not a
confounder. It has been conjectured that ethanol intake in women may be associated with an
increase in insulin sensitivity whereas in men this is less pronounced and is outweighed by
hepatic triglyceride accumulation.
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An alternative explanation is that sex steroid hormones play a direct role in the pathogenesis
of NAFLD. This hypothesis is supported by a Chinese study which showed a higher
prevalence of NAFLD in men than women under the age of 50 years, but this effect
disappeared above 50 years, possibly suggesting a protective effect of oestrogen in pre-
menapausal women(130). These results have been mirrored in a study within the National
Health and Nutrition Examination Study (NHANES) III carried out within the USA which
not only showed that that the prevalence ofNAFLD (diagnosed on the basis of liver enzyme
elevation) was two-fold higher in post-menopausal women than in pre-menopausal women,
but also that the use of hormone replacement therapy in post-menopausal women was
associated with a significantly lower prevalence of NAFLD(151). Moreover, tamoxifen (an
oestrogen receptor antagonist) has also been implicated in drug-induced hepatic
steatosis(l 52). Aside from a possibly protective role of oestrogen, a deleterious role for
androgens is suggested by the higher prevalence of NAFLD in women with polycystic
ovarian syndrome compared with the general population) 153-155).
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2.3 Relationship of NAFLD with Type 2 diabetes
The pathogeneses of NAFLD and Type 2 diabetes are intrinsically interlinked, and this
relationship has been examined in some detail. The central role of insulin resistance in
promoting the development of hepatic steatosis has been described above. In the present
chapter the epidemiological evidence linking NAFLD and Type 2 diabetes will be explored
in three sections: (1) cross-sectional studies that have assessed the association of NAFLD
with Type 2 diabetes within the general population; (2) longitudinal studies that have
indicated a role for NAFLD in the development of Type 2 diabetes; and (3) studies that have
examined the prevalence of NAFLD in populations of people with Type 2 diabetes.
Evidence suggesting a role for diabetes in promoting increasing severity of NAFLD is
considered in subsequent chapters.
2.3.1 Cross-sectional associations of NAFLD and Type 2 diabetes
Several studies, many of which have been described above, have shown a higher prevalence
of diabetes within groups diagnosed with NAFLD than in those with no evidence of liver
disease. Two large-scale population studies within the USA showed a significant association
between ALT elevation (without causative alcohol excess or viral hepatitis) and the presence
of diabetes(89;l46). In a further American study, ultrasound-diagnosed NAFLD (alcohol
excess and hepatotoxic medications excluded) was associated with a significantly higher
prevalence of history of diabetes compared to a normal liver (26.3% vs 7.9%)(95). Similarly,
in the Dallas Heart Study the presence of hepatic steatosis on MRS was associated with a
significantly higher prevalence of impaired fasting glucose or diabetes (18%, vs 11% in
those with no steatosis; defined as a one-off plasma glucose > 6.1 mmol/l)(63). There was
also a significant positive correlation between hepatic triglyceride content and fasting plasma
glucose. In a study of patients within a metabolic clinic there was a stepwise increase in the
prevalence of diabetes in groups with increasing severity of NAFLD on ultrasound, albeit
that the semi-quantitative grading for steatosis was unvalidated (normal liver, 10.2%; mild
steatosis, 23.1%; moderate steatosis, 32.1%; severe steatosis, 40.6%)(92). This significant
association remained valid after adjusting for obesity and hypertriglyceridaemia. The finding
of a significant association between hyperglycaemia/diabetes and NAFLD has been
replicated in a number of other reports(19;20;93;130). Differences in the exact prevalence of
hyperglycaemia and diabetes within the NAFLD cohorts studied are likely a consequence of
differing study populations (in terms of ethnicity and inclusion criteria), varying exclusion of
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secondary causes for hepatic steatosis and inconsistent criteria for the diagnosis of diabetes
(for example, the use of fasting glucose versus a formal oral glucose tolerance test versus a
clinical history of diabetes).
2.3.2 Epidemiological evidence for a role for NAFLD in the development of
type 2 diabetes
There is a growing body of evidence that NAFLD precedes the onset of type 2 diabetes, and
indeed may have a crucial role in its pathogenesis. The first studies to examine this
relationship used LFTs as surrogate markers of fatty liver, but subsequent studies have used
more reliable ultrasound measures.
An early prospective study of 766 middle-aged Swedish men, followed up over 13 years,
showed significantly higher levels of baseline transaminases in those that developed diabetes
(6.1% of the population) compared with those that did not(156). Those in the top quintile of
glutamic pyruvic transaminase at baseline had a relative risk of developing diabetes of 3.9
when compared to those in the bottom quintile. The association remained significant after
adjustment for BMI, WF1R and blood glucose at baseline. Results from a larger study within
the UK, The British Regional Heart Study, were similar(157). In 3500 middle-aged, non-
diabetic men, followed up for a mean of 5 years, ALT levels at baseline were significantly
higher in the 100 participants who developed diabetes (as determined using the National
Health Service central registers) than in those who did not (19.3 1U/1 vs. 15.3 IU/1). This
association persisted after adjustments for other biometric variables including BMI and WC;
the exclusion of heavy drinkers made little difference to the relationship and when entered
into the multivariate analysis alcohol intake did not disturb the relationship. A further study
on the role of liver dysfunction in the development of type 2 diabetes in the Pima Indian
population yielded comparable results(158). Of 370 participants with normal glucose
tolerence at baseline 63 developed diabetes. The relative risk of progression to diabetes of
those in the ninetieth percentile (ALT 70 iu/l) compared to the tenth percentile (ALT 12 iu/l)
was 2.3 (1.4 — 3.6). The predictive effect of a high ALT persisted after adjustment for
percentage body fat, whole-body insulin resistance on clamp study, insulin response to a 25g
intravenous glucose load and hepatic insulin sensitivity measured by hepatic glucose output
during insulin infusion.
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Other studies that have focused on younger(159) and more generalised popuiations(160)
have produced similar results. Only one study had the advantage of strict formal exclusion of
people with a secondary cause for liver disease from the "NAFLD'' cohort(l 60).
The West of Scotland Coronary Prevention Study (WOSCOPS) took investigation of the
relationship between ALT and development of diabetes a step further by examining not only
the effect of baseline ALT on subsequent incipient diabetes, but also serial metabolic
measurements leading up to diabetes diagnosis. In a cohort of almost 6000 men, from whom
those with a known history of diabetes, fasting blood glucose > 7.0 mmol/1 or ALT > 70
units/1 at baseline were excluded, 139 (2.33%) were diagnosed with diabetes over a mean
time of 4.9 years(I61). Mean ALT at baseline was 18% higher in those who progressed to
diabetes and men in the top quartile (ALT > 29 units/1, and therefore well within the normal
range) had a significantly increased risk of developing diabetes relative to those in the lowest
quartile, even after adjustment for multiple physiological and metabolic variables including
BMI, blood glucose, the presence of the metabolic syndrome and CRP. This study included
alcohol intake in its multivariate analysis, although once again other causes of liver
dysfunction were not excluded. On retrospective review of 6-monthly measurements
(including ALT and fasting glucose) in 86 subjects who had developed diabetes along with
860 controls, conversion to diabetes was associated with a stepwise increase in ALT over the
previous 18 months(162). Change in ALT was the variable that was most predictive of
conversion to diabetes in this cohort. Results from this study were supported by those from a
prospective study of 287 Japanese employees who were free of metabolic features or
secondary causes of liver disease (alcohol excess and chronic viral hepatitis) at baseline, and
were subsequently followed up annually(142). In this population, weight gain preceded
hypertransaminasemia which in turn preceded glucose intolerance.
There are a number of limitations that are common to many of the above studies. Studies
were often carried out in selected populations (e.g. men, Pima Indians) and it is unclear how
generalizable results are to the general population of patients with Type 2 diabetes. Criteria
for the diagnosis of diabetes differed between studies (often relying on fasting glucose
measurements alone(156;161;162)) and exclusion of diabetes at baseline was often
incompletely performed(156;157). Thus it is possible that undiagnosed diabetes at baseline
may have influenced the metabolic variables. There was sometimes poor recording of
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secondary causes of hepatic steatosis such as alcohol intake( 156; 158). Of note, the
WOSCOPS study was set up as a randomised controlled trial of pravastatin therapy in people
with moderately high cholesterol, and the analyses described above were post hoc and
retrospective.
The association of GGT and development of Type 2 diabetes has also been examined and
results have been rather more variable, with some studies suggesting a predictive role of
GGT(90;157) and others not(158). In those studies where a significant association was
detected it was often not possible to say if this was independent of ALT. Clearly, alcohol
intake would be an important confounder and this was not universally estimated(l 58).
While the body of evidence described above implicates NAFLD in the pathophysiology of
Type 2 diabetes, the evidence linking a more robust marker of hepatic steatosis (measured
via imaging or biopsy) directly to progression to diabetes in the population has, until
recently, been limited. Within the last decade there have been four studies that have
examined this, all within Far Eastern countries. A study that compared the outcomes of 358
Chinese people with NAFLD with 788 controls found a significantly higher incidence of
diabetes in the NAFLD group (20.3% vs 5.2%), but did not adjust for confounding
variables(l 63). In a Japanese study of over 3000 male employees, in whom alcohol intake >
20 g/day, hepatotoxic medication use and viral hepatitis had been excluded, the presence of
ultrasound-diagnosed NAFLD at baseline was associated with a significantly higher
incidence of diabetes over a mean follow-up period of around 4 years, with an adjusted (for
age and BMI) hazard ratio of 5.5 (3.6 - 8.5)( 164). Results from a Korean study were similar,
but this study performed more thorough adjustment for metabolic variables including fasting
glucose and triglycerides at baseline which may account for the lower, but still significant,
relative risk of development of diabetes in the cohort with fatty liver (1.51 (1.04 —
2.20)( 165). The only study that did not find a significant independent relationship between
hepatic steatosis and incidence of diabetes observed a univariate association, but this was
abolished by adjustment for age and fasting plasma glucose(166). However, this study did
not exclude people with secondary causes of hepatic steatosis.
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In summary, the early evidence linking abnormalities in liver enzymes to subsequent
development of diabetes has been strengthened by studies that have used a more direct
measure of NAFLD. These epidemiological reports are in keeping with the smaller, more
detailed studies examining the association of NAFLD with insulin resistance at a cellular
level, as outlined in Chapter 2.2. The above evidence raises the question as to why NAFLD
is not a ubiquitous finding amongst patients with Type 2 diabetes. It is clear, however, that
Type 2 diabetes is not a homogeneous condition, and it is likely that the primary site of
insulin resistance varies between patients. Indeed it is implied that a certain initial sensitivity
to insulin at the level of the liver is necessary to allow triglyceride accumulation and this
may differ from person to person.
2.3.3 Prevalence of NAFLD in people with Type 2 diabetes
With a rising incidence of Type 2 Diabetes and its incontrovertible association with NAFLD,
an accurate estimate of the prevalence of NAFLD in this population is important for
determining service provision, as well as contributing to an understanding of the underlying
pathogenesis. Despite this, studies examining the prevalence of NAFLD in otherwise
unselected populations of people with Type 2 diabetes have been infrequent.
As within the general population, initial studies in Type 2 diabetes used indirect means to
examine the prevalence of liver disease. The prevalence of abnormal LFTs has been found to
be moderately high in populations with type 2 diabetes (compared to studies described above
which looked at the general population), with some variation between studies. In a study of
118 consecutive patients with Type 2 diabetes in a Finnish outpatient clinic, 22.9% had an
ALT level above normal) 167). Another study of over 9000 patients with Type 2 Diabetes
the prevalence of raised ALT was 16%( 168). In an even larger study from the USA the
prevalence was 7.8%( 169). The inherent limitations of using LFTs as a marker of liver
disease have been described above, and it is clear that these figures represent an
underestimation of the true prevalence. Furthermore, no attempts were made to exclude
people with other causes for elevated LFTS.
A small number of studies have investigated the prevalence of ultrasound-diagnosed NAFLD
in diabetic clinic populations. In an Indian study of 100 patients with type 2 diabetes, in
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whom those with alcohol intake and viral hepatitis had been excluded, 49% were found to
have steatosis on liver ultrasonography, and this was confirmed histologically on all who
went forward for biopsy(170). A further study performed in India, of 124 consecutive
patients with Type 2 diabetes in whom alcohol or hepatotoxic medication use or hepatitis B
or C positivity were excluded, found a prevalence of NAFLD of 57.2%. The prevalence of
hepatic steatosis on ultrasound examination in a small Saudi diabetic population, in which
alcohol and hepatotoxic medication use was excluded, was similar at 55%( 171). In a
Brazilian cohort of 180 patients with Type 2 diabetes enrolled from a tertiary referral unit in
whom alcohol use > 20 g/day, hepatotoxic medication use and chronic viral hepatitis had
been excluded, 69.4% had NAFLD diagnosed on ultrasound scan(172), and this was
subsequently confirmed histologically in 94%( 173).
The prevalence ofNAFLD has been studied in a much larger population of Italian patients
with type 2 diabetes, encompassing an entire type 2 diabetes clinic outpatient population. Of
2839 participants, 2421 (85.3%) had hepatic steatosis of whom 81.5% met the criteria for
NAFLD (i.e. hepatic steatosis without evidence of excess alcohol consumption, viral
hepatitis or causative medications). The prevalence of NAFLD in this population was
therefore 69.5%(18).
In summary, the calculated prevalence ofNAFLD in people with Type 2 diabetes has varied
according to the diagnostic tools used, but is likely to be in the region of 50-70%. Aside from
the Italian study described, studies have been small and undertaken in non-Caucasian
populations (in which the prevalence of NAFLD may be dissimilar to that of a UK
population), or have been large populations in which an indirect measure of NAFLD has
been used. Those that have used imaging have been undertaken in hospital diabetes clinics,
and it is therefore difficult to be sure that these are truly unselected populations. Validation
of ultrasound detection of hepatic steatosis was done infrequently, and only in those patients
with a positive ultrasound scan. Thus the specificity of ultrasound in these populations has
been shown to be good, but sensitivity has not been demonstrated. Finally, exclusion of
secondary causes for liver disease has often been incomplete.
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2.4 Progression of NAFLD - prevalence of advanced liver
disease and risk factors for development
It is well recognised that NAFLD comprises a spectrum of liver disease, from simple
steatosis to NASH and fibrosis. "Cryptogenic" cirrhosis has been shown to share many of the
same risk factors as NAFLD and is now established as the most severe end of this
spectrum(l 1 ;12). Less well understood is the prevalence of these lesions in the general
population of patients with NAFLD, and the likelihood of progression to more advanced
liver disease. These issues have been partially addressed in cross-sectional and longitudinal
biopsy studies.
2.4.1 Prevalence of advanced liver disease
Cross-sectional studies
Cross-sectional studies have estimated a prevalence of NASH of 22 - 72%, significant
fibrosis of 10 - 33% and cirrhosis of 1 — 11% within cohorts of patients investigated for
NAFLD on biopsy. Studies have been diverse in terms of populations studied but have
broadly fallen into two categories: those that have examined biopsy specimens performed on
clinical grounds; and those in which biopsies have been taken specifically to investigate the
prevalence of NAFLD in high risk populations. Three studies in the former category
examined similar patient groups. A retrospective study of 458 Italian patients diagnosed with
NAFLD (on the basis of biopsy results, daily alcohol intake of < 20 g and negative liver
screen, with the significant majority having abnormal LFTs) found a prevalence ofNASH of
72% and prevalence of "severe" fibrosis (perisunusoidal and portal fibrosis, septal or
bridging fibrosis or cirrhosis) of 33%(96). The prevalence of grade 3 (bridging) or 4
(cirrhosis) fibrosis were 9% and 5% respectively. A prospective study within the UK of
consecutive patients diagnosed with NAFLD after biopsy for abnormal LFTs found that 52%
had features of NASH. Bridging fibrosis and cirrhosis were present only in patients with
NASH, and accounted for 5.4% and 4.3% of the study population respectively(l 74). In a
larger prospective study of French patients undergoing liver biopsy during investigation for
abnormal LFTs in the absence of a secondary cause for this, the prevalence of significant
(stage 2-4, portal and septal fibrosis or cirrhosis) fibrosis was 27.4% and cirrhosis was
3.4%( 175). Thus, even in ostensibly similar patient populations, with relatively similar
prevalences of cirrhosis, there is variation in reported rates of fibrosis. This is likely to be
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partly due to different staging systems used, with associated variability in the definition of
severe or significant fibrosis. Inter-observer variability in histological examination may also
play a role. As all biopsies were carried out according to clinical need, subtle differences
between countries and centres in clinical practice may have influenced the results. Clearly an
important limitation of these studies is the highly selected patient populations used, and the
high prevalences of fibrosis and cirrhosis may be unrepresentative of the general population
of patients with NAFLD, many of whom will lack features that may prompt biopsy. This
latter point is illustrated by studies that have examined the results of histological examination
of liver biopsies taken from people who were at low risk for liver disease. In a study of 100
prospective liver donors, who had passed clinical, imaging and serological evaluation, 6%
met minimal criteria for steatohepatitis and no subject had fibrosis on biopsy(148). In a study
of autopsy results from over 500 victims of road traffic accident, portal fibrosis was found in
2% (and this could not be guaranteed to be due to NAFLD) and cirrhosis in nobody(125).
Three studies have examined prevalence of advanced liver disease in subjects with
significant obesity. In a prospective study, 103 consecutive patients (the majority of whom
had normal ALT levels) underwent liver biopsy during bariatric surgery(l 76). Twenty-five
percent had NASH, 1 1% had significant (bridging fibrosis or cirrhosis) fibrosis and only one
participant had cirrhosis. In a population of 237 obese women undergoing bariatric surgery,
32.6% had NASH, 9.4% had "advanced" (bridging fibrosis or cirrhosis) fibrosis and 1% had
cirrhosis(97). The rate ofNASH and fibrosis in these populations appears less than in studies
based within populations undergoing investigation for clinically or biochemically suspected
liver disease. Interestingly, in a study of overweight patients (BMI > 25) with at least one
LFT above the upper limit of normal, the prevalence of NAFLD-related septal fibrosis was
higher at 30% including cirrhosis in 11%(177).
Prevalence of NASH and fibrosis in a population of patients with Type 2 diabetes
In the current setting the one study that has examined the prevalence of advanced liver
disease in a population of patients with Type 2 diabetes is of particular interest(172). This
study comprised participants under the age of 65 years, in which secondary causes for liver
disease had been excluded (alcohol intake > 20 g/day, hepatotoxic drug use, viral hepatitis).
All participants (n = 180) underwent ultrasound imaging of the liver and LFT evaluation and
those with hepatic steatosis (n = 125) or abnormal aminotransferase levels alone (a further 5
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participants) were invited to undergo liver biopsy. This population was therefore relatively
less selected than those that have required abnormalities in LFTs or clinical evidence of
significant liver disease to qualify for biopsy. Of those undergoing biopsy (92 of the 130
invited), 76 - 78% had NASH, and 34 - 60% had significant fibrosis (stage > 2). Prevalence
of Stage 3 fibrosis was 6 - 11%, and that of stage 4 fibrosis (cirrhosis) was 3%. The range of
values reflects differences in grading/staging between two independent pathologists, and
raises some concern regarding inter-observer variability in the staging of fibrosis. If one
makes the (imperfect) assumption that those with normal imaging and biochemistry had a
normal liver, and that those refusing biopsy were similar to those who underwent biopsy, the
prevalences ofNASH, stage 3-4 fibrosis and cirrhosis in the whole cohort are calculated to
be 55 - 56%, 6.5 - 10% and 2.2% respectively.
Longitudinal studies
There are a small number of studies that have looked at serial biopsy specimens to determine
rate and predictors of progression ofNAFLD. One study examined the results of 103 patients
with NAFLD, with mean time between first and final biopsy of 3.2 years (range 0.7 - 21
years)(99). Repeat biopsies had been performed either as part of routine clinical care (n = 26)
or as part of trials of clofibrate or ursodiol (neither of which were shown to affect outcome)
in the context ofNASH (n = 77). Although the performance of repeat biopsy as part of study
procedure limits the bias inherent in re-biopsying in response to clinical change, the
sampling at baseline was weighted towards those with NASH due to drug trial protocols, and
therefore cannot be considered representative of the general population of patients with
NAFLD - 93.2% had NASH, 34% had stage 3/4 fibrosis, of whom around half (16% of the
entire study population) had cirrhosis. At follow-up, 67% of those biopsied more than two
years apart had evidence of progressive fibrosis, and 24% of those biopsied more than 4
years apart had evidence of progression of two or more fibrosis stages. Nine participants
(8.7% of the study cohort) progressed to cirrhosis, of whom two had no evidence of fibrosis
at baseline. Of the three participants who had bland steatosis on initial biopsy, two developed
NASH and one remained unchanged. Three smaller studies have examined outcome of
patients with biopsy-proven NASH at baseline. In one, 4 of 11 (36%) patients who
underwent a second liver biopsy showed evidence of progression of fibrosis, and one of
these developed cirrhosis(l 78). A second retrospective study revealed similar results, with 5
of 13 (38%) patients with serial hepatic biopsies developing progression of fibrosis over a
range of 1.7 - 6.1 years, two of whom developed cirrhosis(179). A third prospective study of
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22 patients with NASH who agreed to undergo repeat biopsy after a median of 4.3 years as
part of study protocol showed progression of fibrosis by at least one stage in 3 1.8%( 180). No
patient progressed to cirrhosis.
Only two studies had a significant proportion of patients with simple steatosis at baseline
within the study population. One of these examined 129 subjects who had been diagnosed
with biopsy-proven NAFLD during investigation for abnormal LFTs were invited to have
follow-up investigations, including a repeat liver biopsy, after a mean time period of 13.8 ±
1.2 years(98). At baseline, 36% had simple steatosis, 9% had steatosis with nonspecific
inflammation, and 55% had NASF1. In those who had a second biopsy fibrosis had
progressed in 41%, but it was unclear what proportion of the progressors had NASH as
opposed to simple steatosis at baseline. Another study exclusively examined outcomes of 40
patients with NAFLD-related steatosis alone, without inflammatory or fibrotic components
and found no evidence of progression in 11 of 12 patients who underwent a second biopsy,
with the remaining patient having evidence of moderate pericellular fibrosis(l81). In the
remaining 28 patients there was no evidence of liver-related morbidity or mortality but this
conclusion relied on the flawed assumption that normal LFTs and imaging excludes
significant fibrosis.
In summary, there is a variable incidence of progression of fibrosis in people with NAFLD,
depending on the population and time course studied. It has been proposed that simple
steatosis is a benign condition with little chance of progression compared with the more
pathogenic NASH(181). Supporting evidence for this view, however, is limited and further
investigation of serial biopsies over longer periods will be required before this can be fully
established.
2.4.2 Risk factors for progression
Many of the studies outlined above have examined risk factors for NAFLD-related fibrosis
and its progression. As expected, there is considerable overlap with risk factors for NAFLD
itself. In this section 1 shall consider both clinical and histological features that are associated
with hepatic fibrosis. The utility of LFTs in screening for advanced liver disease has been
previously described in Chapter 1.4.
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Diabetes is associated with increased severity of NAFLD
The association of Type 2 diabetes with increased prevalence and severity of steatosis,
necroinflammation and fibrosis has been examined in histological studies. Diabetes has been
independently associated with increased severity of steatosis(l 76) and NASH(96;147). In a
cross-sectional autopsy study, those with Type 2 diabetes had a 2.6-fold increase in the
prevalence of steatohepatitis, and this appeared to be independent of the effect of obesity,
with the combination of diabetes and obesity being associated with particularly high
risk(147). In a number of independent studies each with over 100 participants with NAFLD,
diabetes has been shown to be an independent risk factor for the presence of advanced
fibrosis on biopsy(64;96;147;175;l 76; 182). The odds ratio of diabetes in predicting severe
fibrosis has been variously calculated to be between 1.8 and 4.4(96; 176). In a study of 144
patients with NASH, the prevalence of diabetes rose from 14% in the sub-group with no
fibrosis to 54% in the sub-group with stage 3-4 fibrosis(l 82). Showing a comparable trend, a
study of 132 patients with biopsy-proven NAFLD estimated a prevalence of cirrhosis of 25%
in those with diabetes, compared to 10% of the non-diabetic cohort(67). A similar
relationship was seen in a longitudinal study of 103 patients who had undergone serial liver
biopsies in which the presence of diabetes at baseline was associated with a greater rate of
progression of fibrosis independently of baseline histology and obesity(99). This last study
establishes a temporal relationship that is not possible in the cross-sectional studies.
A small number of studies have failed to demonstrate a link between the presence of diabetes
and more severe liver disease(67;126;178-180), but these studies were often small and in
some cases there was a trend that failed to reach statistical significance(67;126;l 80). No
study, to my knowledge, has shown a correlation between the presence of diabetes and less
severe liver disease.
Three studies have looked at severity of diabetes (as measured by glycaemic control or
duration of diabetes) and severity of liver disease. In those that have examined glycaemic
control using HbAlc there has been no difference between histological groups) 167; 173). In
contrast, one study has suggested a link between duration of diabetes and severity of
NAFLD. In this study of 32 patients with Type 2 diabetes and biopsy-proven NAFLD, the
median duration of diabetes rose in a stepwise fashion from 9 months in a group with
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steatosis alone to 60 months in a group with severe NASH, a statistically significant
rise( 170). This result has not been replicated( 173).
One explanation for the association of diabetes with more advanced liver disease is that
diabetes is merely a surrogate marker for longer duration of NAFLD. There are, however,
studies that have suggested a direct effect of hyperglycaemia or hyperinsulinaemia on the
fibrotic process. In vitro studies of rat hepatic stellate cells, the key players in the production
of extracellular matrix proteins and fibrogenesis within the liver, have shown an up-
regulation of connective tissue growth factor (CTGF) mRNA and protein production
following incubation with high-concentration glucose- or insulin-containing solutions(l83).
As CTGF has been shown to stimulate fibrogenesis, the implication is that
hyperglycaemia/hyperinsulinaemia may promote hepatic fibrosis via this pathway. The
evidence for hyperglycaemia (but not hyperinsulinaemia) influencing progression of fibrosis
was strengthened by results from a mouse model of NASH in which induction of diabetes
using streptomycin was associated with an increase in expression of markers of fibrosis, and
this was prevented by insulin treatment^ 84). In human subjects, indirect support for a role
of hyperglycaemia in fibrosis progression comes from a study that demonstrated an
association between an improvement in HbAlc and improvement in hepatic fibrosis in
diabetic subjects undergoing serial assessment 185). The study was, however, small and
non-randomised and the associative relationship between these variables may not necessarily
imply causation.
Other clinical risk factors for progression
Obesity is commonly associated with more advanced liver disease(96;147;150;180) and in
many studies is an independent predictor of progression, over and above the presence of
diabetes(99;175;177;186). In one study, weight gain of > 5 kg was associated with higher
rate of progression of fibrosis(98). Other variables that have been independently associated
with hepatic fibrosis in some studies have been age( 173; 177; 186), male gender(176),
hypertension(176) and triglyceride levels(177).
The role of cytokines in the "second hit" of NAFLD has been described in Chapter 1.3.
Epidemiological^, there is cross-sectional evidence linking higher levels of cytokines with
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progression of NAFLD. TNFa levels have been shown to be higher in patients with NASH
compared to those with simple steatosis, and NAFLD compared to non-steatotic controls
(187-192). In some studies this relationship was independent of confounders, but in others
adjustment for markers of insulin resistance and adiposity abolished the relationship( 188). A
statistically significant relationship of TNFa to hepatic fibrosis has also been observed) 188).
Studies that have not shown a statistically significant relationship between TNFa and
NAFLD severity have often been small or there has been a trend towards an
association) 193; 194). In one study of obese patients in which TNFa levels were similar
across groups of increasing liver disease severity, it is possible that medication use blurred
distinction between the groups(195). Results for IL-6 have generally paralleled those for
TNFa) 188; 190), with a stepwise increase in 11-6 concentration through groups with normal
liver, simple steatosis and NASH(59). In other studies the association of plasma IL-6 with
stage of liver disease has been weaker) 188; 191).
Histological risk factors for hepatic fibrosis
In a number of cross-sectional studies the presence of significant fibrosis has been positively
associated with the severity of steatosis and necroinflammatory change, but this has not been
a universal finding. Results from a study of obese individuals demonstrated age, degree of
steatosis and grade of inflammation to be the only factors independently associated with
stage of fibrosis) 126); similarly, in another obese population, necroinflammatory activity
was strongly associated with the presence of septal fibrosis) 177). This has not, however,
been a universal finding) 180). In longitudinal studies the relationship between baseline
histology and progression of fibrosis has been similarly inconsistent. In one study, with a
moderate prevalence of simple steatosis (rather than more advanced liver disease) at
baseline, those who progressed had significantly more pronounced steatosis at baseline,
whereas necroinflammatory changes were unrelated to progression(98). In contrast, a study
which looked at clinical outcome as related to baseline biopsy findings found that the
presence of features of inflammation, necrosis or fibrosis was related to a significantly
higher incidence of cirrhosis over a mean period of 8.2 years when compared to steatosis
alone (22% vs 4%)(67). A further study showed only fibrosis stage at baseline to be
independently (and inversely) associated with fibrosis progression, whereas baseline severity
or subsequent worsening of steatosis or NASH were not predictive(99). Although the inverse
relationship between fibrosis at baseline and subsequent worsening of liver disease severity
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appears counterintuitive, it can be at least partly explained by the fact that those with the
worst liver disease at baseline have less scope for further progression.
2.4.3 Clinical risk scores in the prediction of hepatic fibrosis
In the absence of an easily-utilised biochemical test for fibrosis several research groups have
constructed clinical risk scoring systems through statistical modelling, which combine
routinely-available, and therefore inexpensive, physical and biochemical characteristics.
Many of these have been discussed above. A key aim of such scores is to accurately define
patients who do not have advanced fibrosis, with the aim of avoiding unnecessary biopsy: a
high sensitivity and NPV is therefore important in excluding fibrosis with accuracy.
The BAAT score was developed in an overweight population (BM1 > 25 kg/m2) and
assigned one point for each of increased age, BMI, ALT and triglycerides^ 77). Using a
positive score of 2 or above to denote the presence of septal fibrosis, the PPV was 45% and
NPV 100%; a score of 3 or above had a PPV of 100% and a NPV of 70-73%. The BARD
score allocated one point for each of increased BMI and the presence of diabetes, and two
points for AST:ALT ratio greater than 0.8(196). With a cut-off of 2 points or more, the PPV
and NPV of determining severe fibrosis (Stage 3 - 4 on the Brunt staging system) were 43%
and 96% respectively. In a validation study within a UK cohort, the PPV was 27% and NPV
95%( 197). The NAFLD fibrosis score uses a formula combining age, BMI, the presence of
diabetes, AST:ALT ratio, albumin and platelet levels to classify participants as low,
indeterminate or high risk for severe (septal or bridging, stage 3 - 4 on the Brunt staging
system) fibrosis(198). The PPV of a high risk score was 90% in the estimation group and
82% in the validation group; the NPV of a low risk score was 93% in the estimation group
and 88% in the validation group. The authors conjectures that biopsy could be avoided in the
75% of participants calculated to be low or high risk, and used mainly in those that were
scored as indeterminate. This score has been further validated in UK, Argentinian and
Chinese populations with similar positive and negative predictive values(197;199;200).
By definition, these scoring systems have been developed and validated in tertiary referral
centres on a selected group of patients in whom biopsy has been felt to be clinically
necessary and in whom elevated liver enzyme levels was often a prerequisite for
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investigation. One must be wary that an association found in patients at the severe end of the
clinical spectrum may be less relevant to those with less severe liver disease. Furthermore,
the PPV and NPV values quoted are by definition dependent on the prevalence of advanced
liver disease in the population studied. No scoring system has been created for use
specifically within populations of patients with diabetes and, interestingly, when the BARD
score was examined in the diabetic subgroup of the original study population it was found to
be less predictive than in the subgroup without diabetes (ROC AUC 0.53 vs 0.80).
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2.5 Outcome of NAFLD - morbidity and mortality
Several studies liave examined the longterm outcome of NAFLD in general populations, in
terms of clinically appreciable endpoints - cirrhosis-related complications, HCC and death.
There is also a considerable body of evidence demonstrating the relationship of diabetes to
these hard outcomes, suggesting a deleterious effect when the pathologies co-exist.
2.5.1 Morbidity - HCC and other complications of cirrhosis
Early studies examining the aetiology of liver disease in registers of patients with proven
HCC found underlying cryptogenic cirrhosis in 7 - 29%, and features of NAFLD in
13%(20l;202). These established NAFLD (both with and without cirrhosis) as a possible
cause of HCC and prompted studies into its incidence within populations of patients with
NAFLD. Incidence of HCC has been estimated to be 2.4% over a maximum follow-up
period of 21 years of patients with biopsy-proven NASH(178), 1.6% over 13 years in a study
of biopsy-proven NAFLD(98), and 0.5% over 7.6 years in a study ofNAFLD diagnosed on
imaging or biopsy(203). In other longitudinal studies, encompassing groups with steatosis
alone and NASH, no cases of HCC were diagnosed over follow-up times of 3 -11
years(99; 179-181). In a study of patients with biopsy-proven NAFLD, 5.4% developed
cirrhosis-related complications, including ascites, HCC and variceal haemorrhage, over 13
years of follow-up(98).
2.5.2 Mortality
The majority of studies to examine the relationship of NAFLD with mortality have found
NAFLD to be associated with a higher mortality rate. A population-based cohort study, in
which patients with NAFLD diagnosed on imaging or biopsy were compared to the age- and
sex-matched general population, found significantly lower survival in the NAFLD group
with a standardised mortality ratio of 1.34(203). On multivariate analysis, only age, the
presence of cirrhosis and the presence of impaired glucose tolerance or diabetes were
independently associated with rate of death. In a second study, of patients with biopsy-
proven NAFLD in the context of elevated LFTs, survival over a mean of 13 years was
significantly lower than in the corresponding reference population(98).
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Conversely, in two studies originating from the NHANES cohort no relationship between
NAFLD and mortality was found. The first was a study comparing patients with elevated
ALT with those with a normal ALT level, after exclusion of people with alcohol excess, viral
hepatitis, iron overload and hepatotoxic medication use(204). There was a trend towards
higher age-matched all-cause mortality rate in the group with high ALT levels but this did
not reach statistical significance. This study had the advantage of a relatively non-selected
patient population, but the disadvantage of the use of a surrogate marker to designate
NAFLD. Interestingly, when data from the same study was analysed using higher cut-offs to
define elevation in ALT, looking at a slightly different age-range of participants and
performing multivariate adjustment for confounding variables, the overall and liver-related
mortality was found to be unquestionably higher in the NAFLD group(205). The second
study used ultrasound (with the same exclusions on the basis of secondary causes for liver
disease as above) to diagnose NAFLD, and found no evidence of an association between
NAFLD and all-cause mortality or deaths due to cardiovascular or liver disease(206). It is
possible that in this unselected population the majority of participants with NAFLD had
simple steatosis, which has been suggested to be of lower risk than more aggressive forms of
liver disease as described below. However, if ultrasound measures were not robust, or if a
proportion of the control group actually had hepatic fibrosis (which would mask the finding
of hepatic steatosis on ultrasound) then a false negative result is possible.
As with biopsy-diagnosed progression of liver disease, there is evidence that mortality is
related to baseline histology. In a study comparing outcome of patients with NASH with
those with simple steatosis alone, there was a trend towards an increase in liver-related death
in the NASH group but this did not reach statistical significance (10% vs 2%, p = 0.08)(67).
Compared to the age-matched general population, however, there appeared to be a very
significantly elevated risk of liver-related death in the NASH group. This was mirrored in
another cohort of patients with NAFLD.(98). In a further study, advanced (bridging or
cirrhosis) fibrosis was the only histological parameter to be significantly associated with
liver-related mortality, with an adjusted hazard ratio of 5.68(207). The relatively better
prognosis in simple steatosis has also been indicated in a study of subjects with fatty liver
alone, in which the survival rate was found to be similar to the general population, with a
liver-related mortality of 1% over 16.7 years(208).
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Although the data regarding the effect ofNAFLD on mortality is not absolutely uniform, the
conclusion that NAFLD is associated with reduced survival appears relatively well-founded.
Results from different studies depend on method of ascertainment of NAFLD and baseline
histology. In cohort studies examining subjects with pre-diagnosed NAFLD there is the
possibility of referral bias - for example, referral may have been more likely in the context
of adverse metabolic features such as diabetes or significant obesity that may in themselves
affect outcome. It has been demonstrated that subjects that undergo liver biopsy have a
poorer prognosis than those that do not, and this is likely due to a higher presence of
indicators of significant liver disease in these patients(203). Examination of the long-term
outcome in unselected patient populations, assessed reliably at baseline for the presence of
NAFLD, would go some way towards overcoming these limitations.
2.5.3 Poor outcome with the combination of NAFLD and Type 2 diabetes
The relationship of diabetes to clinically apparent chronic liver disease and mortality has
been explored in a number of studies. A large cohort study was designed to investigate a
causal role of diabetes in promoting increased severity of liver disease. This study followed
173643 mainly male Veterans with diabetes and 650620 controls for 10-15 years(209). The
presence of a diagnosis of liver disease at baseline was an exclusion criterion for this study,
thus reducing the impact of diabetes that has arisen secondary to cirrhosis. There was a
significantly higher incidence of chronic liver disease in the group with diabetes compared to
that without diabetes (incidence rates 18.13 per 10000 person-years and 9.55 per 10000
person-years respectively, with a relative risk among those with diabetes of 1.98). When
patients with a new diagnosis of hepatitis B or C, alcohol use or alcoholic liver disease were
excluded the relative risk of chronic liver disease in the group with diabetes was 2.15. The
main limitation of this study was failure to formally seek undiagnosed subclinical liver
disease at baseline and, given the indolent nature ofNAFLD, it is possible that a proportion
of patients would already have had evidence of this condition which would detract from
conclusions regarding temporal relationship. Misclassification of a number of patients on the
basis of errors of coding is likely in a study of this magnitude, but is unlikely to have
materially affected the outcome.
Diabetes is an established risk factor for HCC and in one population-based study, diabetes
was associated with around a 2.5-fold increase in incidence of HCC, independent of alcohol
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intake and viral hepatitis(209). This has been mirrored in another similarly large population
study, with reported standardised incidence ratios of primary liver cancer within patients
diagnosed with diabetes of 2.1 in women and 4.0 in men. Secondary causes of liver disease
were not excluded in this study(210). The prevalence and incidence of HCC in the general
population of people with Type 2 diabetes, however, remains unclear, with no cases reported
in NAFLD prevalence studies within Type 2 diabetic populations(18;170;173).
The presence of diabetes has been an independent predictor of mortality in studies outlined
above that have examined the impact ofNAFLD(203;205). These studies have not, however,
been able to fully elucidate the pathogenic processes underlying this, and in particular it is
unclear what proportion of the effect of diabetes is via increased progression of liver disease
versus more established sequelae such as cardiovascular disease and malignancy. In contrast,
in one population-based study investigated death from liver cirrhosis and found the risk to be
2.5 times higher in people with type 2 diabetes compared with the general population(211).
Information on secondary causes of liver disease was not available.
The effect of NAFLD on mortality within a population of patients with a prior diagnosis of
Type 2 diabetes has also been examined(212). In this population NAFLD, after adjustment
for age, gender, duration of diabetes, obesity and other cardiovascular risk factors, was
associated with a significantly increased risk of death compared to a control group, with a
hazard ratio of 2.2. When different causes of death were examined, NAFLD was associated
with a borderline increased risk of death from malignancy but there was no trend towards
increased mortality due to cardiovascular disease. Nineteen percent ofNAFLD patients died
from liver-related causes (liver failure, FICC and variceal bleeding), compared with no
patients in the control group.
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2.6 Treatment of NAFLD
Treatment ofNAFLD involves a multi-faceted approach, in much the same way as is utilised
in the treatment of diabetes. There is considerable overlap in the possible management
strategies used in the two conditions, particularly as proposed treatments for NAFLD have
often focused on improving insulin resistance, also a key target in Type 2 diabetes.
Currently, specific pharmacological interventions for NAFLD (specifically NASH) are
supported by relatively limited evidence, and are considered to be experimental and the
subject of ongoing research. Evidence for benefit in terms of "hard outcomes" such as liver
failure and mortality is lacking. The absence of a definitive treatment is one reason why
patients with Type 2 diabetes are not routinely comprehensively screened for NAFLD, and
there is a perception that making the diagnosis will not change management in this patient
group; concomitant with this is the incomplete knowledge of the natural history of the
disease and the best strategy for following up those who are found to have NAFLD.
Currently, identification of those with NASH might allow their inclusion in clinical trials of
newer agents. Of most importance, however, is recognition of individuals that have (or are at
significant risk of developing) cirrhosis, as screening for oesophageal varices and HCC is
recommended in this group(213). Liver transplantation remains an option for some people
with end-stage liver disease, and NAFLD accounts for over 10% of people on the transplant
waiting list in the UK(8).
A full review of the treatments that have been trial led in NAFLD is beyond the scope of this
review, but below is mention of the most prominent with particular reference to those that
target insulin resistance.
2.6.1 Treatments that target insulin resistance
Lifestyle modification
The role of lifestyle change, specifically with the aim of weight reduction and improved
insulin sensitivity via diet and exercise interventions, has recently been the subject of a
systematic review(2l4). Many of the trials included were small or uncontrolled, and few had
included serial biopsies, with most following participants using imaging or aminotransferase
levels. Almost all studies reported reductions in hepatic fat or liver enzyme levels, often in
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parallel with weight loss. A randomised controlled study has examined the effect of a
lifestyle intervention, including a combination of diet, exercise and behaviour modification,
on liver histology in individuals with biopsy-proven NASH(141). Over the 48-week trial
period there was a reduction in body weight of 9.3% in the intervention group compared to
0.2% in the control group, and this was accompanied by a significantly greater improvement
in NASH clinical activity score. When individual histological features were examined, there
was a significantly greater improvement in the steatosis score in the intervention group,
ballooning injury score improved to a similar extent in both groups, and fibrosis score was
unchanged. Changes in histology were significantly correlated with extent of weight loss in
both groups, and subjects who attained 7% weight loss had significantly greater reductions in
steatosis, lobular inflammation and ballooning injury scores. In general the evidence for
lifestyle modification suggests that moderate, controlled weight loss should be promoted in
patients with NAFLD with the aim of improving steatosis and inflammatory changes; the
evidence for improvement in more advanced liver disease is currently lacking.
Metformin
Metformin is very commonly used as an insulin-sensitizing agent in the treatment of Type 2
diabetes. However, despite an initial trial which suggested an improvement in
aminotransferase levels with metformin treatment, direct evidence for benefit in NAFLD is
Iacking(215). In four high-quality randomised controlled trials in which serial biopsies were
taken, 6-12 months treatment with metformin plus lifestyle intervention did not improve
liver histology over lifestyle alone(216).
Thiazolidinediones
In terms of pharmacological modification of the course of NAFLD, the thiazolidinediones
(peroxisome proliferator-activated receptor y agonists) have most evidence for efficacy.
Their mechanism of action is to ameliorate insulin resistance by redistributing fat from the
liver and muscle to peripheral adipose tissue. The pooled results of five high quality
randomised controlled trials of treatment with thiazolidinediones, in which serial biopsies
were undertaken, have shown improvement in histological steatosis and inflammation but
not fibrosis(216). In the context of Type 2 diabetes, the one study to specifically recruit
participants on the basis of impaired glucose tolerance or diabetes is of particular
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interest(217). In this placebo-controlled study, after 6 months of treatment, there were
significant improvements in steatosis, ballooning necrosis and inflammation, and a trend
towards a significant reduction in fibrosis (p = 0.08). In a larger study of non-diabetic
patients, comparison of pioglitazone therapy with placebo did not meet the pre-specified
level of significance for the primary outcome, which required an improvement of one or
more points in the hepatocyte ballooning score, no increase in the fibrosis score and a
decrease in the NAFLD activity score of at least 2 points or to a final score of 3 or
less(2I8)s. The pioglitazone group, however, had fewer participants with hepatocyte
ballooning at baseline, and this may have contributed to the negative finding of this primary
endpoint. Pioglitazone was superior to placebo in secondary endpoints of reduction in
steatosis, lobular inflammation and the NAFLD activity score.
2.6.2 Other treatments
The treatments outlined above have focused on insulin resistance as a target; an alternative
strategy is to specifically target oxidative stress and inflammation, which are thought to play
a role in the "second hit" of NAFLD. A meta-analysis of antioxidants found no histological
benefit, but there was significant heterogeneity between studies, in particular with regard to
the drug administered and treatment durational6). A two-year randomised placebo-
controlled trial of Vitamin E has stimulated interest, as Vitamin E was associated with a
significantly higher rate of improvement of NASH compared with placebo, and on analysis
of the separate components of severity showed improvement in steatosis, lobular
inflammation and hepatocellular ballooning (but not fibrosis)(218). There are, however,
concerns regarding long-term safety of Vitamin E as it has been associated with an increased
risk of cardiovascular disease and haemorrhagic stroke(219). The anti-TNFa agent,
pentoxifylline, has also been associated with improvements in liver histology (steatosis and
hepatocellular ballooning) compared with baseline in a small study, but outcome compared
to placebo failed to show a statistically significant difference(220).
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2.7 Relationship of NAFLD with cardiovascular disease
The relationship between NAFLD and cardiovascular disease has been explored both in
populations of people with Type 2 diabetes and those without. As described below, a
positive relationship between NAFLD has been found with hard clinical endpoints including
myocardial infarction, stroke and cardiovascular death, and with markers of subclinical
cardiovascular disease.
2.7.1 Association of NAFLD and cardiovascular events
In a prospective study of over 1600 Japanese employees, the presence ofNAFLD diagnosed
on ultrasound at baseline was associated with an increased 5-year incidence of
cardiovascular events (5.2% vs 1.0%, p < 0.001 )(221). This association persisted after
adjustment for traditional cardiovascular risk factors and features of the metabolic syndrome.
Within a population of patients with Type 2 diabetes, 248 participants who suffered non-fatal
coronary heart disease, stroke or cardiovascular death over a five-year period were age- and
gender-matched with control subjects who remained free of cardiovascular disease(222). The
group that developed cardiovascular disease had a significantly higher prevalence of
ultrasound-diagnosed NAFLD at baseline (94% vs 56%, p < 0.001). The univariate
association persisted after adjustment for classical cardiovascular risk factors, diabetes
duration, glycaemic control and medication use(7;222). Adjustment for features of the
metabolic syndrome, including hypertension, attenuated but did not abolish the significant
association. These results have been supported by cross-sectional studies in patients with
Type 2 diabetes that have found similar associations( 18;223).
2.7.2 Association of NAFLD and surrogate markers of cardiovascular disease
Coronary atherosclerosis
NAFLD has been associated with increased prevalence of coronary artery disease. In a study
of Chinese patients undergoing diagnostic coronary angiography, 84.6% of those with
NAFLD on ultrasound had a coronary stenosis of > 50%, compared to 64.1% of those with
no evidence of fatty liver(224). This association remained after adjustment for the other
factors that had a statistically significant association on univariate analysis (age, gender,
diabetes, WC, fasting glucose, high density lipoprotein (HDL) cholesterol and ALT); but
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unfortunately not including smoking or blood pressure, and there was 110 measure of insulin
resistance). In the same study, in patients with proven established coronary artery disease,
there was no association between NAFLD and a composite endpoint including
cardiovascular death, non-fatal MI and need for further coronary intervention over a time
period of up to 120 weeks.
Carotid intima media thickness
NAFLD has been associated with an increased risk of carotid atherosclerosis, as defined
using carotid intima media thickness (CIMT) measurement, a well-validated screening tool
for the prediction of cardiovascular disease in asymptomatic subjects. In a study of 40
patients with USS-diagnosed NAFLD, in whom those with a history of alcohol excess, viral
hepatitis and high transferrin saturation were excluded, and the same number of age- and
gender-matched controls in whom hepatic steatosis was not found on USS, NAFLD was
found to be associated with a significantly higher CIMT and this persisted after adjustment
for traditional cardiovascular risk factors, the presence of the metabolic syndrome and
insulin resistance as measured using the HOMA-1R score(225). A further study of non-
diabetic patients with NASF1, an age- and gender-matched group with chronic viral hepatitis
and a further group of controls who had normal liver enzymes and ultrasonography observed
a statistically significant stepwise increase in CIMT through the normal, viral hepatitis and
NASH groups(226). The relationship between NASH and CIMT remained after adjustment
for traditional cardiovascular risk factors and features of the metabolic syndrome including
insulin resistance as measured using the HOMA-IR score. Similar results have been found in
other study populations including children with NAFLD(227;228). In an additional study in
non-diabetic men the positive association between the presence of NAFLD and CIMT was
independent of insulin resistance as measured by HOMA-IR and WC, but abolished by the
inclusion of visceral abdominal fat as measured on CT cross-sectional imaging, raising the
possibility that visceral fat accumulation is a key component of the relationship between
NAFLD and atherosclerosis(229). The main study to examine the relationship between the
different pathological stages of NAFLD found that CIMT was significantly positively
associated with the presence of NASH over fatty liver alone, and that there were stepwise
increases in mean CIMT through increasing grades and stages of steatosis, inflammation and
fibrosis(230). These associations persisted after adjustment for traditional cardiovascular risk
factors, insulin resistance as defined by the HOMA-IR score and features of the metabolic
syndrome.
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Interestingly, in populations of patients with Type 2 diabetes the association ofNAFLD with
CIMT has been more variable. In one study of Type 2 diabetic patients, in which hepatic
steatosis was quantified using MRS, there was no difference in CIMT in participants with,
versus those without, NAFLD(231). However, there was no attempt made to adjust for
confounding factors such as gender or medication use (there was a significantly higher rate
of metformin use in the NAFLD group). In two other studies of patients predominantly with
Type 2 diabetes there was a significantly higher CIMT in the group with hepatic steatosis or
NAFLD, but this relationship was abolished after adjustment for other variables, in one case
specifically insulin resistance as measured using the HOMA-1R score(228;232). One
possible reason for the variability in results is that the bias in selecting diabetic patients, who
are by definition at high cardiovascular risk and are likely to have higher CIMT
measurements than the general population, makes it more difficult to demonstrate
independent relationships between NAFLD and CIMT. It is also possible that
misclassification of patients on the basis of ultrasound grading of steatosis has contributed to
negative results, but this would be less likely in the case of MRS being used to define
steatosis. It is, however, also possible that the effect ofNAFLD on cardiovascular risk is not
principally mediated by through chronic atherosclerosis, or indeed that NAFLD is not a
direct mediator of increased cardiovascular risk in the diabetic population but instead an
epiphenomenon.
Endothelial dysfunction
Another surrogate marker of early atherosclerotic disease, endothelial function as measured
by flow-mediated vasodilatation of the brachial artery, has been found to be associated with
NAFLD. In a study of NAFLD cases and matched controls the (endothelium-dependent)
vasodilatation of the brachial artery, in response to reactive hyperaemia in the context of an
inflated then deflated blood pressure cuff, was found to be significantly less in the NAFLD
group(233). This was independent of age, gender, BMI and other features of the metabolic
syndrome. Similar results were found in a study of children with NAFLD, when compared to
obese controls(227). Although the working hypothesis was that endothelial dysfunction was




An association between NAFLD and cardiovascular disease now seems established, with the
main area of controversy whether this relationship is independent of insulin resistance.
Several other non-classical risk factors that might implicate a causal role for NAFLD have
been explored, including reductions in circulating levels of the cardioprotective cytokine
adiponectin, and abnormal lipoprotein metabolism that leads to a pro-atherogenic profile
with overproduction of triglyceride- and cholesterol-rich remnant particles(234). In the next
section the focus will be on two pathways that may link the two conditions - a pro-
thrombotic tendency related to increased production of pro-thrombotic mediators, and a






- clot kinetics and pro-thrombotic
2.8.1 Clot kinetics and prothrombotic mediators
Pathways of clot formation and lysis
Formation of occlusive thrombus at the site of rupture or erosion of an atherosclerotic plaque
is the final step in acute vascular events such as myocardial infarction(235). Clot formation
involves a complex interaction between coagulation factors (synthesised by hepatocytes) and
platelets that culminates in a common pathway of thrombin formation and fibrinogen
activation, summarised below in Figure 2.1(236). Fibrinogen is cleaved by thrombin,
enabling interaction between fibrin molecules and the development of a cross-linked fibrin
clot. This clot is additionally stabilised by the incorporation of activated Factor XIII, which
further cross-links the fibrin molecules.
Conversely, the fibrinolytic system mediates the lysis of cross-linked fibrin clot and this
process is again encapsulated in Figure 2.1 below. The initial step in this pathway is
production of tissue plasminogen activator (tPA) from endothelial cells and this molecule
subsequently activates plasminogen to plasmin, which in turn breaks down the fibrin
structure of the thrombus. Plasminogen activator inhibitor type 1 (PAI-1) is a physiological
inhibitor of this process, by binding to and inactivating tPA.
There is a finely-balanced equilibrium between coagulation and fibrinolysis in health. This
can be disturbed by subtle perturbations in concentration and function of the components of
these systems. A hypercoagulable state has been linked to increased cardiovascular risk, and
the evidence behind this is discussed in subsequent sections.
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Figure 2.1
Formation and lysis pathways of the fibrin-rich clot.
tPA, tissue plasminogen activator; PAI-1, plasminogen activator inhibitor type 1
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Association between clot dynamics and cardiovascular disease risk
An area of particular interest is the effect of inter-individual differences in clot structure and
propensity to lysis on cardiovascular risk. Research in this field has been enabled by the
development of techniques that allow observation of changes in clot density over time in
vitro, including turbidimetric assays that measure scatter of light by solid particles (clot
turbidity having been shown to be directly proportional to the cross-sectional area of the
fibrin fibres)(237), and thromboelastography which assesses viscoelastic changes during clot
formation and breakdown(238). In addition, confocal and electron scanning microscopy has
allowed detailed assessment of clot microstructure.
It has been observed that individuals at high cardiovascular risk have higher clot density,
altered clot morphology and longer clot lysis times compared with controls(239-242). In a
study comparing 33 young post-myocardial infarction patients with age- and sex-matched
healthy controls, clots from the post-myocardial infarction patients had a more compact
architecture - with thinner, more numerous fibrin fibres and smaller pores - than the
controls(241). This was paralleled by resistance to clot lysis in these patients, with
independent predictors of clot lysis time including fibrin fibre length and stiffness, and
concentration of PAI-1. A less porous clot structure has also been observed in healthy
relatives of patients with coronary artery disease, in whom examination could be performed
in the absence of confounding factors such as ubiquitous aspirin use(240).
Similar alterations in clot structure and lysis times have also been seen in individuals with
the metabolic syndrome or diabetes(239;243-245). Clots formed using purified fibrinogen
from patients with Type 2 diabetes have been shown to be more dense when compared to
those formed from the fibrinogen of age- and sex-matched controls, with a positive
association between worsening glycaemic control and less permeable clot structure(244).
Similarly, the presence of the metabolic syndrome has been associated with denser clots and
longer clot lysis times compared to controls, and there was a progressive stepwise increase in
these variables though increasing numbers of metabolic syndrome components(239). In a
different study, clot lysis times were longer in children with Type 1 diabetes than in controls
and were significantly shorter after improvement of glycaemic control(243). The results
from these studies suggest that part of the increased cardiovascular risk associated with
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insulin resistance, diabetes and poor glycaemic control is mediated through alteration in clot
formation and lysis kinetics.
Association of pro-thrombotic mediators, clot kinetic variables and cardiovascular
disease
Many of the above studies have also examined the relationship of plasma levels of
prothrombotic mediators with clot formation and lysis kinetics. Fibrinogen concentration and
structure, as might have been expected, has been particularly strongly associated with clot
density measures but has also been shown to contribute to variation in clot
lysis(239;240;246;247). PAI-1 contributed 7-13% of variation in clot lysis in one study, and
was related to fibrinolysis rate in further reports(239;241 ;243;248). Administration of an
antibody to PAI-1 resulted in a doubling of tPA-induced thrombolysis in one experimental
model(249).
The distinctions between pro-thrombotic and pro-inflammatory mediators has become
blurred in recent times and it is now recognised that there is considerable overlap between
the two systems. Thus, fibrinogen and PAI-1 have been acknowledged as acute phase
proteins, while complement C3, a central component of the innate immune system, has been
shown to play a role in clot formation. In a study performed in children with Type 1 diabetes
and age-, sex- and weight-matched controls, both C3 and C-reactive protein (CRP) were
higher in the diabetic group, but only C3 level correlated with clot lysis variables(243). C3
was shown to be incorporated into clots with subsequent prolongation of clot lysis time. The
association between C3 concentration and clot lysis time has been confirmed in further
studies in adults(250;251).
The associations of plasma levels of fibrinogen, PAI-1 and C3 with clot formation and lysis
dynamics have been mirrored by their relationship with clinically meaningful cardiovascular
endpoints. Fibrinogen has been the most extensively studied. An early meta-analysis found a
positive association between fibrinogen concentration and incident cardiovascular disease in
all seven studies that had previously examined that relationship, with an overall odds ratio of
2.3 (95% confidence intervals 1.9 - 2.8) for upper versus lower tertiles of fibrinogen(252).
This effect persisted after adjustment for established confounders such as age, smoking, BP
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and lipid measures, but studies were inconsistent in their inclusion of measures of obesity
and glycaemia. Furthermore, pre-existing cardiovascular disease was not always an
exclusion criterion, and therefore reverse causation could not be discounted. The positive
association of fibrinogen with subsequent cardiovascular events was confirmed in a later and
larger meta-analysis of 31 studies including over 154000 participants in total, in which a
hazard ratio of 2.4 (95% confidence intervals 2.2 — 2.6) in predicting coronary heart disease
was observed for each 1 g/1 increase in fibrinogen(253). This report attempted to address the
limitations inherent in the earlier meta-analysis: only subjects in whom there was no history
of clinically apparent coronary heart disease or stroke were included (although attempts were
not made to exclude subclinical atherosclerosis); and, when possible, a full adjustment for
other cardiovascular risk factors (including BMI and the presence of diabetes) was
performed. After such an adjustment the hazard ratio was 1.8 (95% confidence intervals 1.6
— 2.1). Similar results have been seen in populations of patients with Type 2
diabetes(254;255). Despite the consistent associations between higher fibrinogen levels and
increased incidence of cardiovascular disease in epidemiological studies, a firm association
is yet to be shown between genetic determinants of higher fibrinogen levels and subsequent
risk of cardiovascular disease(256-258). This raises the possibility that fibrinogen does not
play a direct role in the pathogenesis of cardiovascular disease, but instead may be a marker
for other causal factors. An alternative explanation is that environmental influences on
fibrinogen level are more potent than genetic ones, or indeed that higher fibrinogen levels are
a product of the interaction between genetic and environmental effects.
The relationship of PA1-1 to cardiovascular disease has similarly been investigated, but
results have been rather less uniform. One early study suggested an independent association
between PAI-1 and myocardial re-infarction in 109 survivors of first myocardial infarction
who were followed for three years(259). Higher PAI-1 at baseline remained an independent
predictor after adjustment for traditional cardiovascular risk factors, angiographic findings
and in-depth measures of glucose tolerance and insulin sensitivity. A later study carried out
in 147 patients with Type 2 diabetes showed a significant cross-sectional relationship
between PAI-1 and coronary heart disease that was unattenuated by adjustment for
traditional risk factors, the metabolic syndrome and diabetes variables(260). In contrast,
other studies have observed a trend only towards higher PAI-1 levels in participants that go
on to have a cardiovascular event(261), or an initially significant association that is fully
attenuated by adjustment for traditional and metabolic risk factors(262-264). A meta-analysis
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of studies that examined the effect of PAI-1 gene polymorphisms (specifically the 4G
polymorphism within the promotor region that has been associated with approximately 20%
higher PAI-1 levels) found weak associations between this polymorphism and myocardial
infarction (relative risk 1.04 (1.00 - 1.09), but the strength of the findings was reduced by
concern over publication bias(265). In summary, there is fairly consistent evidence for a
positive association between PAI-1 and cardiovascular disease, but variable support for its
independence of other metabolic variables, calling into question the theory that it has a direct
causative role.
The relationship of complement C3 to cardiovascular events has been the subject of fewer
reports than that of fibrinogen and PAI. In one study of 860 participants within an Italian
population, C3 levels at baseline were shown to be independently related to incident
ischaemic events including any form of coronary heart disease and myocardial infarction
after adjustment for traditional risk factors and obesity(266). An independent association was
also found in another study of 1200 middle-aged and elderly participants, in which relative
risk of coronary heart disease for each standard deviation increase in C3 was 1.35 (95%
confidence intervals 1.09 - 1.67) after adjustment for age, sex, presence of the metabolic
syndrome, smoking status and CRP amongst others(267). In contrast, other authors have
observed complete attenuation of the relationship of C3 and coronary events following
adjustment for established cardiovascular risk factors(268). Adjustment for direct measures
of insulin resistance was not carried out in any of these studies.
Relationship of NAFLD with clot formation and lysis dynamics, and components of
the coagulation cascade and fibrinolytic system
The theory that the relationship of NAFLD with cardiovascular disease may be in part
mediated by altered clot formation and lysis dynamics and a pro-thrombotic state has been
based on a number of considerations. The liver, as the primary site of production of most
components of the coagulation and fibrinolytic systems, is integral to the clotting cascade.
Furthermore there is evidence to suggest that hepatic production of some pro-thrombotic
mediators, such as PAI-1, is enhanced in response to liver injury(269). As has been outlined
above, hepatic steatosis is intrinsically bound up with the subclinical inflammatory state that
accompanies visceral adiposity and insulin resistance, and this leads to a vicious circle of
pro-inflammatory cytokine release and upregulation of pro-thrombotic mediators(270-274).
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Thus, NAFLD may modulate cardiovascular risk directly via hepatic synthesis of these
mediators, but may also be representative of a high-risk environment in which adipose tissue
also plays a role.
To date, investigation of clot dynamics in patients with NAFLD has been limited to one
small study. This analysis compared clotting kinetics, measured using thomboelastography,
in 28 patients with NAFLD (either diagnosed on ultrasound or on biopsy) and 22 control
subjects(275). A higher clot strength and reduced clot lysis was demonstrated in the group
with NAFLD, independent of the presence of diabetes or features of the metabolic syndrome.
Although a robust relationship between pro-thrombotic mediators and insulin resistance has
been demonstrated(276;277) there have been conflicting results when associations with liver
disease have been examined. The steatotic liver has been directly implicated in increased
production of PAI by a small histological study, in which hepatocyte staining for PAl-1
protein was significantly greater in the NAFLD versus the control group(278). These results
were supported by the finding of a significant relationship between liver histology in
NAFLD and circulating PALI levels that persisted after adjusting for insulin resistance and
features of the metabolic syndrome(279). A large study of over 500 subjects revealed an
association between ALT and C3 levels which persisted after adjustment for insulin
resistance(277). In contrast, two studies have observed complete attenuation of the
relationship between hepatic steatosis and higher fibrinogen and PAI-1 levels after
adjustment for components of the metabolic syndrome(274;280). The relationship of these
pro-thrombotic mediators to clot kinetics has been little studied in relation to NAFLD in





The following chapters describe work undertaken within the Edinburgh Type 2 Diabetes
study with the aim of enhancing understanding of the prevalence and epidemiology of
NAFLD within a large population of people with Type 2 diabetes.
3.1.1 Use of ultrasound to diagnose hepatic steatosis
Ultrasound imaging is an established modality in the diagnosis of hepatic steatosis, both
clinically and in large-scale studies. However, diagnostic accuracy has varied between
studies and a degree of subjectivity in ultrasound grading of steatosis is well-recognised.
Despite this, most studies that rely on an ultrasound measure for steatosis have not had this
measure validated, and formal examination of intra- and inter-observer variation of
ultrasound grading has been infrequently performed.
Our primary aim was to validate our ultrasound measure of steatosis in a subgroup of
participants, by comparing ultrasound gradings with hepatic fat fraction on MRS, the non¬
invasive gold standard measure of steatosis. In so doing, we intended not only to substantiate
the measure on which the rest of our study depends, but also to add to the literature
describing the accuracy of ultrasound by performing the first comparison with MRS. This is
particularly valid as biopsy (the accepted gold standard) is imperfect and in particular
samples a tiny proportion of the liver as a whole, and significantly less than either MRS or
ultrasound.
A secondary aim was to investigate intra- and inter-observer variability in ultrasound grading
between three graders: an ultrasonographer, who was responsible for scanning all study
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participants; a specialist registrar in radiology; and a consultant radiologist. Thus we aimed
to provide a measure of variability that encompassed "real life" variation in graders.
3.1.2 Prevalence of and risk factors for hepatic steatosis and NAFLD in Type 2
diabetes
Despite the established pathophysiological and epidemiological associations between Type 2
diabetes and NAFLD, few studies have examined the prevalence of NAFLD in diabetic
populations. Those that exist have often focused on small, hospital-based cohorts, or have
used an unvalidated ultrasound measure or incomplete exclusion of secondary causes for
liver disease. Screening for liver disease in people with Type 2 diabetes routinely involves
performing liver enzyme measurements. Studies performed in the general population have
suggested that these biochemical markers are poorly sensitive in identifying fatty liver, but
there are few data from within populations of patients with Type 2 diabetes looking at this
issue.
The main aim of the study was to accurately determine the prevalence of hepatic steatosis
and NAFLD in a large, unselected population of older people with Type 2 diabetes, using a
MRS-validated ultrasound measure and strict exclusion of secondary causes for liver disease.
It is anticipated that the results will have public health implications in estimating the number
of patients that might require monitoring for more advanced liver disease, and in preliminary
identification of those that may in the future benefit from disease-modifying agents.
Secondary aims were to examine the clinical and biochemical correlates of hepatic steatosis
and NAFLD and determine the diagnostic accuracy of liver enzymes in predicting hepatic
steatosis in this population. The results may have practical consequences in determining the
optimal mode of screening these patients within clinical practice.
3.1.4 Prevalence and markers of advanced liver disease in Type 2 diabetes
Type 2 diabetes has been identified as a risk factor for the progression ofNAFLD to fibrosis
and cirrhosis. Despite this there are few data that have assessed the prevalence of more
advanced liver disease and its sequelae in populations of people with Type 2 diabetes.
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In this section, the prevalence of hepatic fibrosis, cirrhosis and hepatocellular carcinoma
(HCC) were assessed. The invasive nature of liver biopsy makes its use unethical in large
scale studies of essentially healthy volunteers. Therefore non-invasive markers were used in
this study - HA and clinical risk scores as indicators of hepatic fibrosis, ultrasound to
diagnose cirrhosis and (in combination with alpha-fetoprotein (AFP)) HCC, and platelet
count/spleen diameter ratio as a surrogate marker of portal hypertension. The relationship of
liver enzymes with markers of advanced liver disease was also examined. In the clinical
setting, accurate identification of patients with more advanced liver disease allows screening
for complications and, if appropriate, consideration for clinical trials of disease modifying
agents. The results of this study were anticipated to guide means of detection of such patients
and subsequent service provision.
3.1.5 Relationship of hepatic steatosis and NAFLD with clot formation and
lysis dynamics, and pro-thrombotic mediators
NAFLD has been associated with a higher prevalence of cardiovascular disease than is
present in the general population. Emerging risk factors for cardiovascular disease in this
context include a systemic pro-thrombotic tendency, and one area of interest is inter-
individual differences in formation and structure of the fibrin-rich clot and its lysis.
The aim of this study was to examine the relationship between hepatic steatosis and NAFLD
and measures of clot formation, density and lysis. It was hypothesised that steatosis and
NAFLD would be associated with a prothrombotic tendency - specifically greater clot
density, longer clot lysis times and higher levels of pro-thrombotic and inflammatory
mediators. By studying this pathway it was hoped to provide further insight into mediators of
cardiovascular risk in people with NAFLD, and one might anticipate that this might provide




4.1 The Edinburgh Type 2 Diabetes Study
All work described in subsequent chapters was performed within the Edinburgh Type 2
Diabetes Study (ET2DS) cohort. The background to this study, along with the ascertainment
and recruitment of study participants will be described in detail in the present chapter.
4.1.1 Background
The ET2DS was initially conceived as a population-based prospective cohort study, designed
to examine cognitive function and factors associated with its decline in a population of older
people with Type 2 diabetes. At baseline, in a year-long period spanning 2006 - 2007, over
1000 participants attended the dedicated research clinic and underwent a variety of
assessments, with a focus on detailed cognitive testing and assessment of modifiable risk
factors including microvascular disease, hormones of the hypothalamic-pituitary-adrenal axis
and inflammatory mediators. The recognition of the contribution that this well-characterised
Type 2 diabetic cohort could make to the understanding of the epidemiology of hepatic
steatosis and NAFLD gave rise to the "liver study" that is the focus of this thesis.
4.1.2 Participant selection and recruitment
Study participants were selected from over 20000 patients recorded as having Type 2
diabetes on the Lothian Diabetes Register (LDR). The LDR is a computerised database,
established in 2001, that contains details of all people with ascertained diabetes living in the
Lothian region of Scotland. Thus the study population contained both patients looked after
within primary care and those seen within a hospital clinic. Inclusion criteria were an age
between 60 and 74 years, and a diagnosis of Type 2 diabetes. Exclusion criteria were: (l)
non-English speakers (as fluent English was required for the cognitive testing); (2) visual
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acuity worse than 6/36 for distance vision or unable to read large print text (as moderate
vision was required for cognitive testing); (3) unwilling or unable to give informed consent;
(4) physically unable to complete the clinical or cognitive examination.
People with Type 2 diabetes aged between 60 and 74 years on 1st August 2006 were selected
by gender and 5-year age bands from computer-randomised lists of eligible subjects
extracted from the LDR. Between 20th June 2006 and 1st June 2007, 5454 invitations to
participate in the study were mailed by the custodians of the LDR. Of these, no response was
received from 2104, and a further 64 were returned as being unknown at the address
recorded on the LDR. Of the 3286 individuals who replied, 1252 were interested in
participating in the study. Another randomly-selected subject, from the same sex and five-
year age band, replaced subjects that had not replied or were disinclined to participate.
Significant efforts were made to ensure that all who agreed to participate were actually
assessed, including multiple contacts by the ET2DS team, payment of travel expenses and
provision of transport if required, a choice of clinic dates and reminder telephone calls on the
day preceding the appointment. A total of 1077 participants attended, and of the remainder
56 could not be contacted, 111 were unwilling or unable to attend, 5 repeatedly failed to
attend and 3 had died. Of the 1077 participants, 4 were excluded as they were unable to
complete the physical or cognitive examinations and 7 were excluded as they did not fulfil
the criteria for a diagnosis of Type 2 diabetes as outlined below. The final baseline study
population numbered 1066 participants, as summarised in Figure 4.1.
One year later, all original participants who were alive and had consented to be contacted
about additional studies were invited to return to the Year 1 clinic, whose focus was on
hepatic assessment. Of the 1066 participants in the baseline, 1054 were invited to re-attend.
Of the remainder, 2 were known to have died, 5 had refused consent to be contacted about
further studies, 3 were deemed unsuitable for contact by study team and 2 had withdrawn
from any further contact after the baseline examination. A total of 940 subjects attended the
Year 1 clinic. Reasons for not attending were: unable to contact subject (n = 19);
unable/unwilling to attend on health grounds (n = 23); unable/unwilling to attend for other
reasons (n = 38); cancelled/did not attend appointment (n = 21); and death (n = 13). One of
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Figure 4.1
Participants in the Edinburgh Type 2 Diabetes Study
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the participants was unable to complete the examination and the study population for the
Year 1 liver study therefore numbered 939 participants (Figure 4.1)
4.1.3 Confirmation of Type 2 diabetes diagnosis
The study went to considerable lengths to ensure that that diagnosis of Type 2 diabetes, as
entered on the LDR by the patient's primary or secondary care physician, was correct. A
diagnosis of diabetes was accepted in any individual treated with oral antidiabetic agents
and/or insulin, and in any individual treated with dietary modification alone whose HbAlc
was > 6.5%. The clinical records of all subjects treated with dietary modification alone and
with an HbAlc < 6.5% at the research clinic were reviewed by a consultant diabetologist (Dr
Mark Strachan) to ensure that the diagnosis of diabetes was accurate. With regard to the
classification of'Type 2' diabetes, the clinical records of individuals who either: (I) started
on insulin within one year of diagnosis of diabetes, (2) reported evidence of pancreatic
surgery or disease at the research clinic or (3) were treated with insulin and were aged
<35years at diagnosis were also reviewed. Such individuals were considered to be at greatest
risk of mis-classification. Any subject in whom it was not possible to confirm a clinical
diagnosis of type 2 diabetes by review of hospital or general practitioner records was
excluded as has been outlined above.
4.1.4 Power calculation and sample size
The original power calculation was based upon requirements for baseline and follow-up
testing of the cognitive function variables(281). With a sample size of 1000 it was calculated
that there would be a 90% power at the two-sided 5% level of significance to detect a
Pearson correlation co-efficient of > 0.10 between the continuous outcome measures and
predictor variables, and with expected drop-outs and deaths a sample size of 800 would have
90% power to detect a correlation coefficient of > 0.12 between risk factors and outcome
measures. It was also estimated that, with a population of 800, it would be possible to detect
any risk factor that contributed 1 % or more to the variance in outcome.
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4.1.5 Ethical permission and consent
Ethical permission for both the baseline and liver studies was granted by the Lothian
Medical Research Ethics Committee. The Lothian Diabetes Services Advisory Group and
the Caldicott Guardian for NHS Lothian gave permission for the use of the Lothian Diabetes





Subjects attended the baseline clinic after an overnight fast for an assessment that included
physical examination and venepuncture. Examination was carried out by one of six trained
research nurses and measurement technicians, using pre-specified standard operating
procedures. Subjects also submitted a completed questionnaire including information on
demographic characteristics, diabetes history and treatment, medication use, alcohol intake
and smoking history. A full summary of data points collected at baseline is summarised in a
published study protocol(28l). Only these that are directly applicable to the work presented
here will be considered further at present.
Body mass index
Standing height was measured to the nearest millimetre using a wall-mounted vertical rule
(without shoes). Weight was assessed to the nearest 0.1 kg without outdoor clothing or shoes
using SECA 761 electronic weighing scales. BMI was defined in the usual manner as weight
(kg) divided by the square of the height (m).
Waist circumference
Waist circumference was measured during exhalation at the level midway between the lower
rib margin and the iliac crest (pre-marked at the mid-axillary line on each side of the subject)
with the subject standing with feet 30 cm apart and hands by their sides. Measurement was
made with a non-expandable tape measure. The average of two readings taken to the nearest
0.5 cm was taken as the final measurement.
Venepuncture
Venous blood samples were taken at baseline after an overnight fast. Fibrinogen levels were
assessed on plasma samples using the automated Clauss assay (MDA-180 coagulometer,
Organon Teknika). CRP was assayed using a high-sensitivity immunonephelometric assay.
TNFa and IL-6 levels were determined using high-sensitivity EL1SA kits (R&D Systems,
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Oxon, UK). Hyaluronic acid (HA) was measured using a radiometric assay (Pharmacia,
Uppsala, Sweden).
Record linkage
Details of discharge diagnoses following admission to any non-psychiatric, non-obstetric
ward in a Scottish hospital, between 1981 and September 2007, were collected on all
participants at baseline, using record linkage from the Information and Services Division of
NHS Scotland.
4.2.2 Year 1 ("liver") clinic
Subjects attended the Year l clinic after a four-hour fast. The main procedure performed was
ultrasound of abdomen and the details of this are described in Chapters 5 and 6. In addition
subjects had BP and venepuncture performed as outlined below. Questionnaires were
submitted with details of alcohol consumption (as described in Chapter 6), medication use
and history of liver or joint disease.
Blood pressure
Systolic and diastolic blood pressures were measured twice after subjects had been supine
for at least 25 minutes, and the mean of each used. Either an aneroid 6 inch dial, desk
standing sphygmomanometer or a mercurial sphygmomanometer was used. All
measurements were taken from the left arm unless this was undesirable or impossible.
Venepuncture
Venous blood samples were obtained after a 4-hour fast. Bilirubin, ALT, AST, AlkP, GGT,
AFP triglycerides, total and HDL cholesterol were measured on the Vitros Fusion chemistry
system (Ortho Clinical Diagnostics, Bucks, United Kingdom). Ferritin was measured by
immunoassay on the ADVIA Centaur (Siemans Healthcare Diagnostics Inc., Illinois, USA).
Hepatitis B surface antigen and hepatitis C antibody index were measured on the Abbott
Architect immunochemistry system (Abbott Laboratories, Illinois, USA). ANA, anti-smooth
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muscle antibody and anti-mitochondrial antibody were measured by immunofluorescence
using the Beeline slide analyser (HTZ Ltd, London, UK). PAJ-1 and C3 levels were
determined using ELISA kits (Invitrogen, Paisley, UK, and GenWay Biotech, San Diego,
USA respectively).
Collection and analysis of samples for clot lysis dynamics is described in Chapter 8.
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4.3 Representativeness Data
Non-identifiable data were gathered from the LDR on those who were invited to attend but
did not. Baseline study participants (n=1066) were shown to be representative, in terms of
age, HbAlc, duration of diabetes, insulin treatment and total cholesterol, of all those
randomly selected to participate (n=5454) and therefore of the target population of older men
and women with type 2 diabetes living in the general population(282). There was a
significant difference in the percentage of men in the study compared to the percentage
invited, and this was due to the methodology of the study which demanded similar numbers
of men and women in each age range. Information on the spread of participants looked after
within primary and secondary care was not available, but the other parameters examined
suggested that the population was likely to be representative. Representativeness data are
shown below in Table 4.1.
Table 4.1
Representativeness data from the ET2DS cohort(282).
n 1066 4386
Age (years) 67.9 ±4.2 67.9 ±4.4
Gender (% male) 51.3 41.9
Duration diabetes (% > 5 years) 51.6 51.3
HbAlc(%) 7.4 ± 1.1 7.4 ± 1.4
Insulin user (%) 17.4 16.1
sBP (mm Hg) 133.3 ± 16.4 137.2 ± 18.2
Total cholesterol (mmol/l) 4.3 ± 0.9 4.2 ± 1.0
*p < 0.01 on student's t-test or chi-squared analysis.
Representativeness of the Year 1 cohort is considered in Chapter 6.
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Chapter 5
Analysis 1: Use of Ultrasound to Diagnose Hepatic Steatosis
5.1 Introduction
Hepatic steatosis and NAFLD are commonly found within the general population and, as
outlined in detail in Chapter 2, there is evidence to support a higher prevalence of these
conditions within populations of people with Type 2 diabetes( 18; 170; 171). It is important
to accurately detect this condition as it may result in considerable morbidity and mortality in
this patient group(99;182;209-21 1), and can independently predict the risk of cardiovascular
events(223;271). Its identification can be used to initiate screening and target treatment for
more advanced liver disease.
5.1.1 Evidence for the diagnostic utility of ultrasound in the detection of
hepatic steatosis
Ultrasound imaging is the predominant imaging modality in the diagnosis of hepatic
steatosis, both clinically and in large-scale studies. Although several grading systems have
been proposed for the assessment of hepatic steatosis using ultrasound, no consensus has
been achieved(l 6;80-83). Detection of hepatic fat is based on well-established characteristics
including an echogenic parenchyma (especially in relation to the right kidney), posterior
attenuation and areas of focal fatty sparing(l6;82-85). Compared with liver biopsy it has
been reported to have a sensitivity of 53-100% and specificity of 77-100% in the diagnosis
of hepatic steatosis(75;76;80;82;84;86); advantages over biopsy include safety, ease of
acquisition and ability to assess the whole liver. The variability in diagnostic accuracy of
ultrasound is likely to be due to a number of factors as described in Chapter 1, including
differing levels of obesity between populations and evolving scanning technology.
Although a degree of subjectivity is recognised when diagnosing hepatic steatosis by
ultrasound examination, few studies have examined intra- and inter-observer variability in
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making this diagnosis. One study of 25 patients with biopsy-proven NAFLD (less than a
quarter of whom had diabetes) reported that the inter-observer correlation between two
radiologists in determining severity of steatosis was 0.40 (representing fair agreement), and
the intra-observer correlation was 0.63 (suggesting more substantial agreement)(80). A
different study - of 168 patients - who had undergone abdominal ultrasonography for a
variety of abdominal disorders, demonstrated inter-observer agreement between three
radiologists on the presence and severity of hepatic steatosis, of 0.40-0.51 and intra-observer
agreement of 0.58 (moderate agreement)(88). In both studies, the assessment of the severity
of steatosis was based on the presence and severity of increased echogenicity of the hepatic
parenchyma and attenuation of the ultrasound beam. Neither study was carried out in people
with Type 2 diabetes, in whom one might conjecture rates of obesity would be higher than in
the general population.
A valid inference from the above data is that studies employing ultrasound imaging in the
diagnosis of hepatic steatosis should validate their ultrasound measure. This, however, has
not been commonly carried out.
5.1.2 MRS in the measurement of hepatic steatosis
In comparison to USS, MRS, the non-invasive gold standard for measurement of hepatic fat,
is expensive but has a high correlation with liver fat concentration on biopsy, of the order of
0.7 - 0.9(70;7l). Different "norma!" values for hepatic FF on magnetic resonance imaging
have been reported previously(63;73;74). The Dallas Heart Study used MRS to determine
hepatic FF in a population of 345 participants who had normal BMl, glucose tolerance and
LFTs and non-excessive alcohol use (i.e. a very low risk for developing hepatic steatosis). In
this group the 95lh percentile of hepatic triglyceride content (expressed as grams triglyceride
per 100 grams wet liver tissue) was 5.5%, corresponding to an MR FF of 6.1 %(70), and this
was taken as the upper limit of normal(63). In an earlier smaller study, 28 healthy volunteers
underwent MR scanning by a modified Dixon gradient echo technique. All had a MR hepatic
FF under 9% and this was later considered as being the upper limit of normal(73;74). In the
same study seven subjects with cystic fibrosis underwent both MRI scanning and liver
biopsy: two subjects with no steatosis on biopsy had a FF on MRI of < 9%; five subjects
with mild to severe steatosis had a FF of> 9%.
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No study has compared qualitative ultrasound gradings with FF on MRS. This is particularly
relevant as there are theoretical advantages of MRS over biopsy in terms of the higher
proportion of liver sampled and possible reduction in inter-observer variability.
5.1.3 Study aims
The aims of the present study were to compare ultrasound gradings of hepatic steatosis,
performed by three graders, with hepatic FF on MRS and also to examine inter- and intra-




The selection of subjects for the Edinburgh Type 2 Diabetes Study has been described in
detail in Chapter 4. A total of 939 participants attended for liver assessment by liver
ultrasound examination (USSi) at a specially set up research clinic. All ultrasound
examinations were performed after a four-hour fast by a single ultrasonographer (Grader l),
using a Sonoline Elegra Ultrasound Imaging System (Sieman's Medical Systems Inc,
Washington, USA), software version 6, with a 3.5 MHz transducer. The appropriate pre-set
("medium" or "large" abdomen) was chosen for each subject according to the
ultrasonographer's judgement - these pre-sets remained constant throughout the study.
Participants were scanned raised at an angle of 30-40° onto their left side. Right lobe images
were subcostal or intercostal depending on the body habitus of the participant; left lobe
images were obtained in the midline of the abdomen. The following images were obtained:
longitudinal images of the right lobe and caudate lobe with inferior vena cava, right lobe
with the portal vein, right lobe in the mid-clavicular line, right lobe of liver with kidney (at
least two images) for comparison, right lobe close to the diaphragm and left lobe in its
midline; transverse images of the right lobe at the level of the hepatic veins entering the
inferior vena cave and at the level of the main portal vein, the right lobe close to the
diaphragm, the right lobe at the level of the right portal vein and /or right hepatic vein, the
right lobe of liver with kidney for comparison and the left lobe at the level of the left hepatic
vein and/or left portal vein. The liver was graded for evidence of hepatic steatosis using
accepted criteria including a bright hepatic echo pattern (compared with the right kidney),
increased attenuation of the echo beam (impaired visualisation of the diaphragm or
intrahepatic vessels) and the presence of focal fatty sparing(l 6;80-83). Participants were
given an overall liver grading based on a subjective measurement of the severity of
steatosis: normal, indeterminate (i.e. possible slight increase in echogenicity or slightly
impaired visualisation of the diaphragm or intrahepatic vessels, or difficulty in grading as a
result of a diseased or absent right kidney); mild steatosis (i.e. definite increase in
echogenicity and/or definite impaired visualisation of the intrahepatic vessels and
diaphragm, no or little evidence of focal fatty sparing); severe steatosis (i.e. marked increase
in echogenicity and/or poor or no visualisation of the diaphragm and intrahepatic vessels,
with or without focal fatty sparing).
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5.2.2 MRS Subgroup: participant selection
A subgroup of participants from the cohort described above were selected to have MRS. 20
participants were selected at random into each of three groups on the basis of their USS]
grading: normal (with normal biochemical tests of liver function); indeterminate or mild
steatosis (a pre-determined merging of these two gradings into one group); and severe
steatosis. In addition, those with steatosis were selected following exclusion of a secondary
cause (excess alcohol intake, hepatotoxic medication use, viral hepatitis or autoimmune
hepatitis) and therefore had NAFLD. Other exclusion criteria were maximal diameter over
60 cm (in order to fit the dimensions of the scanner) and contraindications to magnetic
resonance imaging. One participant who did not tolerate the procedure was replaced by
another participant who had the same grading classification. MRS measurements were
unsuccessful in two participants and therefore 58 participants who attended for imaging had
successful FF measurements.
5.2.3 MRS subgroup: study protocol
At the MRS visit, participants underwent a repeat ultrasound scan (USS2), using the above
protocol, 2 hours prior to MRS. This measurement was made to ensure that the ultrasound
grading reflected the presence or absence of steatosis in the liver at the time of MRS.
The MRS examination was performed using a 1.5T HDX scanner (GE Healthcare,
Amersham, UK) and consisted of a PRESS-localised volume of interest (VOI) of dimensions
30 x 30 x 30 mm. placed away from vascular structures. The scanner's body coil was used
for transmission and reception. A repetition time (TR) of 5 s allowed substantial T1
relaxation of the signals, and a short (40 ms) echo time (TE) was used to minimise T2 decay.
Automatic shimming achieved a water linewidth of typically 11 Hz. Sixteen acquisitions
were averaged. Water-suppressed spectra (64 acquisitions) were also collected but are not
reported here. The MRS data files were transferred from the scanner to a computer
workstation for analysis. Quantification consisted of normalisation for scanner transmit and
receive gains and actual VOI volume, followed by modelling of the water and fat peaks
using the MRUI package (www.mrui.uab.es). FF was defined as the ratio of the area under
the fat peak to the combined areas under the water and fat peaks.
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5.2.4 Intra- and Inter-observer Variability
Sixty participants from the MRS subgroup had USS2, and 71 participants from the initial
cohort had USS|, graded by three independent graders using the four-point grading system
outlined above (normal, indeterminate, mild steatosis and severe steatosis). The 71
participants from the initial cohort represented all who were scanned during a particular
calendar month. The three graders comprised the sonographer who performed the scans
(grader 1, 15 years scanning experience), a consultant radiologist (grader 2, 12 years
scanning experience) and a medical trainee in radiology (grader 3, 2.5 years scanning
experience). Grader 1 scored images at the time of acquisition; still images from the scans
were recorded and saved for examination by graders 2 and 3. The three graders were blinded
to each other's gradings and to the MRS result. All graders were unaware of the clinical and
laboratory results of the participants.
After an interval of at least two months, each of the three graders re-graded the still images
from the 60 USS2 scans, in a blinded fashion, to allow assessment of intra-observer
variability. Inter-observer variability in these re-gradings was also examined, as this was the
only instance when all three graders were grading from still images.
5.2.5 Statistical Analysis
Median and inter-quartile ranges of FF on MRS were calculated in each group according to
ultrasound gradings. The Kruskal Wallis test was used to compare FF between all three
groups, and the Mann-Whitney test was used for post-hoc comparisons between pairs of
groups. Sensitivity and specificity of the USS2 gradings were determined with reference to
MRS data, using two separate cut-offs of FF to define "normality"- 9% and 6.1%(63;70;74).
The results of sensitivity and specificity analysis for Grader 1 were later adjusted to take into
account the proportion of subjects in the entire cohort receiving each grading. Inter- and
intra-observer variability were analysed using the marginal homogeneity test. Data were
analysed using SPSS version 14.0.
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5.3 Results
5.3.1 MRS Subgroup: comparison of hepatic FF between participants grouped
according to ultrasound grading
All 58 subjects with spectroscopy measurements had USS2 graded by three graders; the
number of participants put into each category for each grader is noted below in Table 5.1.
For Grader l, median MRS FF was 4.2% (interquartile (IQ) range 1.2 - 5.7%) in the group
graded normal, 4.1% (IQ range 3.1 - 8.5%) in the group graded indeterminate/mildly
steatotic and 19.4% (IQ range 12.9 - 27.5%) in the group graded severely steatotic (Figure
5.1). As shown in Figure 5.1, there were two outliers in the indeterminate/mildly steatotic
group, both with a FF on MRS of over 30%. There was a significant difference in median FF
between the three groups (p < 0.001). The group with severe steatosis had significantly
higher FF than either the normal (p < 0.001) or the indeterminate/mild steatosis groups (p <
0.001). There was no significant difference in FF between the normal and indeterminate/mild
steatosis groups. Results were similar for the gradings of the other two graders (Table 5.Q.
Table 5.1
Median (interquartile range) FF on MRS for each of three groups of gradings on
USS (normal, indeterminate/mildly steatotic, severely steatotic) as performed by
three graders. The number (N) of participants placed in each group by each grader
is also noted.
Normal Indeterminate/mild Severe


















* significant difference in FF between the normal, indeterminate/mild and severe
groups (p < 0.001)
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Figure 5.1
Boxplot showing median percentage fat on MR spectroscopy in each of three
groups of ultrasound gradings by Grader 1 (normal, indeterminate/mild steatosis,
severe steatosis). Upper and lower ends of rectangles correspond to 75th and 25th
centiles respectively. Whiskers represent maximum and minimum values. Outliers in
the indeterminate/mild steatosis group are marked by ".The group with severe
steatosis had a significantly higher median FF than those with normal or




5.3.2 MRS subgroup: diagnostic utility of ultrasound gradings compared with
MRS FF
For Grader 1, all 17 subjects in the group who were graded as normal on USS2 had a FF less
than 9%, and 14 of these subjects had a FF less than 6.1%. In the indeterminate/ mildly
steatotic ultrasound group, 16 subjects had a FF less than 9% and, of these subjects, 10 had a
FF under 6.1%. In the severely steatotic group, all but one participant had a FF of greater
than 9%, with the remaining subject having a FF of 8.45%. Results for the other two graders
were similar and are shown in Table 5.2.
Table 5.2
Comparison of ultrasound gradings with proposed cut-offs of "normality" of FF on
MRS - < 6.1% and 9%(63;73)
Grading ► Normal Indet/mild Severe
Grader ► 1 2 3 1 2 3 1 2 3
Total no. participants 17 16 26 19 20 14 22 22 18
MRS cut-off <9% 17 16 23 16 17 10 1 2 2
9% >9% 0 0 3 3 3 4 21 20 16
MRS cut-off <6.1% 14 14 19 13 13 7 0 0 1
6.1% >6.1% 3 2 7 6 7 7 22 22 18
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Sensitivity and specificity were calculated with both MRS FF cut-offs and results, with 95%
confidence intervals, are presented in Table 5.3. For Grader 1 using a liver FF of >9% on
MRS to denote hepatic steatosis, sensitivity of ultrasound in detecting
indeterminate/mi Id/severe steatosis was 100% and specificity was 50.0%. If those graded
indeterminate/mild steatosis were instead grouped with those graded normal (in view of the
similar median MRS FF in these groups) sensitivity was 87.5% and specificity 97.1%. When
a liver FF of >6.1% was used to define hepatic steatosis, sensitivity of ultrasound in
detecting indeterminate/mild/severe steatosis was 90.3% and specificity was 51.9%. When
those with indeterminate/mild steatosis were grouped with those graded normal, sensitivity
was 71.0% and specificity 100%. Results were extremely similar for grader 2. For grader 3,
sensitivity in detecting indeterminate/mild/severe steatosis was lower (87.0% and 78.1% for
the 9% and 6.1% cut-offs respectively) but specificity was higher (65.7% and 57.6% for the
9% and 6.1% cut-offs respectively).
Since sensitivity and specificity of a test can be affected by the prevalence of the underlying
condition (and in our study, subjects were selected according to presence of the condition on
USS, thereby pre-determining the prevalence), the results of Grader 1 were adjusted to take
account of the proportion of subjects in the entire cohort of 939 subjects who received each
grading (24% normal, 19% indeterminate/mild steatosis, 57% severe steatosis). The results
were not substantially different from the unadjusted data (Table 5.3).
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Table 5.3
Sensitivity and specificity of ultrasound in identifying presence of hepatic steatosis,
using two cut-offs of hepatic FF on MRS (<9% and <6.1%). Data are shown for the
grouping of the indeterminate/mild steatosis group with either the normal or the
severe steatosis groups. Both unadjusted values and those that have been adjusted
to take account of the proportion of each grading in the entire study cohort are



























































5.3.3 Inter- and intra-observer variability
Inter-observer variability was determined in a group of 131 participants, comprising the 60
subjects in the MRS subgroup and scans from a further 71 subjects from the original cohort.
Calculation of inter-observer agreement between the three graders revealed exact consensus
in 51% (67/131 given the same grade). Inter-observer agreement within one grade was seen
in 79% of cases (104/131). Inter-observer variation of 2 grades was seen in 17% (22/131)
and variation of 3 grades was seen in 4% (5/131). On pairwise analysis, there was no
significant variation in the gradings of Graders 1 and 2 (68 % exact consensus), or between
those ofGraders 2 and 3 (65% exact consensus). When the gradings of Graders 1 and 3 were
compared, however, there was found to be significant variation (disparity in 41% of results,
p = 0.024).
When the 71 subjects from the original cohort were examined separately, there was no
significant variation between gradings from different graders. In contrast, there was
significant variation between the gradings of the 60 participants in the MRS subgroup
between Graders 1 and 3 (p = 0.005), and Graders 2 and 3 (p = 0.01 1).
For the 60 participants in MRS group, inter-observer analysis was repeated using the three
graders' second grading, so that all three graders were using still images for grading
purposes. Exact consensus was achieved in 57% (34/60 given the same grade). Inter-
observer agreement within one grade was seen in 68% (41/60). Inter-observer variation of 2
grades was seen in 25% (15/60) and variation of 3 grades was seen in 7% (4/60). On
pairwise analysis, variability between gradings was similar to that seen for the cohort as a
whole (71% exact consensus between Graders 1 and 2; 65% exact consensus between
Graders 2 and 3; and 60% exact consensus between Graders 1 and 3).
Intra-observer variation was minimal for Graders 1 and 2 (87% and 77% exact concordance
between the Is1 and 2nd readings respectively), but statistically significant for Grader 3, with
38% disparity between readings, p = 0.039).
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5.4 Discussion
To my knowledge this is the first study to examine both the relationship between ultrasound
gradings of steatosis and MRS, and the inter- and intra-observer agreement in ultrasound
grading. The present study was broad in its scope, including both participants who were
likely to have a normal liver and those considered to have varying degrees of hepatic
steatosis, mainly NAFLD. In addition, the use of ultrasound has been examined in
diagnosing hepatic steatosis in people with Type 2 diabetes, a population who are at high
risk of developing hepatic steatosis, and in whom screening for the condition may be
considered.
5.4.1 MRS as gold standard: comparison of methodologies
The current study has relied on MRS as the non-invasive gold standard (against which our
ultrasound measure has been validated) and has utilised data from previous studies, in
particular the Dallas Heart Study(63), in order to define "normal" values for hepatic
triglyceride content. This necessitates justification of the MRS protocol used in the present
study, and comparison between this and the protocol used in the Dallas Heart Study. The
main aspects of scanning methodology are listed in Table 5.4.
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Table 5.4
Comparison of MRS scanning methodologies in the ET2DS and the Dallas Heart Study.




VOl 3x3x3 cm 3x3x3 cm
TR 5 seconds 3 seconds
TE 40 milliseconds 25 milliseconds
Measurement
reported
Fat fraction - ratio of methylene
to combined methylene and
water signals
Hepatic triglyceride
concentration - ratio of
methylene to combined
methylene and water signals,
expressed as weight percent
(g triglyceride per 100 g wet
liver tissue)
T, Tesla; VOl, volume of interest; TR, repetition time; TE, echo time
In the ET2DS, the magnetic field strength capacity of the scanner available was 1.5T and this
has been similar in other studies including the Dallas Heart Study(63;283;284). The use of a
higher field strength (e.g. 3T) would have been theoretically associated with the advantage of
a higher signal-to-noise ratio(285), but this higher signal-to-noise ratio is not always
achievable, and in the case of fat and water spectroscopy does not represent a significant
benefit. Longer repetition times (> 2 seconds) and shorter echo times have been shown to
improve spectral quality: the longer repetition time in the ET2DS (compared to the Dallas
Heart Study and other MRS studies) meant that correction for relaxation effects was
unnecessary; the echo times used in the ET2DS and Dallas Heart Study were comparable,
and other studies have quoted echo times of 10 - 135 milliseconds(283;284). Although the
final data reported in the two studies were different (fat fraction in the ET2DS; hepatic
triglyceride concentration in the Dallas Heart Study) both studies initially calculated a ratio
of fat to combined fat and water signals, with the Dallas Heart study then going on to express
this in tenns of weight percent of wet liver tissue. It is therefore valid to use the algebraic
equations adopted in this study(70) to transform their cut-point for normal hepatic
116
triglyceride content back to hepatic fat fraction for comparison with the data obtained in the
ET2DS.
5.4.2 Comparison of USS gradings with MRS
When compared to MRS, a normal ultrasound grading was an excellent predictor of a normal
hepatic FF, and a severe steatosis grading was an excellent predictor of the presence of
hepatic steatosis. The grading of a mildly steatotic liver was less secure, and in particular
considerable overlap in hepatic FF was evident compared with those who had a normal liver
on ultrasound. It is therefore reasonable to suppose that those graded indeterminate/mild
steatosis had subtle changes on ultrasound that were within the limits of normality. An
alternative explanation is that the relatively bright liver seen in the "mild steatosis" group is
indicative of another pathology, such as inflammation or fibrosis. It is notable that two
subjects with very high FF were graded indeterminate/mild steatosis and, in grouping these
participants with the normal group, the diagnosis of steatosis would have been missed. In
clinical practice, a grading of indeterminate/mild steatosis should be interpreted in
conjunction with clinical and biochemical factors, and it may be appropriate to repeat the
ultrasound scan after an interval of time. The performance of the three graders was similar
when gradings were compared to MRS. It should be emphasised that USS images were
obtained within hours of MRS measurements to ensure that they were truly comparable, as
hepatic steatosis can vary over time.
Individuals were pre-selected into the MRS subgroup based on their USS| gradings, with the
intention of having broadly equal numbers of participants in each of three groups. It was
acknowledged that the proportion in each group was different to the proportion of each grade
in the entire cohort, as graded by Grader 1. Adjusted figures were therefore provided for
comparison, with the assumption that if the number of subjects in each USS grading group
had been selected according to overall proportion in the total cohort, then the proportion of
subjects in each group testing below and above the cut-offs of MRS FF would have stayed
the same
No accepted definition of "normal" FF on MRS currently exists. Biopsy data from normal
livers and MRS FF have rarely been compared. Furthermore, studies looking at "healthy"
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volunteers may be skewed by the presence of overweight individuals or those who drink
alcohol in amounts greater than 14 units/week - both of which are known to predispose to
hepatic steatosis. It seems likely that the proposed figure of 6.1% (corresponding to 5.5%
hepatic triglyceride content, if expressed as grams triglyceride per 100 grams wet liver
tissue) for the upper limit of normal is the most accurate available, as this was calculated
using a population from which those with risk factors for steatosis, such as BMI > 25 kg/m2,
glucose intolerance and excessive alcohol use had been excluded(63).
It is acknowledged that MRS gives information regarding FF within a portion of the liver
rather than in the liver as a whole, and that it was theoretically possible that participants with
focal fatty change could be misclassified as a result. In this study, however, the volume of
interest for MRS was fairly large in order to minimise any effects of local heterogeneity.
Indeed, examination of MRS data from the 15 participants with focal fatty sparing on USS
revealed FF that were in keeping with their overall ultrasound grading (data not shown).
5.4.3 Intra-and inter-observer variation in USS gradings
Comparison of the gradings by three experienced graders revealed some variation, but exact
concordance in a majority of cases, with most differences being small (one-point only);
intra-observer concordance was high in two of three graders, but was lower for the grader
with the least experience (a medical trainee in radiology). Comparison of rates of consensus
between the graders did not reveal consistently better results when all three graders used still
images for grading purposes (as compared with Grader 1 grading dynamic images at the time
of image acquisition and Graders 2 and 3 grading from still recorded images). Of the two
previous studies to examine inter- and intra-observer variability, one was a small study
whose scope was limited to patients with abnonnal biochemical LFTs and biopsy-proven
NAFLD(80). The other was more comparable in size and scope to the present study, but
results cannot be directly compared due to different statistical methods used. The present
study compared gradings from graders with different training (a sonographer, a senior
consultant radiologist and a medical trainee in radiology). This is reflective of clinical
practice and is particularly relevant at a time when increasing numbers of ultrasound scans
are being performed by experienced sonographers both clinically and within research
studies.
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5.4.4 Limitations of the study
Participants in the MRS sub-study were necessarily less than 60 cm in maximal diameter so
excluding people with very severe obesity. It is widely acknowledged that ultrasound is more
difficult in the most obese patients and it could be anticipated that accuracy (compared to
MRS) and inter-/intra-observer concordance would be less in this population. It is, however,
important to note that inter-observer variation in the MRS sub-group was not superior to that
of the essentially randomly selected group from this general study population.
It is acknowledged that USS gradings were compared with the non-invasive gold standard
(MRS) rather than the "true1' gold standard (biopsy). Biopsy would have been neither
feasible nor ethical in this essentially healthy study population. In addition MRS may have
an advantage in terms of proportion of the liver sampled.
5.4.5 Conclusions
In conclusion, hepatic ultrasound provides a good measure of the presence of hepatic
steatosis, and in particular a nonnal grading and severe steatosis grading were respectively
excellent predictors of a normal and high MRS FF. Hepatic ultrasound has advantages over
other measures of hepatic fat in its ease of use and lack of adverse side-effects and is likely
to remain a mainstay of investigation, both in research and clinical situations.
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Chapter 6
Analysis 2: Prevalence and clinical correlates of hepatic
steatosis and NAFLD in Type 2 diabetes
6.1 Introduction
6.1.1 Association of NAFLD and Type 2 diabetes
The relationships between NAFLD and Type 2 diabetes are well established, and have been
discussed extensively in Chapter 2 of this thesis. In addition to the recognised cross-sectional
associations(63;92;95), NAFLD has been implicated in the pathogenesis of Type 2
diabetes( 157; 158; 161; 162) and, conversely, diabetes has been shown to be a risk factor for
the progression of NAFLD to more advanced liver disease including fibrosis, cirrhosis and
FICC(99;209;210). Furthermore, data suggest that some classes of anti-diabetic agents
(including thiazolidinediones and incretin mimetics) may be beneficial in ameliorating
NAFLD(217;286;287).
6.1.2 Prevalence of NAFLD in populations of people with Type 2 diabetes
Despite the recognised association between type 2 diabetes and NAFLD, few large-scale
studies of the prevalence of NAFLD in unselected populations of people with Type 2
diabetes are available. Studies estimating the prevalence using liver ultrasound have been
performed in secondary care rather than community setting and have generally examined
small numbers of patients(170;171). A large study in Italian outpatients with type 2 diabetes
reported that 85% had hepatic steatosis and that 70% met the criteria for NAFLD (defined in
that study as hepatic steatosis without evidence of excess alcohol consumption, viral
hepatitis, or causative medications)(l 8). This study, however, was confined to patients
attending a hospital clinic and also failed to systematically identify and exclude participants
with less common causes of liver disease such as autoimmune hepatitis. Furthermore,
ultrasound measurements were not compared with a gold standard in the population studied,
an important factor given the variable sensitivity and specificity of ultrasound assessment for
hepatic steatosis as reviewed in Chapter 1.
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6.1.3 Clinical associations of NAFLD
The cross-sectional relationship between NAFLD and features of the metabolic syndrome,
including insulin resistance, (central) obesity and dyslipidaemia has been well documented
within the general population(l9;20;63;93;l30;l43;144;149). The correlations have,
however, been less frequently examined in populations of people with Type 2 diabetes. In
the Italian study quoted above, there were univariate associations between NAFLD and
higher age, BMI, duration of diabetes, FlbAlc, triglyceride levels and blood pressure, and an
inverse relationship between NAFLD and HDL cholesterol levels, but multivariate analysis
was not undertaken(l 8). In contrast, in a smaller study within a Saudi diabetes department,
no significant correlation was found between the presence of NAFLD and duration of
diabetes or glycaemic control(l 71).
6.1.4 Utility of liver enzymes in screening for hepatic steatosis and NAFLD
Screening for liver disease in Type 2 diabetes typically involves measuring circulating levels
of liver enzymes that have been released from damaged hepatocytes. ALT and, to a lesser
extent, GGT have been used as a surrogate markers of NAFLD(89;90), but the diagnostic
utility of these measures within the general population has been questioned(63;92;93). There
are, however, few analyses that have formally examined the diagnostic accuracy of ALT. In
one study, using the laboratory cut-off of 39 units/I to denote an abnormal ALT level, and
comparing with ultrasound findings of steatosis, the sensitivity and specificity were found to
be 8.2% and 98% respectively(93). The use of a lower ALT cut-off of 19.5 units/I, derived
from a ROC curve, gave sensitivity of 72% and specificity of 60%. In another study, in
which the estimated prevalence of hepatic steatosis was estimated to be around 60%, the
PPV of a high ALT level in predicting the presence of steatosis on ultrasonography was
calculated to be 78%(94).
Laboratory reference ranges for liver enzymes rely upon historical data generated from
general populations that may have included people with covert liver disease (particularly
undiagnosed NAFLD). Thus, the upper part of the traditional ALT reference range may
reflect values that are more typical of liver disorder than of normality. As a result, new
reference ranges have been derived that are based on data from an Italian population at low
risk for liver disease (no medication use and normal BMI, lipid profile and glucose); the
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upper limit of normal (95th percentile) of ALT in this group was 30 units/1 in men and 19
units/1 in women(91). These more stringent cut-offs have not, however, been widely adopted.
6.1.5 Study Aim
Given the rising incidence and prevalence of type 2 diabetes, an accurate estimate of the
prevalence ofNAFLD, is important to predict the number of patients who will require to be
monitored for more advanced liver disease or who may benefit from future disease-
modifying agents. Accurate determination of the (routinely-measured) clinical correlates of
NAFLD may aid identification of those patients who should undergo screening for the
condition. There is, however, justifiable concern that the current screening tool for liver
disease in Type 2 diabetes (hepatic enzymes) may be inadequate for the task of identifying
individuals with hepatic steatosis and NAFLD, but its accuracy has not been formally
examined in the context of Type 2 diabetes.
The aim of the present study was to determine the prevalence of hepatic steatosis and
NAFLD in a large randomly-selected population of older people with type 2 diabetes, using
MRS to confirm ultrasound grading classifications and thorough screening for secondary
causes of liver disease, and to examine their correlation with clinical and biochemical
characteristics. In addition, the relationship of hepatic steatosis with standard tests of liver
function, using both traditional and newly suggested reference ranges above for ALT, was to




The recruitment and baseline examination of subjects for the Edinburgh Type 2 Diabetes
Study has been described in Chapter 4. Briefly, subjects recorded as having type 2 diabetes
and aged 60-74 years, were selected at random by sex and 5-year age bands in years 2006—
2007 from the Lothian Diabetes Register, a comprehensive database of people with type 2
diabetes living in Lothian. The study population therefore includes both patients attending a
hospital clinic and those managed solely in primary care. Study participants (n= 1066) have
been shown previously to be representative, in terms of age, HbAlc, duration of diabetes,
insulin treatment and total cholesterol, of all those randomly selected to participate (n=5454)
and therefore of the target population of older men and women with type 2 diabetes living in
the general population(282). At the time of recruitment into the study, participants attended a
baseline examination which included measurement of demographic and anthropometric
variables (age, gender, BMI, WC), platelets and HA. One year after baseline examination,
939 participants (out of the 1054 invited) attended a Year 1 clinic for assessment of liver
structure and function.
6.2.2 Ultrasound Examination and Comparison with MRS
Subjects attended the year 1 research clinic after a 4-hour fast for an ultrasound examination
of abdomen.
All ultrasound examinations were performed by a single ultrasonographer, who was unaware
of the clinical and laboratory results of the participants, using a Sonoline Elegra Ultrasound
Imaging System (Sieman's Medical Systems Inc, Washington, USA), software version 6,
with a 3.5 MHz transducer. The liver was graded for markers of hepatic steatosis using
established criteria(l 6;84;85) including a bright hepatic echo pattern (compared with the
echo response of the right kidney), increased attenuation of the echo beam and the presence
of focal fatty sparing. Participants were given an overall liver grading based on a subjective
measurement of the severity of steatosis: Grade 0 (normal appearance of liver on ultrasound,
and initially graded as a "normal ultrasound"), Grade 1 (possible slight increase in
echogenicity or slightly impaired visualisation of the diaphragm or intrahepatic vessels, or
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difficulty in grading as a result of a diseased or absent right kidney - initially termed an
"indeterminate ultrasound"); Grade 2 (definite increase in echogenicity and/or definite
impaired visualisation of the intrahepatic vessels and diaphragm, no or little evidence of
focal fatty sparing, initially graded as "evidence of mild steatosis on ultrasound"); Grade 3
(marked increase in echogenicity and/or poor or no visualisation of the diaphragm and
intrahepatic vessels, with or without focal fatty sparing, initially graded as "evidence of
severe steatosis on ultrasound"). Evidence of hepatic cirrhosis was also sought
systematically.
Comparison of the ultrasound gradings for hepatic steatosis with ]H MRS, the non-invasive
gold standard for quantification of hepatic fat, in a subgroup of 58 participants was described
in detail in Chapter 5. In brief, 17 participants with a Grade 0 ultrasound grading, 19 with
Grade 1 or 2 grading and 22 graded as Grade 3 underwent MRS. A Grade 0 grading on
ultrasound was associated with a "normal" hepatic FF on MRS of < 6.1 %(63;70) in 14/17
cases (and a FF of < 9%(73;74) in all cases) and was accepted as "no steatosis". A grading of
Grade 3 on ultrasound was associated with and MRS hepatic FF > 6.1% in all cases and this
was therefore taken as "definite steatosis". The group with Grade 1 or 2 on ultrasound had an
MRS FF of < 6.1% in 13/19 cases, and a FF of < 9% in 16/19 cases, thus displaying
considerable overlap with those regarded as normal. In view of this the group with Grade 1
or 2 on ultrasound scan were considered to have a "probable normal" scan. If a liver FF of
>6.1% on MRS was used to denote hepatic steatosis, sensitivity, specificity, positive and
negative predictive values (adjusted for the portion of the whole study cohort receiving each
grading) of ultrasound in detecting "definite steatosis" were 86.8%, 100%, 100% and 80.0%
respectively.
6.2.3 Clinical Examination
Average alcohol intake per week over the previous year, a history of alcohol excess and use
of hepatotoxic medications within the previous six months were determined by
questionnaire. Average alcohol intake was determined using two questions adapted from the
AUDIT-C screening tool(288): "How often did you have a drink containing alcohol in the
past year? Consider a "drink" to be a can or bottle of beer, a glass of wine, or one cocktail or
a measure of spirits (like scotch, gin or vodka)." (A drink was considered to be the
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equivalent of one unit of alcohol); and "How many drinks did you have on a typical day
when you were drinking in the last year?*'.
All subjects underwent venepuncture for LFTs (bilirubin, ALT, AST, AlkP and GGT),
HbAlc and a lipid profile. Those participants with evidence of hepatic steatosis or abnormal
blood tests of liver function had further investigations performed including serology for
Hepatitis B and C, anti-nuclear antibody (ANA), anti-smooth muscle antibody, anti-
mitochondrial antibody and ferritin. Brachial blood pressure (BP) was measured in all.
Information on previous diagnoses of chronic liver disease was collected from participants
by questionnaire at Year 1, and supplemented using data on liver diagnoses which had been
obtained at baseline via record linkage to hospital discharges at the Information and Services
Division (ISD) ofNHS Scotland.
6.2.4 Definition of NAFLD
NAFLD was defined as the presence of definite hepatic steatosis on ultrasound scan (i.e.
Grade 3) in the absence of a secondary cause for hepatic steatosis. Secondary causes were
defined as alcohol consumption > 14 units/week(l 0) or participant report of current/previous
alcohol excess, use of hepatotoxic medication(17) (glucocorticoids, isoniazid, methotrexate,
amiodarone and tamoxifen) within the six months prior to the Year 1 clinic, positive hepatitis
B or C serology, ferritin concentration > 1000 ug/1 (milder hyperferritinemia can be
associated with obesity, insulin resistance and NAFLD(17;289)), clinically significant
positive immunology titres (anti-smooth muscle antibody titre > 1:160(290) or anti-
mitochondrial antibody titre > 1:40(291)) or a previous diagnosis of a persistent secondary
cause for chronic liver disease. Subjects were considered to have a previous diagnosis of a
secondary cause for chronic liver disease if ISD linkage revealed such a diagnosis, or if a
participant report of a diagnosis was confirmed by their medical records. Subjects were
excluded from calculations on the prevalence ofNAFLD if data on the above measures were
missing such that a secondary cause could not be excluded.
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6.2.5 Definition of Metabolic Syndrome
As per Adult Treatment Panel III criteria(26), subjects were considered to have the metabolic
syndrome if, in addition to type 2 diabetes, they had at least two of the following: BP >
130/85 or on antihypertensive treatment; triglycerides > 1.7 mmol/1 or taking a fibrate; HDL
cholesterol < 1.04 mmol/1 (men) or 1.29 mmol/1 (women); WC > 102 cm (men) or 88 cm
(women).
6.2.6 Statistical Analysis
Analysis was performed using SPSS software version 14.0. Data that did not conform to the
normal distribution (duration of diabetes, triglycerides and GGT) were log-transformed prior
to parametric analysis. Statistical analysis included the independent t-test, chi-squared test
and one-way ANOVA to compare characteristics between groups. Levels of statistical
significance were reported as p < 0.05 and, following Bonferroni correction, p < 0.003.
Binary logistic regression analysis was used to assess the independence of variables in their
association with hepatic steatosis and NAFLD. Variables included in this model were age,
gender, BMI, duration of diabetes, HbAlC, systolic BP, HDL and LDL cholesterol,
triglycerides and the use of metformin, sulphonylureas, thiazolidinediones, incretin mimetics
and insulin. Alcohol use > 14 units/week or previous alcohol misuse was used as a
categorical variable in the model examining hepatic steatosis, but not that examining
NAFLD. Results were reported as estimated odds ratios (OR) and 95% confidence intervals
(CI). Sensitivity, specificity, positive and negative predictive values and ROC analysis were




The characteristics of participants attending the Year 1 clinic are shown in Table 6.1.
Baseline characteristics of subjects attending the Year 1 clinical examination were similar to
those of the total ET2DS population suggesting that the study population attending for liver
assessment remained representative of the target general population with type 2 diabetes.
Table 6.1
Characteristics of participants in the Year 1 liver clinic
Characteristic Year 1 (n=939)
Age (years) 68.9 ±4.2
Sex (% (n) male) 52.0 (488)
Race (% (n) Caucasian) 98.3 (923)
BMI- measured at baseline clinic (kg/m") 31.3 ±5.7
WC - measured at baseline clinic (cm) 106.7 ± 12.8
Duration of diabetes (years) 9.0 ±6.4
HbAlC (%) 7.19 ± 1.06
Diet-controlled (% (n)) 19.4(182)
Oral antidiabetic agent users (% (n)) 74.4 (699)
Insulin users (% (n)) 15.8(148)
Systolic blood pressure (mmHg) 138.1 ± 18.5
Diastolic blood pressure (mmHg) 74.1 ±9.6
Total cholesterol (mmol/l) 4.15 ± 0.81
High density lipoprotein cholesterol (mmol/l) 1.23 ±0.34
Low density lipoprotein cholesterol (mmol/l) 2.17 ± 0.68
Triglyceride (mmol/l) 1.66 ±0.90
Statin users (% (n)) 81.6 (767)
Aspirin users (% (n)) 67.7 (636)
Angiotensin converting enzyme inhibitor users (% (n)) 52.0 (488)
Current or ex-smokers (% (n)) 60.0 (563)
Data are mean ± standard deviation or proportions, in whole cohort of participants
unless stated.
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6.3.2 Prevalence of hepatic steatosis and NAFLD
Of the 939 subjects undergoing abdominal ultrasound, data on steatosis grading was
incomplete for 2 subjects and these were excluded from the analysis. Hepatic steatosis was
graded as definite (Grade 3) on ultrasound examination in 56.9% (n=533) of the remaining
participants. The appearance of the liver was normal (Grade 0) in 23.5% (n=220) of
participants. Twenty-two subjects (2.3%) were graded as Grade 1 (in 3 of these cases it was
commented that the liver was difficult to scan as it was located high up under the costal
margin) and a further 16.9% (n=158) were graded as Grade 2, giving a total of 180 subjects
(19.2%) who were classified as "probable normal". In addition, 0.4% subjects (n=4) had a
liver in which ultrasound identified cirrhosis - steatosis gradings in these subjects were
Grade 0 in two participants, Grade 1 in one participant and Grade 2 in one participant. These
findings are summarised in Figure 6.1.
Among those with evidence of definite hepatic steatosis (Grade 3), 123 subjects had
evidence of one or more secondary causes for steatosis: 78 had alcohol intake > 14
units/week or a history of excess; 40 had used a hepatotoxic medication, as outlined above,
in the previous 6 months; 1 each had serological evidence of hepatitis B and C; 3 had ferritin
levels > 1000 ug/1; 1 had anti-smooth muscle antibody titre > 1:160; 1 had anti-
mitochondrial antibody titre > 1:40; 7 had previously-diagnosed liver disease (2 alcoholic
liver disease, 1 haemachromatosis, 1 autoimmune hepatitis, 1 recurrent cholangitis, 1 biliary
cirrhosis, 1 hepatic carcinoid metastases). In a further 19 subjects data were missing such
that a secondary cause could not be excluded. In addition, a further 160 participants had at
least one positive immunology titre > 1:40, which were not considered significant. Of these,
most had borderline ANA or anti-smooth muscle titres (< 1:80; n = 120); 40 participants had
ANA titre > 1:160.
Using the pre-defined criteria, 391 out of 918 participants with a full dataset had definite
hepatic steatosis on ultrasound grading with no secondary cause, giving a prevalence of
NAFLD of 42.6% in this study population.
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Figure 6.1
Flow diagram showing the gradings of hepatic steatosis and cirrhosis on ultrasound scan, and diagnosis
6.3.3 Clinical and biochemical associations with hepatic steatosis and NAFLD
Physical and biochemical characteristics of study participants according to steatosis groups
are shown in Table 6.2 below. On univariate analysis, participants in the group with definite
steatosis (Grade 3) were significantly younger than the combined normal/probably normal
groups (Grades 0, I and 2, p < 0.003). BMI, WC, HbAlC, diastolic BP and triglycerides
were significantly higher, and HDL cholesterol significantly lower, in the definite steatosis
group. Metformin use was more common in the definite steatosis group. No significant
differences in the use of other anti-diabetic agents (sulphonylureas, glitazones, incretin
mimetics or insulin) were found. The higher prevalence of alcohol intake over 14 units per
week in the definite steatosis group was of borderline significance (p = 0.003).
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Table 6.2
Comparison of participant characteristics across gradings of steatosis









Age (years) 69.4 ±4.2 68.5 ±4.8 69.5 ±4.4 68.5 ±4.0"
Sex (% (n) male) 59.9(132) 40.9 (9) 49.4 (78) 50.1 (267)
BMI (baseline, kg/m2) 28.8 ± 5.18 35.1 ± 8.4 30.7 ±4.9 32.4 ±5.5"








Duration diabetes (years) 9.6 ±7.6 10.5 ±6.0 9.8 ±6.5 8.4 ±5.8*
HbAlC(%) 7.02 ± 0.97 7.15 ±0.93 6.99 ±0.98 7.33 ± 1.12"
Systolic BP (mmHg) 140 ±22 141 ±22 136 ± 19 138 ± 17
Diastolic BP (mmHg) 73.4 ±9.5 76.3 ±11.2 72.1 ± 9.5 74.9 ± 9.4*
Total cholesterol (mmol/l) 4.14 ± 0.81 4.53 ±0.81 4.01 ±0.75 4.17 ±0.82
HDL cholesterol (mmol/l) 1.28 ±0.69 1.16 ± 0.27 1.30 ±0.35 1.19 ±0.32"
LDL cholesterol (mmol/l) 2.24 ±0.70 2.57 ±0.72 2.08 ±0.65 2.14 ± 0.67
Triglyceride (mmol/l) 1.37 ±0.69 1.76 ±0.67 1.37 ±0.63 1.86 ± 1.00#
ALT (units/litre) 29.9 ± 10.8 26.8 ±7.1 30.4 ± 10.0 36.4 ± 14.3"
AST (units/litre) 28.0 ± 8.2 28.2 ±9.7 29.9 ±9.2 32.1 ± 11.6#
GGT (units/litre, median
(IQ range))













70.2 (153) 86.4 (19) 78.3 (123) 91.2 (485)"
Alcohol intake (% (n) over
14 units/week)
6.4 (14) 0.0 (0) 7.6(12) 12.9(69)*
Metformin use (% (n)) 48.2 (106) 50.0(11) 63.3 (100) 70.9 (378)"
* Significant difference Grade 3 vs Grade 0/1/2 by t-test or chi-squared test, p<0.05
#
Significant difference Grade 3 vs Grade 0/1/2 by t-test or chi-squared test, p<0.003
Data are mean ± standard deviation unless stated otherwise.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass
index BP, blood pressure; GGT, gamma-glutamyltransferase; HDL, high density
lipoprotein; IQ, interquartile; LDL, low density lipoprotein; WC, waist circumference
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In multivariate analysis, independent predictors of definite hepatic steatosis (compared with
those classed as normal/probable normal) on ultrasound scan were BMI (OR 1.07, CI 1.04,
1.10), lesser duration of diabetes (OR for log duration diabetes 0.53, CI 0.30, 0.92), HbAlC
(OR 1.35, CI 1.15, 1.59), triglycerides (OR for log triglycerides 20.76, CI 8.85, 50.85),
alcohol intake > 14 units/week (OR 3.13, CI 1.80, 5.43) and use of metformin (OR 2.19, CI
1.59,3.00).
Similar results were obtained when those with secondary causes for liver disease were
excluded from analysis. Independent predictors of NAFLD were BMI (OR 1.07, CI 1.03,
1.10), lesser duration of diabetes (OR for log duration diabetes 0.46, CI 0.25, 0.83), HbAlC
(OR 1.29, CI 1.08, 1.54), triglycerides (OR for log triglycerides 17.57, CI 6.68, 46.18) and
use of metformin (OR 2.25, CI 1.60, 3.17).
Of the 400 participants who had gradings of normal/probable normal liver parenchyma on
ultrasound scan, 74 had at least one of the following features suggestive of possible hepatic
fibrosis or cirrhosis: spleen size > 13 cm (16 participants); HA > 75 ng/ml (the upper end of
normal on the laboratory reference range) in the absence ofjoint disease (54 participants); or
platelet count < 150 x 109/1 (20 participants). If these participants were excluded from
regression analysis, independent predictors of definite steatosis and NAFLD were unchanged
(data not shown).
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6.3.4 Relationship of hepatic steatosis with liver enzymes
Levels ofALT, AST and GGT were significantly higher in participants with hepatic steatosis
compared with those with a normal liver on ultrasound. Mean values, however, remained
within normal limits and the significant majority of subjects with hepatic steatosis had LFT
values within the laboratory normal range, as is shown in Table 6.3.
Table 6.3
Comparison of LFTs between groups with hepatic steatosis and normal liver
Normal liver Hepatic steatosis
(Grade 0-2) (Grade 3)
N = 400 N = 533
ALT (units/I) 29.9 ± 10.3 36.4 ±14.3*
ALT >50 units/I (%) 3.4 12.0*
AST (units/l) 28.7 ±8.7 32.1 ± 11.6
AST >45 units/1 (%) 4.4 11.1*
GGT (units/1) 13 (8-22) 20(12-34)*
GGT >55 units/1 (%) 7.7 12.0#
Data are mean ± standard deviation or median (interquartile range) unless otherwise
stated. * p < 0.003 for comparison between groups; #p < 0.05 for comparison
between groups
Sensitivity, specificity, PPV and NPV were calculated for ALT (using both our laboratory
upper limit of normal, and the previously suggested upper limits of normal of 30 units/1 for
men and 19 units/1 for women(91)), AST and GGT. Results are shown in Table 6.4.
Lowering the cut-off that defines a positive ALT result improved the sensitivity of the test,
but at the expense of a significant reduction in specificity, and the NPV of a "normal" result
remained suboptimal. As is demonstrated on ROC curve analysis (Figure 6.2), there is no
one cut-off of ALT with high enough sensitivity and specificity to be used in clinical
practice. Combining baseline and Year 1 values for ALT, AST and GGT did not improve on
the performance of Year I values alone (data not shown).
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Table 6.4
Sensitivity, specificity, positive (PPV) and negative predictive values (NPV) of LFTs
in the diagnosis of hepatic steatosis. Cut-off values for a positive result are noted in
brackets.
Sensitivity Specificity PPV NPV




81.4(77.8-84.6) 36.2(31.6-41.1) 62.6 (58.9-66.2) 59.8 (53.3-65.9)
AST (45 units/I) 11.0(8.6-14.1) 95.6(93.0-97.3) 76.6 (65.3-85.2) 44.9 (41.6-48.3)
GGT (55 units/I) 12.0(9.4-15.1) 92.3 (89.2-94.7) 67.4 (56.9-76.4) 44.4 (41.0-47.8)
Figure 6.2
ROC curve examining the sensitivity and specificity of ALT in the diagnosis of




LFTs were also compared between Groups 0, 1 and 2 using the original grading system for
steatosis (Table 6.2). AST and GGT levels were statistically significantly higher in Group 2
(which contained participants who, on the original grading system, were felt to have changes
suggestive ofmild steatosis) than in Group 0 (the normal group), but these differences were
numerically small. There was no difference in ALT or hyaluronic acid levels.
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6.4 Discussion
This is the first study to examine the prevalence of hepatic steatosis and NAFLD in a
population of people with type 2 diabetes using an ultrasound classification that had been
refined by comparison with MRS and with detailed exclusion of secondary caused of
steatosis. The study population included the full clinical spectrum of type 2 diabetes and
included people who were being managed in the community as well as in hospital clinics.
6.4.1 Prevalence of hepatic steatosis and NAFLD: accuracy of diagnosis and
comparison with previous studies
Previous studies have estimated that a hepatic FF on MRS of under 6.1-9% is consistent
with a normal liver, whereas hepatic steatosis is associated with higher FF(63;70;73;74).
Comparison of our ultrasound gradings with MRS suggested that the "definite steatosis"
grading was an excellent predictor for the presence of hepatic steatosis. In contrast,
considerable overlap was observed between those graded initially as having "indeterminate"
or "mild" steatosis (Grade 1 or 2) and the normal group, and it was considered that these
participants probably had a normal liver. Our prevalence of hepatic steatosis, at 56.9%, was
therefore considerably lower than in previous studies including that of a large Italian
population of patients with type 2 diabetes, in which 85.3% were considered to have hepatic
steatosis(l 8). In view of these findings, caution should be used with regard to the
prevalences reported by previous studies that have used ultrasound measurements that have
been less rigorously examined for the diagnosis of hepatic steatosis.
NAFLD was the most common cause for steatosis, accounting for 76% of all cases. In
comparison to previous studies, our analysis had the advantage of a more systematic
identification and exclusion of secondary causes of liver disease in those with steatosis, both
by the use of ISD linkage to identify previously-diagnosed chronic liver disease and by the
routine measurement of autoantibody titres and ferritin in all participants with steatosis. The
use of these additional measures identified a further 12 subjects with a secondary cause for
hepatic steatosis, representing 2.3% of participants with steatosis and 1.3% of the study
population as a whole. The systemic identification and exclusion of subjects with any
possible secondary cause of steatosis from the diagnosis of NAFLD may have caused an
underestimation of the prevalence of NAFLD which may in some cases have been a co-
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existent patliology(22). It is recognised that the cut-offs used to define exclusions to the
diagnosis of NAFLD are, to some extent, arbitrary and the prevalence will depend upon the
precise definition used.
The majority of exclusions from the diagnosis of NAFLD were on the basis of excess
alcohol intake. It is recognised that estimation of alcohol consumption can be unreliable, and
in particular that subjects and investigators may underestimate intake. This, in turn, can lead
to over-estimation of the prevalence of NAFLD. The prevalence of alcohol intake > 14
units/week as a secondary cause for steatosis was relatively low in our study population
(14.6%) when compared to a similar age band in the general population of England, in which
the prevalence of alcohol intake > 21 units/week for men and > 14 units/week for women has
been quoted as 23% and 10% respectively(292). It is possible that this reflects genuinely
lower alcohol consumption in a frailer population in which use of multiple prescription
medications is not uncommon. It is, however, possible that underestimation of alcohol
consumption has played a role and interestingly, when participants in this study counted
number of alcoholic drinks consumed over the previous week alone, a further 24 participants
had intake > 14 units.
Subjects in this study were all aged 61 to 76 years at the time of examination, and were
predominantly Caucasian. Previous studies have shown that the prevalence of NAFLD
increases with age (although we did not find evidence of that within our age range) and
therefore it is possible that the prevalence of NAFLD in our study population was greater
than that of the general diabetic population. The results may be less applicable to populations
in other countries, particularly those in which the prevalence of other causes of liver disease
(such as viral hepatitis) is markedly different to that in the United Kingdom.
6.4.2 Clinical and biochemical correlates
It has previously been shown that NAFLD is associated with features of the metabolic
syndrome within the general population(6;19;29;150), and the same was true in this
population of people with type 2 diabetes. The association of a shorter duration of diabetes
with liver disease was in this study of borderline statistical significance, but has been
described before (although conversely, longer duration of diabetes has also been associated
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with NAFLD and more advanced liver disease(l 8;l 70)). One theory is that the greater
degree of hyperinsulinaemia in early type 2 diabetes drives uptake of FFA by hepatocytes.
Another possible explanation is that longer duration of diabetes is associated with hepatic
fibrosis and regression of steatosis thus giving a false negative on ultrasound scanning;
against this theory is the fact that duration of diabetes remained a significant inverse
predictor of hepatic steatosis and NAFLD after participants with any biochemical indication
of fibrosis were removed from the analysis. Similarly, the relationship of HbAlc to liver
disease has varied between studies, with a positive association on univariate analysis in
another large scale study in people with Type 2 diabetes but a negative result in another
smaller stndy( 171). Studies that have examined the relationship of HbAlc to progression of
NAFLD have found no association(167;173). Unexpectedly, the use of metformin was
associated with the presence of NAFLD, independently of BMI and glycemic control.
Previous studies of the use of metformin in NAFLD have shown a positive or neutral effect
in individuals(286), and it therefore seems unlikely that there is a causative link between
metformin use and NAFLD here. It is possible that those participants who were on
metformin had other risk factors for NAFLD that were not accounted for in the present
analysis, such as inflammatory markers. Furthermore, it is possible that results were
confounded by indication, i.e. participants may have been previously prescribed metformin
in an attempt to treat hepatic steatosis. Finally, it is possible that the significant association
between metformin and steatosis was a consequence of a type 1 statistical error.
Levels of significance were quoted for p values < 0.05 and < 0.003. This second value was
chosen following Bonferroni correction for the number of variables examined on univariate
analysis. It is recognised that using the more stringent cut-off will reduce the chance of false
positive associations, but at the expense of false negative results. This is especially true when
there is a plausible biological hypothesis to link the variables under scrutiny.
6.4.3 Utility of LFTs in the diagnosis of hepatic steatosis
Although ALT, AST and GGT levels were significantly higher in the group with definite
steatosis compared with the normal/probable normal group, mean values remained within the
normal range. This is in keeping with previous studies carried out within the general
population that have found the diagnostic accuracy of liver enzymes in predicting hepatic
steatosis to be low(93). A study performed since the above work was carried out, in a
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Brazilian population of patients within a tertiary referral centre for diabetes, produced very
similar results for a cut-off of ALT of 36 units/1 (sensitivity 52%, specificity 76%, PPV 81%
and NPV 41%). In the present study, even when the upper limit of normal of ALT was
reduced to lower previously-suggested levels the NPV remained low. There were no cut-off
values that discriminated between normal and steatotic livers and, importantly, low levels of
hepatic enzymes did not preclude overt hepatic abnormality demonstrated by
ultrasonography. To take account of intra-individual variation in LFT values, NPVs of
consistently normal LFTs were examined (i.e. in individuals who had "normal" values of
ALT, AST or GGT at both the baseline and Year 1 clinics); disappointingly this did not
improve on the ability of normal LFTs to predict a normal liver on ultrasound.
At present, liver screening in Type 2 diabetes is commonly carried out using conventional
LFTs and it is of concern that normal levels of liver transaminases and GGT are found in
almost 90% of those with hepatic steatosis, suggesting that most cases will not be identified
by current methods.
The results were mixed when levels of liver enzymes were compared between the "normal"
and "probable normal (originally "mild steatosis") groups, with statistically significantly
higher levels of AST and GGT, but not ALT or hyaluronic acid, in the "probable normal"
group. Consistent evidence that the "probable normal" group is a subgroup with liver disease
other than steatosis which is picked up on ultrasound (such as inflammation or fibrosis) is
therefore lacking.
6.4.4 Methodological limitations
One limitation of this study is that subjects did not have a liver biopsy and histological
examination, the gold standard technique for identifying steatosis; performance of this
invasive procedure would neither have been feasible nor ethical in a population study of this
magnitude. It was recognised that some participants with a normal USS could have
undiagnosed hepatic fibrosis and thus be at the severe end of the spectrum of NAFLD. Of
note, any misclassified cases would tend to underestimate the prevalence of NAFLD and
reduce rather than magnify any differences in clinical associations between groups.
Furthermore, re-analysis excluding those participants with a normal liver USS but other
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evidence of possible fibrosis revealed similar results to the main analysis. A further
limitation is that only approximately one fifth of patients invited to attend the baseline clinic
from the Lothian Diabetes Register did so. Significantly, however, analysis revealed that this
population was representative of that invited in terms of duration of diabetes, HbAlC and
treatment with insulin.
It is acknowledged that while data on most variables were gathered concomitantly with
hepatic ultrasound examination, BMI was calculated one year previously during the baseline
examination. It is therefore possible that the results of the regression analysis are less robust
than they would have been with fully contemporaneous data collection. It seems likely,
however, that changes in BMI over one year would in most cases be small and would be
unlikely to significantly affect the results of analysis.
6.4.5 Conclusions
In conclusion, in assessing the prevalence of NAFLD in people with type 2 diabetes, this
study has advantages of robust ultrasound gradings, systematic exclusion of other causes for
liver disease, and a relatively large, unselected population. In the future it is possible that the
association of liver disease with other features of the metabolic syndrome could be used to
target screening for NAFLD. Current screening methods that rely on liver enzyme
measurement alone are almost certainly inadequate. Further research is required to ascertain
whether the risk of progression of NAFLD to fibrosis and cirrhosis in patients with type 2
diabetes in the clinical setting is as high as that predicted - if so, this would provide further
impetus towards improved screening to aid early diagnosis so that people might be eligible
for entry into clinical trials, screening for complications and ultimately new therapies.
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Chapter 7
Analysis 3: Prevalence and markers of advanced liver
disease
7.1 Introduction
7.1.1 Prevalence of advanced NAFLD: relationship to Type 2 diabetes
NAFLD encompasses a spectrum of liver disease from simple steatosis to steatohepatitis,
fibrosis and, ultimately, cirrhosis. Cross-sectional data suggest that in populations of patients
with NAFLD the prevalence of advanced fibrosis (bridging fibrosis or cirrhosis) may be of
the order of 9 - 14%, with a higher proportion of the population having lower-grade
fibrosis(96; 174; 175). In longitudinal studies, it has been estimated that 8% of patients with
simple steatosis progress to hepatic fibrosis, with a higher proportion progressing when
steatohepatitis is evident at presentation(99;l81 ;293). These figures are, however, based on
biopsy results from highly-selected patient populations and there is little consensus on how
they might relate to patients in whom biopsy is not clinically justified. Although type 2
diabetes is an established risk factor for the progression of NAFLD(64;209), few studies
have examined the prevalence of advanced liver disease in this population. Existing evidence
is often indirect or has originated from small studies or those undertaken in highly selected
populations. In one population-based study, the risk of death from liver cirrhosis was 2.5
times higher in people with type 2 diabetes compared with the general population(211). In
another study of 132 patients with NAFLD (44 of whom had diabetes) who had undergone
liver biopsy in a tertiary referral centre, 25% of those with diabetes had cirrhosis, compared
to 10% of the non-diabetic cohort(67).
7.1.2 Non-invasive markers of advanced liver disease
Screening for liver disease in Type 2 diabetes generally involves the measurement of
standard LFTs alone. Not only are these tests insensitive markers of hepatic steatosis, as has
been described in detail in Chapters l and 6(63;96), but it has also been previously
demonstrated that the progression of NAFLD to fibrosis can occur without significant
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perturbation of liver enzymes(64;96). It has been suggested that lowering the upper limit of
normal of ALT to 30 units/1 in men and 19 units/1 in women may improve sensitivity of this
measure in detecting NAFLD(91), but this has not been widely adopted. It is therefore likely
that many cases of NAFLD in the people with diabetes are not identified and progressive
liver disease is often missed. However, few data are available on the applicability of LFTs to
diagnose hepatic fibrosis in people with diabetes.
Other approaches have been taken in the pursuit of a reliable non-invasive method of
distinguishing those patients who have significant fibrosis. HA is a component of the
extracellular matrix, whose production is increased, and degradation by the liver decreased,
in hepatic fibrosis. Several small studies have suggested that cut-off values of 42-50 ng/ml
give optimal sensitivity and specificity in determining the presence of significant
fibrosis( 102-105). Fligher levels may be associated with increasing severity of liver disease
and increased specificity in diagnosing fibrosis and cirrhosis. One study found both
sensitivity and specificity in detecting hepatic fibrosis to be in excess of 90% using a HA
cut-off value of 149 ng/ml(106). A further study suggested that a level > 100 ng/ml had a
78% specificity and 83% sensitivity for predicting cirrhosis, with specificity being raised to
96% if a cut-off of 300 ng/ml was used(107). One potential confounder is that levels of HA
can also be raised in patients with active joint disease(294;295).
Routinely-available markers that are predictive of fibrosis have been combined into scoring
systems. The BAAT score assigned one point for each of increased age, BMI, ALT and
triglycerides, and while a score of 2 gave 71% sensitivity and 80% specificity in detecting
septal fibrosis, a score of 3 gave 14% sensitivity but 100% specificity(l 77). The BARD
score allocated one point for each of increased BMI and the presence of diabetes, and two
points for AST:ALT ratio greater than 0.8 - with a cut-off of 2 points, the PPV and NPV of
determining severe fibrosis were 43% and 96% respectively(l 96). The NAFLD fibrosis
score, using a formula combining age, BMI, the presence of diabetes, AST:ALT ratio,
albumin and platelet levels, classified 75% of participants low risk or high risk groups for
severe fibrosis, with a low cut-off (below -1.455) giving a NPV of 93% and a high cut-off
(above 0.676) a PPV of 90%( 198).
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Ultrasound scanning has diagnostic accuracy of 80-86% in the diagnosis of cirrhosis or
extensive fibrosis in chronic liver disease(l!9) and can detect consequences of portal
hypertension such as increased spleen size. A low platelet count is a well established marker
of splenomegaly and the PSR has been shown to be a reliable predictor of oesophageal
varices in people with cirrhosis(123), and can therefore be used as a surrogate marker of
portal hypertension.
HCC is a well-recognised complication of hepatic cirrhosis. Diabetes is an established risk
factor for HCC and in one population-based study, diabetes was associated with around a
2.5-fold increase in incidence of HCC(209), independent of alcohol intake and viral
hepatitis. The prevalence of HCC in the general population of people with Type 2 diabetes,
however, remains unclear.
7.1.3 Study aim
The present study aimed to estimate the prevalence of fibrosis, cirrhosis and HCC, using a
range of different markers and scoring systems, in this randomly-selected population of
people with type 2 diabetes (the Edinburgh Type 2 Diabetes Study (ET2DS)), and to analyse




The study population for this analysis comprised the 939 participants of the Year 1 liver
study of the ET2DS, as described in Chapters 4 and 6. To summarise, subjects recorded as
having type 2 diabetes mellitus, aged 60 - 74 years, were selected at random into sex and 5-
year age bands from the Lothian Diabetes Register, a computerised database which contains
details of over 20,000 patients with type 2 diabetes living in Lothian, Scotland and includes
both patients attending hospital and those seen only in primary care. Study participants have
been shown previously to be representative of all those randomly selected to participate and
therefore of the target population of older men and women with type 2 diabetes living in the
general population(282).
7.2.2 Procedures
Subjects attended a specially established research clinic, based in the Wellcome Trust
Clinical Research Facility, Western General Hospital, Edinburgh, at baseline and after one
year (Year 1). At Year 1, participants attended, after a 4-hour fast, for an ultrasound
examination of abdomen and venous blood sampling.
All ultrasound examinations were performed by a single ultrasonographer as previously
described(281;296). Evidence of cirrhosis and hepatic masses were sought systemically and
spleen length was measured. Participants were also given an overall liver grading based on a
subjective measurement of the severity of steatosis, and validation of the gradings for hepatic
steatosis with 'fl MRS has previously been described in detail in Chapter 5.
Alcohol intake, use of hepatotoxic medications (amiodarone, isoniazid, methotrexate,
tamoxifen and glucocorticoids) within the previous six months and history of joint disease
were determined by questionnaire. Those participants with evidence of hepatic steatosis or
abnormal blood tests of liver function had further tests performed for liver disease performed
including serology for Hepatitis B and C, ANA, anti-smooth muscle antibody, anti-
mitochondrial antibody, ferritin and alpha fetoprotein (AFP). In addition, all participants
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(including those with normal liver and LFTs) seen after a certain date had these same
screening blood tests performed (n=644). Triglycerides and HDL cholesterol were measured
at Year 1. BMI, platelets and HA had been previously measured at the baseline clinic.
Participants who had significant abnormalities on hepatic USS or blood tests were referred
for standard follow-up within the National Health Service. Those with focal lesions on USS
had these reviewed by a consultant radiologist and received further imaging as necessary,
and those with raised AFP>20 kU/1 were referred for review in a liver clinic.
Data on previous diagnoses of chronic liver disease were collected from participants by
questionnaire at Year 1. In addition, data on liver diagnoses were obtained at baseline from
discharge summaries via record linkage at the ISD ofNHS Scotland.
Upper limits of normal on the laboratory reference range of bilirubin (Bi), ALT, AST and
GGT were 18 umol/1, 50 units/1, 45 units/1 and 55 units/1 respectively. Analysis was also
carried out using lower upper limits of normal for ALT - 30 units/1 for men and 19/units/l for
women(91).
7.2.3 Definition of NAFLD, hepatic fibrosis, HCC and PSR
NAFLD was defined as the presence of definite (Grade 3) hepatic steatosis on ultrasound
scan in the absence of a secondary cause for hepatic steatosis. In addition, for this study, the
definition was widened to include people with markers of fibrosis but no evidence of hepatic
steatosis on ultrasound, in acknowledgement of the fact that steatosis can regress in patients
with significant fibrosis. Secondary causes were defined as alcohol consumption > 14
units/week or participant report of a current or previous problem with alcohol excess, use of
hepatotoxic medication (glucocorticoids, isoniazid, methotrexate, amiodarone and
tamoxifen) within the six months prior to the Year 1 clinic, positive hepatitis B or C
serology, ferritin > 1000 ug/1, clinically significant positive immunology titres (anti-smooth
muscle antibody titre > 1:160 or anti-mitochondrial antibody titre > 1:40) or a previous
diagnosis of a secondary cause for chronic liver disease (alcoholic liver disease, autoimmune
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hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis or liver metastases)(296).
Subjects were considered to have a previous diagnosis of a secondary cause for chronic liver
disease if ISD linkage revealed such a diagnosis, or if a participant report of a diagnosis was
confirmed by their medical records.
Hepatic fibrosis was defined on the basis of HA levels - values of over 100 ng/ml, in the
absence of arthritis, were taken as evidence of definite fibrosis and possible cirrhosis(107). A
cut-off of 50 ng/ml was taken to indicate possible fibrosis( 102-105); values over 75 ng/ml
are also reported as this is the upper limit of normal on our laboratory reference range.
HCC was defined, in accordance with accepted guidelines(297), by one of the following: two
imaging techniques showing a focal lesion over 2cm in diameter with arterial
hypervascularisation; one imaging technique showing a focal lesion over 2cm in diameter in
association with AFP Ievels>400 ng/ml (484 kU/1); suggestive histology following biopsy of
a lesion. PSR was defined as the ratio of platelet count (/mm3) to spleen diameter (mm)(123).
7.2.4 Fibrosis clinical scoring systems
Participant scores on established scoring systems (BAAT, BARD and NAFLD Fibrosis
scores) were calculated. The BAAT(177) and BARD(196) scoring systems are outlined
above. NAFLD Fibrosis Score was calculated as previously published(198). Scores of 2-4 on
both the BAAT and BARD scores were considered to be predictive of hepatic fibrosis. On
the NAFLD Fibrosis Score, a score of >0.676 was considered to be predictive of fibrosis,
and a score of-1.455-0.676 was indeterminate for fibrosis. In view of the fact that these
systems have been developed to assess the severity ofNAFLD alone, they were used only in
those participants in whom another secondary cause for liver disease had been excluded.
7.2.5 Statistical analyses
Statistical analysis was performed using SPSS software version 14.0 (SPSS Inc., Illinois,
USA). Data not conforming to a normal distribution (in this study GGT measurements) were
log-transformed prior to parametric analysis. Statistical analysis included the one-way
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analysis of variance and chi-squared test to compare biochemical characteristics between
groups. PPV and NPV were used to analyse the utility of LFTs in predicting hepatic fibrosis.
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7.3 Results
7.3.1 Prevalence of markers of fibrosis, cirrhosis and HCC
Baseline characteristics of the 939 participants, aged 61 - 75 years, who attended the Year l
clinic are described in Chapter 6. Hepatic cirrhosis on ultrasound scan was found in four
members of the study population, a prevalence of 0.4%. Portal hypertension, defined as a
PSR <909, was present in 10 participants (1.1%), including one participant who had cirrhosis
on ultrasound scan. A total of 876 participants were fully assessed for secondary causes of
liver disease. Of these, 663 participants had no secondary cause identified, and in this
subgroup findings suggestive of fibrosis or cirrhosis would be presumed secondary to
NAFLD. Hepatic cirrhosis on ultrasound scan was found in one person (0.2%) in this
subgroup and PSR < 909 in four other people (0.6%).
The prevalence of definite hepatic fibrosis, defined as HA level > 100 ng/ml in the absence
of joint disease, was 5.7% in the entire study population of 939 participants. The
corresponding figures for HA level > 50 ng/ml and > 75 ng/ml were 23.6% and 12.2%
respectively. 0.5% of the population had HA level > 300 ng/ml. An additional 20.6% of
participants had HA levels > 50 ng/ml but also had evidence of arthritis. Of the 13
participants with evidence of cirrhosis on ultrasound scan or a low PSR, 4 (30.8%) had HA
levels 50-100 ng/ml and a further 6 (46.2%) had HA levels > 100 ng/ml.
In the subgroup of participants with no secondary cause for liver disease, 40 participants
(6.1%) had HA >100 ng/ml in the absence ofjoint disease, 166 participants (25.2%) had HA
> 50 ng/ml, 86 participants (13.0%) had HA > 75 ng/ml and 4 participants (0.6%) had HA >
300 ng/ml.
The prevalence of hepatic fibrosis was similar among participants who had evidence of
hepatic steatosis on ultrasound and among those without steatosis. In the group with hepatic
steatosis, the prevalence of hepatic fibrosis (HA > 100 ng/ml in the absence ofjoint disease)
was 5.6%; in the group without steatosis this figure was 5.7% .
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Two participants had definite HCC, a prevalence in the study population of 0.2%. In one
case this was confirmed on histology following biopsy of a 3.7cm liver mass on a
background of cirrhosis seen on USS, in association with raised AFP levels of 40 kU/1. A
second participant had a very high AFP (2712 kU/1); no mass was seen on USS, but
appearances on magnetic resonance imaging were supportive of a diagnosis of F1CC. Neither
participant had a secondary cause for liver disease, giving a prevalence of 0.3% in the group
with possible NAFLD.
7.3.2 Comparison of clinical fibrosis scoring systems with radiological and
biochemical markers
The three clinical scoring systems for prediction of fibrosis secondary to NAFLD were used
as alternative means of calculating prevalence of fibrosis in the subgroup with no secondary
cause for liver disease. The BARD score was positive in 92.6% compared to 79.3% for the
BAAT score, while 16.4% of the subgroup had a positive NAFLD Fibrosis Score, and in a
further 66.8% this score was indeterminate.
The only participant in this subgroup to have cirrhosis on ultrasound scan had positive
BARD, BAAT and NAFLD Fibrosis scores. When the prevalence of positive fibrosis scores
were compared across three groups based on HA measurements (HA < 50 ng/ml (or arthritis
present); HA 50 - 100 ng/ml in the absence of arthritis; and HA > 100 ng/ml in the absence
of arthritis) the only positive correlation was with the NAFLD Fibrosis Score with the
prevalence of a positive score rising from 13.7% to 21.3% to 42.5% in the three HA groups
respectively (p < 0.001). Conversely, 72.5% of those with a positive NAFLD Fibrosis Score
had a HA measurement greater than 50 ng/ml.
7.3.3 Comparison of tests of liver function with markers of fibrosis
Standard tests of liver function were compared between three groups according to HA level
in participants with no secondary cause for liver disease (Table 7.1). There was a significant
rise in mean AST, but not mean ALT, through the groups, but mean levels ofALT, AST and
GGT remained within the laboratory normal reference range in all three groups. Similarly,
mean levels of ALT, AST and GGT remained within the normal range in all three groups
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when participants were divided according to NAFLD Fibrosis Score (< -1.455; -1.455—
0.676; and >0.676: data not shown). The PPV and NPV of ALT and GGT in predicting
fibrosis as diagnosed using HA levels and the NAFLD Fibrosis Score are presented in Table
7.2. The PPV and NPV of proposed new upper limits of normal of ALT (>30 units/I for men,
>19 units/I for women) are also shown in Table 7.2.
Table 7.1
Comparison of ALT, AST and GGT between participants grouped according to HA
level.
HA < 50 ng/ml HA 50-100 ng/ml HA >100 ng/ml Cirrhosis on
(n = 494) (n = 126) (n = 40) USS (n = 1)
ALT (units/1) 33.3 ± 12.5 34.0 ± 13.5 34.9 ± 14.5 38.0
ALT > 50
units/1 (No. 34 (6.9) 9(7.1) 5 (12.5) 0(0)
(%))
AST (units/1) 30.1 ±9.9 31.5 ±9.4 35.3 ± 12.6* 62.0
AST > 45











7 (17.5)*units/1 (No. 36(7.3) 7(5.6) 0(0)
(%))
ALT: alanine aminotransferase, AST: aspartate aminotransferase, GGT: gamma
glutamyltransferase, HA: hyaluronic acid.
Data are mean ± standard deviation or median (interquartile range) unless stated
otherwise.
Significant differences between the groups stratified according to HA level by one¬
way ANOVA, Kruskal-Wallis or chi-squared tests (p < 0.05)
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Table 7.2
Positive and negative predictive values of standard LFTs (ALT (using standard and
alternative upper limits of normal) and GGT) in the diagnosis of fibrosis secondary to
NAFLD, as defined using HA levels or the NAFLD Fibrosis Score.
ALT ALT GGT
(cut-off 50 units/I) (alternative cut-offs+) (cut-off 55 units/1)
PPV (%) NPV (%) PPV (%) NPV (%) PPV (%) NPV (%)
HA* 29.2 75.1 25.1 74.8 28.0 75.1
(cut-off 50 ng/ml)
HA* 10.4 94.3 6.0 93.7 14.0 94.6
(cut-off 100 ng/ml)
NAFLD Fibrosis 15.9 13.6 20.5 10.3 22.9 14.6
Score#
'Participants with arthritis were grouped with those with a HA level below the cut-off
"PPVs are predictive of a NAFLD Fibrosis Score > 0.676; NPVs are predictive of a NAFLD
Fibrosis Score < -1.455.
+Upper limit of normal taken as 30 units/1 for men and 19 units/1 for women
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7.4 Discussion
Detection of advanced liver disease using non-invasive methods is challenging. This study
examines the prevalence of markers of hepatic fibrosis and cirrhosis, and their relationship to
standard tests of liver function, in a large randomly-selected cohort of older people with
Type 2 diabetes. The prevalence of hepatic fibrosis using HA was 5.7% and that of
ultrasound-diagnosed cirrhosis under 1%. The use of LFTs as a screening tool missed the
majority of cases of fibrosis predicted by raised HA levels.
7.4.1 Prevalence of advanced liver disease in type 2 diabetes: comparison
with previous studies
Previous reports have estimated and predicted the prevalence of hepatic fibrosis, cirrhosis
and HCC secondary to NAFLD in people with Type 2 diabetes to be higher than in the non-
diabetic population - but results have often either been extrapolated from other data or based
on results from relatively highly-selected patient populations. In comparison, the present
study has the advantage that participants were selected at random from a register of all
people in the South-East of Scotland who had Type 2 diabetes, and therefore represented the
entire spectrum of this condition. It is the first study to include people with diabetes who are
receiving their routine review in the community as well as those in the secondary care
setting. These factors are likely to have contributed to the lower rates of severe fibrosis and
cirrhosis seen here, relative to previous studies of patients with clinical indications for liver
biopsy seen within tertiary referral centres(96;l 74; 1 75). It is also possible that the high rate
of use of anti-diabetic agents in the population, particularly metformin, may have had a
disease modifying effect on NAFLD and contributed to the lower than expected rates of
fibrosis and cirrhosis.
The prevalence of HCC in our cohort was 0.2%, a figure which is comparable to that
previously found on screening both a general population in Italy (prevalence of 0.7%)(298).
It is also in keeping with the only previous large-scale study, carried out in Taiwan(299), that
has looked at prevalence of HCC in a subgroup of people with type 2 diabetes, in which the
prevalence was 0.1%. This population, unlike ours, had a high prevalence of viral hepatitis.
In contrast, prevalence of HCC is higher in populations with known cirrhosis, and in one
small-scale study the prevalence in an obese group with cryptogenic cirrhosis was 30%(300).
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Longitudinal studies in people with NAFLD (diagnosed on biopsy) have found a variable
incidence of HCC, ranging from no cases during a follow-up time of 11 years in a population
with simple steatosis alone, to 2.4% of the research population in a study of NASH over a
maximum follow-up period of 21 years(178;181).
7.4.2 Use of non-invasive markers of fibrosis and portal hypertension
HA was the main marker of fibrosis used in this study, with cut-offs for fibrosis and cirrhosis
defined as in previous reports(102-105;107). Liver biopsy, the gold standard, would have
been neither feasible nor ethical, and by contrast HA measurement is relatively non-invasive.
Transient elastography was not available to us, and is not without its drawbacks in a largely
overweight patient population. We attempted to improve specificity of HA by excluding
participants with arthritis (another cause of raised HA) from the fibrosis categories, and also
by using a high cut-off (100 ng/ml) for our definition of definite evidence of fibrosis. While
we can be reasonably confident that the proportion of the study population with fibrosis is
over 5.7% (those with HA levels > 100 ng/ml, without joint disease), it is possible that the
prevalence of fibrosis was lower than the 26% predicted by HA levels > 50 ng/ml. It is of
interest that, contemporaneously with the submission of our data for publication, a study
examining prevalence of advanced liver disease in a population of Brazilian Type 2 diabetic
patients, based within a hospital clinic, was published( 173). In this study, participants (who
had already been screened for secondary causes of liver disease) with hepatic steatosis were
automatically referred for the gold standard liver biopsy: between 6.5 and 10% of the entire
study population had advanced fibrosis; and 2.2% had cirrhosis. Results were therefore
broadly in keeping with the findings of the present study.
The only clinical scoring system to positively correlate with HA measurements was the
NAFLD Fibrosis Score, which predicted definite fibrosis in 16.4% of participants with no
secondary cause for liver disease. A further 66.8% of subjects had an indeterminate score.
This is a much higher proportion than in the original paper, which suggested that such
patients should be considered for liver biopsy) 198). The BARD and BAAT scores both
estimated that a very high percentage of participants in this study had fibrosis but in view of
the emphasis on age, BMI and diabetes in these scoring systems, this could have been
anticipated. Interestingly, when the BARD score was validated in a subgroup with type 2
diabetes in the initial study, the AUC was lower than in the group as a whole (0.53 vs 0.80).
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This supports the concept that these more simple scoring systems, while useful in the general
population of patients with NAFLD, may be less applicable to populations of people with
type 2 diabetes. The risk of their indiscriminate use is that they may identify large numbers
of patients for biopsy without any definitive evidence of a high prevalence of advanced liver
disease.
A low platelet count is a well-established consequence of hypersplenism, and the PSR has
previously been validated as a marker of portal hypertension (123). This validation was,
however, carried out in patients with known cirrhosis and it is possible that its use is less
applicable in our study population. In particular it is possible an alternative diagnosis may
have underpinned the finding of hypersplenism in some of our participants and this may
have contributed to the lack of overlap seen in our measures of cirrhosis and PSR.
7.4.3 Analysis of data in the absence of the accepted gold standard
As discussed above, the validity of the results in this chapter has been weakened by the fact
that the use of the accepted gold standard measure for advanced liver disease (biopsy) was
not possible. This is a problem that is by no means unique to the current work, and it is not
uncommon to encounter situations where a gold standard cannot be used in all participants,
where the gold standard is imperfect or where there is no gold standard(301 ;302).
Several mechanisms have been used to overcome these drawbacks. One group of solutions
that is particularly relevant to the current scenario is the use of multiple test results to
construct a reference standard outcome(301 ;303). There are three recognised means of
combining the results of tests in this context. The first (the "composite reference standard")
is to use a predefined rule to classify patients, a procedure that is transparent and easy to use,
but is perhaps simplistic and may result in a relatively high proportion of misclassified
patients. The second ("panel diagnosis") is to utilise a panel of experts to combine the data
and reach a consensus on individual participants, which may produce a more flexible
approach that more closely reflects personal concepts of the target condition. The third
("latent class analysis") is to use statistical modelling based on actual data, which has the
disadvantage that the condition is not defined in a clinical fashion and so it may not be clear
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how the results relate to clinical practice. A secure evidence base for each approach is
currently lacking.
The use of any one of the above methods can be envisaged as having a contribution to make
to the understanding of the data presented. The use of a pre-defined rule to classify patients,
such as by a certain combination of HA results and ultrasound findings, would be relatively
straightforward, whereas the panel approach, while potentially providing a more accurate
representation of individuals within the population, might be prohibitively time-consuming
in a study of this size. Statistical modelling of data has previously been shown to be
rewarding in this setting, such as in the NAFLD Fibrosis Score. Future work might focus on
validating these approaches in the current setting, perhaps by using future clinical outcome
as the validation measure.
7.4.4 Comparison of LFTs with biochemical markers of hepatic fibrosis
Although significant increases were noted in the values of AST through the groups with
increasing evidence of liver damage, mean values of all three LFTs examined remained
within normal limits. This is consistent with previous studies which have shown that
progression to cirrhosis can occur without major perturbation in the LFT values(64).
Although the NPVs for ALT and GGT were high in predicting lower HA levels, these values
are affected by the very low population prevalence of HA-diagnosed fibrosis. The use of
lower values for the upper limit of normal of ALT did not materially change the results.
Currently, liver screening in Type 2 diabetes is carried out using conventional LFTs alone,
and our data suggest that such an approach misses the majority of cases of hepatic fibrosis.
7.4.5 Limitations of this study
The main limitation of this study (as detailed above) was the use of surrogate markers of
advanced liver disease rather than histological examination, the acknowledged gold standard
investigation. However, to perform liver biopsy routinely in a study population of essentially
healthy volunteers would have been unethical due to its invasive nature. Subjects in this
study were all aged 61-76 years at the time of examination, and were predominantly
Caucasian. Previous studies have shown that the prevalence of NAFLD and its progression
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to fibrosis and cirrhosis increases with age. It is therefore possible that the results from our
study population may not be representative of those from other age ranges. Furthermore, at
baseline, only approximately one fifth of people invited to attend from the Lothian Diabetes
Register did so - but analysis has suggested that this population was representative of that
invited, most importantly in terms of duration of diabetes, HbAlc and treatment with insulin.
7.4.6 Conclusion
In conclusion, this study provides an estimate of prevalence of hepatic fibrosis in a large
population of older people with Type 2 diabetes. There are challenges in detecting advancing
liver disease, and current screening methods using conventional LFTs are almost certainly
inadequate. Further work is required to refine identification of these patients, particularly in
those in whom liver biopsy would be difficult to justify. This may require a panel of
biochemical markers, for example the ELF panel or cytokeratin-18, or a radiological method
such as transient elastography. Future work might also focus on how best to combine the
multiple data points available, in order to produce a more meaningful categorisation of
participants into those with and those without more advanced liver disease, by utilising
mechanisms such as panel diagnosis.
156
Chapter 8
Analysis 4: Association between hepatic steatosis/NAFLD
and clot lysis dynamics in Type 2 diabetes
8.1 Introduction
NAFLD encompasses a spectrum of disease from simple steatosis to NASH, fibrosis and
cirrhosis. It has been shown to be a risk factor for cardiovascular disease both in the general
population(205;233) and in patients with type 2 diabetes(l 8;222). Emerging risk factors for
cardiovascular disease (CVD) in this context include a systemic pro-thrombotic tendency
and subclinical inflammation.
8.1.1 Clot formation and lysis dynamics: relationship to pro-thrombotic
mediators, diabetes and NAFLD
One area of interest is inter-individual differences in clot structure and lysis. Previous studies
have shown that individuals at high cardiovascular risk have higher clot density, altered clot
morphology and longer clot lysis times compared with controls(239-242). Similar alterations
in clot structure and lysis times have also been seen in individuals with type l and type 2
diabetes, and have been correlated with glycaemic control(243;244). Study of clot dynamics
in patients with NAFLD has been limited. One small study compared clotting kinetics,
measured using thomboelastography of whole blood samples, in 28 patients with NAFLD
(either diagnosed on ultrasound or on biopsy) and 22 control subjects, and demonstrated
higher clot strength and reduced clot lysis in the group with NAFLD, independent of the
presence of diabetes or features of the metabolic syndrome(275).
The formation and stability of the platelet-rich clot depends on the establishment of a fibrin
mesh, which in turn is dependent on a complex interaction of components of the coagulation
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cascade and other plasma proteins. Fibrinogen(239;240;247), PAI-1 (239;241) and
complement C3(243;250), a central component of the innate immune system, concentrations
have been shown to contribute to variation in clot morphology and clot lysis in non-diabetic
and diabetic populations. They have also been individually associated with an increased risk
of cardiovascular disease(252;266;276;304;305). There have been conflicting results when
associations with liver disease have been examined(274;277;279;280). The relationship of
these pro-thrombotic mediators to clot kinetics has not been studied in relation to NAFLD.
Hepatic triglyceride accumulation and subsequent hepatocyte damage has been shown to be
associated with increased cytokine release. TNFa and IL-6 production from nearby visceral
fat further perpetuates this vicious cycle(271 ;272). Studies in patients with NAFLD have
revealed higher serum concentrations of inflammatory markers, including TNFa, IL-6 and
CRP, compared to controls(270;273;274). There are several mechanisms by which the
increase in cytokines associated with NAFLD may affect the risk of cardiovascular
disease(236); of interest here is the possible contribution to increased hepatic production of
pro-coagulant factors such as fibrinogen and the antifibrinolytic protein PAI-1.
8.1.2 Study aim
The primary aim of the current study was to examine the association of hepatic steatosis and
NAFLD with clot formation and lysis dynamics and inflammatory mediators in a large, well-
defined population of people with Type 2 diabetes. We hypothesised that participants with
hepatic steatosis and NAFLD would have a greater prothrombotic tendency (higher clot




The 939 participants in the Year l liver clinic, as described in Chapters 4 and 6, are the
subject of this further investigation.
8.2.2 Liver ultrasound examination and clinical examination
Subjects attended the year l research clinic after a 4-hour fast for an ultrasound examination
of abdomen as described in previous chapters. The liver was graded for markers of hepatic
steatosis using established criteria(306-308) including a bright hepatic echo pattern
(compared with the echo response of the right kidney), increased attenuation of the echo
beam and the presence of focal fatty sparing. Following validation of ultrasound gradings
with 'H MRS, the gold-standard non-invasive method of quantifying hepatic fat content,
subjects were graded as hepatic steatosis present or absent(296;309). Further investigations
were carried out to detect secondary causes for liver disease as outlined in Chapter 6.
At the time of recruitment into the study, participants attended a baseline examination whicb
included measurement of demographic and anthropometric variables (age, gender, BMl),
fibrinogen, platelets and HA. At year 1 further measurements were performed including BP,
LFTs (bilirubin, ALT, AlkP and GGT), HbAlc, triglycerides, high-density cholesterol
(HDL) and low-density cholesterol (LDL).
8.2.3 Definitions of liver disease
Three groups were defined: the steatosis group had definite hepatic steatosis of any cause on
ultrasound; the NAFLD group was a subgroup of the steatosis group with no secondary cause
for liver disease; the normal group had no evidence of hepatic steatosis or cirrhosis on
ultrasound scanning. Secondary causes for steatosis were alcohol consumption > 14
units/week(l 0) or participant report of a current or previous problem with alcohol excess,
use of hepatotoxic medication(l 7) (glucocorticoids, isoniazid, methotrexate, amiodarone and
tamoxifen) within the six months prior to the Year 1 clinic, positive hepatitis B or C
serology, ferritin concentration > 1000 ug/1 (milder hyperferritinemia is known to be
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associated with obesity, insulin resistance and NAFLD(17;289)), clinically significant
positive immunology titres (anti-smooth muscle antibody titre > 1:160(290) or anti-
mitochondrial antibody titre > 1:40(291)) or a previous diagnosis of a persistent secondary
cause for chronic liver disease. The secondary exclusions from NAFLD are strict and it is
possible that some participants who have NAFLD as a primary or coexistent diagnosis may
be excluded from this definition (for example those with relatively modestly elevated alcohol
intake below that traditionally felt to cause alcoholic liver disease). Therefore analysis has
been performed both with and without exclusions from the steatosis group.
8.2.4 Analysis of clot formation and lysis
Blood samples were taken without a tourniquet after a 4h fast. The first 5 mis were used for
clinical tests and subsequent 9 mis of whole blood was added to 1 ml of 0.9% citrate and
samples were spun down within 2 hours of collection with plasma stored at -40°C until
analysis. Clot turbidity and lysis measurements were conducted as previously described
(310). Briefly, 25 pi of plasma samples was added to 75 pL lysis mix composed of assay
buffer (50 mmoF1 Tris, 100 mmof1 NaCl, pH 7.4) and 83 ng/ml tPA (Technoclone, Vienna,
Austria), followed by the addition of 50 pL of activation mix containing assay buffer, 0.03
U/mL thrombin (Calbiochem) and 7.5 mmol/L CaCL. Plates were shaken and read at 340
nm every 12 sec for 60 min then every 2 minutes for 9 hours in an ELx-808 IU
ultramicroplate reader (BIO-TEK. Instruments INC, USA). A software application was used
to analyse the data and variables were recorded as follows:
Lag time is the time until sufficient protofibrils have formed to enable lateral aggregation,
effectively the time taken until the beginning of the exponential rise in maximum
absorbance.
Clot formation time is the time from start of lateral aggregation to full clot formation. Both
clot density and effectiveness of fibrinolysis contribute to this measurement.
Maximum absorbance is a measure of fibrin network density and fibre thickness, clot
tubidity being directly proportional to the cross-sectional area of fibrin fibres
Clot lysis time represents time from full clot formation to 50% lysis.
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8.2.5 Measurement of prothrombotic and inflammatory mediators
Fibrinogen levels were assessed on plasma samples using the automated Clauss assay
(MDA-180 coagulometer, Organon Teknika). PAI-1 and C3 levels were determined using
ELISA kits (Invitrogen, Paisley, UK, and GenWay Biotech, San Diego, USA respectively).
CRP was assayed using a high-sensitivity immunonephelometric assay. TNFa and IL-6
levels were determined using high-sensitivity ELISA kits (R&D Systems, Oxon, UK).
8.2.6 Statistical analysis
Statistical analysis was performed using SPSS software version 14.0. The student t-test,
Mann-Whitney and chi-squared tests were used to compare variables between groups.
Spearman's correlation coefficient was used to determine correlations between variables,
many of which were not normally distributed. Data that did not conform to the normal
distribution were log-transformed prior to parametric analysis. As multiple univariate
comparisons were carried out a Bonferroni calculation was made for each analysis, and
significance at p < 0.003 levels (in addition to p < 0.05) was quoted where possible. For
Spearman correlations, computer programming constraints meant that significance at p <
0.01 was the lowest possible. Linear regression analysis was used to examine the
independence of variables in their association with clot lysis. Independent contributors were
presented as standardised correlation coefficient (P). Tolerance measures did not suggest
significant multicollinearity. Variables included in the model were age, gender, presence of
NAFLD/steatosis (vs. no steatosis), BMI, triglycerides, duration of diabetes, FlbAlc,




Participant characteristics, grouped according to the presence of hepatic steatosis or the









Age (years) 69.4 ± 4.3 68.514.0 68.5 + 4.0
Gender (% (n) male) 54.4 (221) 50.1 (267) 46.8 (183)
BMI (kglm') 29.9 ± 5.5 32.4 + 5.5 32.6 + 5.7
Duration diabetes (yrs) 8.0 (4.3-13.0) 7.0 (4.0-11.0) 7.0 (4.0-11.0)
HbA1c(%) 7.0 ± 0.1 7.3 1 1.1 7.3 i 1.1
Diet-controlled (% (n)) 22.4 (91) 17.1 (91) 15.9 (62)
Systolic BP (mm Hg) 138.4±20.6 137.9 1 16.7 137.1 1 15.8
Diastolic BP (mm Hg) 73.0 ± 9.6 74.9 1 9.4 74.6 + 9.3
Total cholesterol (mmol/l) 4.1 ± 0.8 4.2 1 0.8 4.1 1 0.8
HDL cholesterol (mmol/l) 1.3 ± 0.4 1.2 1 0.3 1.210.3
LDL cholesterol (mmol/l) 2.2 ± 0.7 2.1 1 0.7 2.1 1 0.7
Triglyceride (mmol/l) 1.2 (0.9-1.7) 1.6 (1.3-2.2) 1.6 (1.3-2.2)
Metformin users (% (n)) 54.2 (220) 70.9 (378) 72.4 (283)
Sulphonylurea users (%
(n))
30.5 (124) 31.5 (168) 30.7 (120)
Thiazolidinedione users
(% (n))
17.0 (69) 17.8 (95) 19.9 (78)
Insulin users (% (n)) 17.0 (69) 14.8 (79) 15.3 (60)
Aspirin users (% (n)) 67.2 (273) 68.1 (363) 70.3 (275)
ACE inhibitor users (%
(n))
52.5 (213) 51.6 (275) 50.4 (197)
Current smokers (% (n)) 14.0 (57) 11.3 (60) 10.2 (40)
Data are expressed as mean ± standard deviation or median (interquartile range)
unless otherwise stated. *p < 0.05 compared with Normal group
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8.3.2 Relationship of hepatic steatosis and NAFLD with clot formation and
lysis dynamics
Clot lysis time was significantly higher in participants with hepatic steatosis compared to the
normal group (657 (498 - 850) vs 597 (468 - 774) seconds, p = 0.002). A similar result was
obtained when the NAFLD sub-group was compared to the nonnal group. There were no
significant differences between the steatosis/NAFLD and normal groups in lag time, time to
clot formation or maximum absorbance. These results are detailed in Table 8.2.
Table 8.2
The association of hepatic steatosis and NAFLD with clot formation and lysis







LT (seconds) 522 (451 -679) 538 (464-680) 539 (468-692)
CFT (seconds) 538 (462 - 624) 528 (464 - 624) 528 (468 - 624)
MA(au) 0.33 ± 0.13 0.32 ± 0.11 0.32 ± 0.11
CLT (seconds) 597 (468 - 774) 657 (498 - 850) 672 (492 - 888)








3.70 ± 0.77 3.56 ± 0.70 3.58 ± 0.69
C3 (g/l) 1.29 ± 0.48 1.38 ± 0.49 1.36 ± 0.51
CRP (mg/l) 1.44 (0.66-3.35) 2.14 (0.99-4.58) 1.86 (0.89-4.27)
TNFa (pg/ml) 1.06 (0.68-1.63) 1.09 (0.71 - 1.63) 1.07 (0.68- 1.62)
IL-6 (pg/ml) 2.64(1.67-4.26) 2.90 (2.06-4.40) 2.78 (2.02-4.19)
Platelets (x10s/l) 254 ± 70 260 ± 68 263 ± 66
Data are expressed as mean ± standard deviation or median (interquartile range) unless
otherwise stated. LT, lag time; CFT, clot formation time; MA maximum absorbance; CLT,
clot lysis time. *p < 0.05 when compared with the normal group; **p < 0.003 when
compared with the normal group.
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8.3.3 Relationship of hepatic steatosis and NAFLD with pro-thrombotic and
inflammatory mediators
PAi-1 and C3 levels were significantly higher, and fibrinogen levels significantly lower, in
the group with steatosis and the sub-group with NAFLD when compared to the normal group
(Table 8.2 above). CRP was also significantly higher in the steatosis and NAFLD groups
compared with the normal group, but there was no significant difference in TNFa between
the groups. IL-6 was significantly higher in the steatosis group compared with the normal
group, but the result did not reach statistical significance when the NAFLD group was
compared with the normal group. Platelet number was not significantly different between the
groups.
8.3.4 Determinants of clot formation and lysis dynamics
Univariate analysis to analyse the associations of clot formation and lysis dynamics (clot
formation time, maximum absorbance and clot lysis time) was carried out separately on
people with a normal liver on ultrasound and on those with NAFLD. The results are
presented in Table 8.3. Fibrinogen and CRP levels were consistently correlated with all three
clot dynamic measures. C3 was correlated with clot lysis time in both groups, but with
maximum absorbance in the normal group only. PAI-1 was associated with clot lysis time in
the NAFLD group but not in the normal group. Lipids (HDL and LDL cholesterol, and
triglycerides) were significantly associated with clot lysis time in the normal group (inverse
association of HDL cholesterol) but not in the NAFLD group.
In a separate analysis, BMI was significantly correlated with PAI-1, fibrinogen, C3, CRP and
IL-6 in the normal group; in the NAFLD group the correlations with PAI-1, fibrinogen, CRP
and IL-6 remained but here BMI was not associated with C3 (data not shown). HbAlc was
significantly associated with C3, but not the other mediators, in both groups.
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Table 8.3
Association of clinical characteristics, prothrombotic and inflammatory mediators
with clot formation and lysis dynamics in the study population. Data are Spearman







Age (years) 0.00 0.07 0.09
Duration diabetes (years) 0.10 0.10 0.00
HbA1c (%) 0.00 0.09 0.13
BMI (kg/rrT) 0.07 0.11 0.10
Triglycerides (mmol/l) 0.04 -0.04 0.10
HDL cholesterol (mmol/l) -0.07 -0.07 -0.12
LDL cholesterol (mmol/l) -0.10 0.00 0.16
PAI-1 (pg/ml) 0.18 0.10 0.08
Fibrinogen (mg/ml) 0.32 0.45 0.15
C3 (g/l) 0.049 0.14 0.28
CRP (mg/l) 0.16 0.31 0.20
TNFa (pg/ml) 0.13 0.00 0.05
IL-6 (pg/ml) 0.13 0.16 0.07
NAFLD
Age (years) -0.06 -0.04 -0.07
Duration diabetes (years) 0.03 0.04 -0.03
HbA1c(%) 0.02 0.11 0.19
BMI (kg/m') 0.16 0.18 0.15
Triglycerides (mmol/l) 0.08 -0.08 0.05
HDL cholesterol (mmol/l) 0.09 0.14 0.02
LDL cholesterol (mmol/l) -0.02 0.07 0.08
PAI-1 (pg/ml) 0.17 0.14 0.14
Fibrinogen (mg/ml) 0.34 0.38 0.14
C3 (mg/l) -0.02 0.02 0.26
CRP (mg/l) 0.16 0.17 0.14
TNFa (pg/ml) 0.13 0.03 0.05
IL-6 (pg/ml) 0.07 0.22 0.07
Significant factors in bold. *p < 0.05, "p < 0.01
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The association of fibrinogen with use of medication was investigated, in a post-hoc
analysis. Participants on metformin had significantly lower levels of fibrinogen than
participants who did not take this drug (3.59 ± 0.70 vs 3.72 ± 0.77 mg/ml, p < 0.05).
However the lower levels of fibrinogen persisted (statistically significantly in the steatosis
vs normal analysis, and as a trend in the NAFLD vs normal analysis) in the steatosis/NAFLD
group even after participants on metformin were excluded from analysis. There were no
significant differences in Fibrinogen levels between users and non-users of
thiazolidinediones, aspirin, statins or angiotensin converting enzyme inhibitors. The lack of
association between hepatic steatosis/NAFLD and clot formation or maximum absorbance
remained after adjustment for fibrinogen levels and metformin use.
As hepatic steatosis and NAFLD were significantly associated with clot lysis time, this
relationship was examined in more detail. On multivariate analysis, the association between
NAFLD and clot lysis time was attenuated by the separate addition of each of ambient
glucose, BMI, WC, PAI-1, C3, fibrinogen and inflammatory markers (CRP, TNFa and IL-
6), but a statistically significant association remained. However, the association was lost
when full adjustment was made for clinical and biochemical variables (Table 8.4).
Independent predictors of clot lysis time were C3, HbAlc and LDL cholesterol. NAFLD was
not an independent predictor of clot lysis time in this model. This model accounted for
1 1.3% of the variance in clot lysis time (adjusted R2 = 0.113).
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Table 8.4
Multivariate analysis of the association between clot lysis, NAFLD and clinical and
biochemical characteristics.
Standardised p coefficients
Model 1 Model 2 Model 3 Model 4
NAFLD 0.105* 0.072 0.056 0.059
Age -0.054 -0.046 -0.021 -0.018
Sex 0.143 0.100 0.093 0.078
In(PAI-l) 0.068 0.047 0.056
C3 0.224 0.216 0.219
Fibrinogen 0.016 0.011 0.022
In(CRP) 0.055 0.028 0.015
Platelets 0.076 0.080 0.072
ln(duration diabetes) -0.083 -0.074
Ambient glucose 0.022 0.020
HbAlc 0.117 0.108





Model 1: NAFLD + age/sex
Model 2: NAFLD + age/sex + prothrombotic and inflammatory mediators
Model 3: NAFLD + age/sex + prothrombotic and inflammatory mediators +
diabetes/metabolic syndrome variables
Model 4: NAFLD + age/sex + prothrombotic and inflammatory mediators +
diabetes/metabolic syndrome variables + traditional cardiovascular risk factors
Significant values in bold. *p < 0.05
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8.4 Discussion
In this large, randomly-selected, population of older people with type 2 diabetes, the
presence of hepatic steatosis or NAFLD was associated with a longer ex vivo clot lysis time
and higher levels of PA1-1 and C3. Following multivariate adjustment for these, and other
clinical characteristics, the independent association ofNAFLD and clot lysis time was lost.
We therefore hypothesise that NAFLD affects clot lysis dynamics via increased hepatic
synthesis of pro-coagulant factors, thus contributing to a systemic pro-thrombotic tendency.
Another possible explanation is that NAFLD is a marker of visceral adiposity and increased
adipocyte production of hypofibrinolytic mediators.
8.4.1 Relationship of NAFLD with clot dynamics: role of pro-thrombotic
mediators
We have shown higher C3 levels in participants with NAFLD. and C3 is itself independently
associated with clot lysis time, both in the present study and previous reports(243;25l). We
therefore hypothesis that the production of C3 by the liver is increased in NAFLD and this is
one mechanism by which NAFLD prolongs clot lysis time and predisposes to cardiovascular
disease. It is of interest that in the NAFLD group (unlike in the normal group) C3 was not
significantly correlated with BMI; this adds weight to a possible direct role of hepatocytes,
rather than an indirect association via visceral adiposity. A previous study, comparing
children with type l diabetes with controls, showed higher C3 concentration and
incorporation into clots in the diabetic subjects(243). This suggested a role of C3 that is
intrinsic to the coagulation process rather than an indirect effect via its inflammatory
properties. It is important to note, however, that in the present study C3 was positively
correlated with maximum absorbance in the normal group but not in the NAFLD group,
which might argue against a significant change in clot structure via C3 in this group.
One further mechanism is via an increase in PAl-l production from the liver, with higher
levels of PAI-l seen in the NAFLD group in the present study, and the inclusion of PAI-l
attenuating the relationship between NAFLD and clot lysis time on regression analysis. In
addition, PAI-l was significantly correlated with clot lysis time in the NAFLD group but not
in the normal group. Animal studies have suggested that after fat accumulation in the liver,
hepatocytes become a more important site of PAI-1 production(311); in humans, a positive
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correlation between the presence of hepatic steatosis and liver PAI-1 expression has
previously been demonstrated(278). In the present study, PAI-1 was significantly positively
correlated with BMI in both the NAFLD and normal groups, and so the possibility that
steatosis and NAFLD are markers of increased adipocyte production of this protein cannot
be excluded.
Contrary to expectation, NAFLD was associated with lower fibrinogen levels than were seen
in participants with a normal liver on ultrasound. One possible explanation was the differing
use of metformin in the two groups. We have previously documented a positive association
between NAFLD and metformin use(296), most likely due to confounding by indication, and
in the present cohort participants taking metformin had statistically significantly lower levels
of fibrinogen. It might therefore have been possible that the lower levels of fibrinogen in the
NAFLD group are due to the higher rate of metformin use in this group(312). Against this
theory is the fact that the association between lower levels of fibrinogen and
steatosis/NAFLD persisted after participants on metformin were removed from the analysis.
Another possibility is that the time lag between measurement of fibrinogen and assessment
of liver for NAFLD may have played a role. Against this hypothesis, fibrinogen showed the
expected positive correlations with clot formation markers, which were measured
simultaneously with liver assessment. The negative correlation of fibrinogen and NAFLD
therefore remains unexplained but may itself be responsible for the fact that NAFLD was not
associated with longer clot formation time and higher clot density. Despite the higher levels
of fibrinogen in the normal group, clot lysis time was significantly shorter suggesting that
this protein plays a marginal role in the susceptibility of the clot to lysis.
Although it is possible that increased hepatic production of prothrombotic factors is
responsible for the results documented, an alternative hypothesis is that hepatic steatosis is
merely a marker for abdominal obesity, insulin resistance, and associated higher production
of acute-phase proteins from tissues other than the liver such as adipocytes and mononuclear
cells. The fact that BMI (and WC) attenuated rather than abolished a significant association
between the presence ofNAFLD and clot lysis time would go against this. Although we did
not perform analysis of production of C3 and PAI-1 at a tissue level, our conclusions that an
increase in hepatic production is at least partly responsible for the higher plasma levels is
supported by previous studies as outlined above.
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The pathogenesis of NAFLD is both affected by and contributes to a pro-inflammatory
milieu. In our analysis, CRP was significantly associated with clot lysis time and with higher
levels of prothrombotic mediators. The relative influence of inflammation at the level of the
liver, as opposed to inflammatory activity elsewhere remains unclear, and it cannot be
excluded that NAFLD is a marker of (rather than a significant contributor to) a systemic
inflammatory and prothrombotic state.
8.4.2 Association of glycaemic control with clot lysis time
Higher HbAlc was an independent predictor of clot lysis time, whereas ambient glucose
level at the time of venepuncture was not. Our data therefore suggests that longterm
glycaemic control is more important than short term perturbations in glucose. The
observation that higher HbAlc predicts longer clot lysis time is in keeping with a previous
study that has shown higher clot lysis time in patients with, versus those without,
diabetes(243;313). An independent association between higher HbAlc and the presence of
NAFLD in this cohort has been demonstrated in Chapter 5 and this is likely due to the
increase in insulin resistance associated with hepatic steatosis. One hypothesis is that poorer
glycaemic control promotes formation of clots that have a denser, less porous structure and
are more resistant to Tibrinolysis(244), and that this effect is partially mediated by glycation
of the fibrinogen molecule. Alternatively, it is possible that glucotoxicity associated with
poorer glycaemic control indirectly affects clot composition via an increase in C3 as has
been previously postulated.
8.4.3 Strengths and limitations of the current study
The present study has a number of strengths. In particular, our cohort of participants is large,
representative and well-characterised. There are few previous studies that have examined the
association of NAFLD with clot dynamic and inflammatory mediators and those that exist
are small and often in selected populations. Furthermore, we have used robust methodology
in identifying participants with hepatic steatosis and NAFLD including validation of our
ultrasound measure with MR spectroscopy and stringent exclusion of participants with any
possible secondary cause for liver disease.
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Limitations of this study include its cross-sectional design, which restricts conclusions that
can be drawn regarding causality. Participants were diagnosed with NAFLD on the basis of
ultrasound scanning rather than on biopsy and histological examination - biopsy would have
been neither feasible nor ethical in a study population of this size. The effect of
misclassification would be to weaken the conclusions drawn. Our population was aged
between 61 and 76 years at the time of the study and is therefore representative of many
patients seen within diabetic clinics - it is however possible, although unlikely, that our
conclusions cannot be generalised to a younger population. It was not possible to quantify
insulin resistance formally - clamp studies would not have been feasible in a population of
this size and models such as the HOMA-IR model are not accurate in patients with Type 2
diabetes who are on antihyperglycaemic medication. We have not examined genetic
polymorphisms underlying structural and functional differences in the components of the
coagulation cascade, or the expression of genes at a cellular or tissue level, and it likely that
such analysis would add further depth to the observations made on the basis of plasma
concentration alone.
8.4.4 Conclusions
In conclusion, we have demonstrated an association between NAFLD and impaired clot lysis
time in this population of people with type 2 diabetes, and postulate that this is one mediator
of the increased cardiovascular risk previously observed in such patients. Further research
into the association ofNAFLD and clot lysis dynamics with longitudinal cardiovascular and




9.1 Discussion and Conclusions
9.1.1 Use of ultrasound to diagnose hepatic steatosis (Chapter 5)
The main finding in this study was that an initial ultrasound grading suggesting an
indeterminate (Grade I) or mildly steatotic (Grade 2) liver was, after comparison with the
non-invasive gold standard MRS, more in keeping with normality than steatosis. Initial
"normal" or "severe steatosis" gradings were found to be consistent with normality and
steatosis respectively. Intra-observer variation in ultrasound gradings was minimal for the
sonographer who performed gradings for the study as a whole, but higher and statistically
significant for a registrar trainee in radiology. Inter-observer variability was higher than
intra-observer variability, but non-significant when gradings of the sonographer were
compared with those of a consultant radiologist.
The implications for the current study were that participants with an "indeterminate" or
"mild steatosis" grading were essentially grouped with those with a "normal" grading and
were excluded from a diagnosis of hepatic steatosis and NAFLD. A valid inference is that
results from previous studies that have used an unvalidated ultrasound measure should be
questioned, as quoted prevalence rates may represent an over-estimate of the true prevalence.
Future research that utilises an ultrasound measure should strongly consider validating
gradings.
It is accepted that the gold standard used in the current study was MRS rather than the "true"
gold standard of biopsy. Biopsy would not have been considered ethical in an essentially
healthy population. In addition, MRS may have advantages over biopsy in terms of
proportion of liver sampled. In a large meta-analysis, sensitivity and specificity of MRS
versus biopsy were 88.5% and 92% respectively, and it is difficult to know whether the
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relatively minimal deficit was due to limitations of MRS (such as sampling variability) or to
sampling variability and inter-observer variability in histological assessment(78).
Intra- and inter-observer variation in ultrasound gradings is an area of concern both clinically
and in large-scale research studies. There is an element of subjectivity in gradings that
appears to preclude exact concordance with MRS. Further study in this area might focus on
development of a quantitative ultrasound measure, using computer software to calculate
differences in echogenicity between the liver and right kidney for example. Another
approach would be to move to using MRS as the standard method for ascertaining hepatic
steatosis in population studies, and this scanning modality has already been used in a large-
scale study in the general population in the USA(63). Currently cost (and indeed the inability
to scan the most obese members of the population) is a significant barrier to routine adoption
ofMRS in such studies, but this may change in the future.
9.1.2 Prevalence and clinical correlates of hepatic steatosis and NAFLD in
Type 2 diabetes (Chapter 6)
The primary aim of this phase of the ET2DS was to accurately define prevalence of hepatic
steatosis and NAFLD in a large population of people with Type 2 diabetes. The respective
prevalences of 56.9% and 42.6% are considerably lower than those quoted in previous
studies, and it is likely that this was due to validation of the ultrasound measure used and
rigorous exclusion of those with a secondary cause for steatosis from the diagnosis of
NAFLD(l8). A second finding was that BMI, HbAlc, triglycerides and lesser duration of
diabetes were independently associated with the presence of hepatic steatosis and NAFLD.
Thirdly, the diagnostic accuracy of liver enzymes in this context was relatively poor.
The study population of the ET2DS was designed to be representative of older people with
Type 2 diabetes within the Lothian region of Scotland. Representativeness data suggest that
this was achieved, but it is possible that such analysis does not test subtle differences
between people who chose to take part in an epidemiological study compared to those who
were not willing or able. It is possible that results cannot be generalised to younger people
with diabetes, but it should be remembered that the 60 - 75 age group makes up a significant
proportion of the Type 2 diabetic population as a whole and results are therefore of interest.
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The most accurate measure of population prevalence would come from studying an entire
population, potentially via opportunistic screening (with informed consent) at the time of
routine diabetes care, and one previous study captured data on the significant majority of
patients with Type 2 diabetes attending a hospital clinic(18). This, however, would be
difficult when the population in question is very large, and particularly when care is
undertaken at a number of sites including hospital outpatient departments and general
practitioner practices.
The criteria that defined secondary causes of hepatic steatosis (and thus exclusion from the
diagnosis of NAFLD) are worthy of further discussion. The approach in this study was to
define exclusions strictly, with the intention of characterising a population that we could feel
confident had NAFLD. In particular, it is a strength that the rarer causes of liver disease were
systematically sought by biochemical testing and use of record linkage. The limitations of
this approach are that it is likely that a proportion of those labelled as having a secondary
cause for steatosis (e.g. those with a modest increase in alcohol intake outwith the range
usually felt to be consistent with alcoholic liver disease) actually had NAFLD. Furthermore,
it is appreciated that NAFLD can co-exist with other liver diseases and this would not have
been picked up using the present methodology. There is no one accepted definition of the
secondary causes of steatosis and this has led to heterogeneity between previous studies.
These limitations underline the shortcomings of the current means of defining NAFLD,
which is currently principally a diagnosis of exclusion. Future work might focus on building
a definition of NAFLD that is based on positive features such as those identified on
multivariate analysis in the current study population — obesity, Type 2 diabetes/glycaemic
control and hypertriglyceridaemia — in addition to clear exclusions such as significant
alcohol excess.
The observation that traditional LFTs are poorly sensitive in the diagnosis of hepatic
steatosis and NAFLD is in keeping with previous studies carried out in the non-diabetic
population. Use of previously-suggested lower cut-offs for upper limit of normal of ALT
resulted in improved sensitivity but at the expense of specificity(91). There are three
conclusions that can be drawn from this. Firstly, in the context of Type 2 diabetes, any ALT,
AST or GGT level above the laboratory reference range is highly indicative of liver
pathology and should be followed up with further investigation. Secondly, LFTs in the
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middle and upper parts of the normal range do not preclude overt abnormality on ultrasound
and should therefore not be viewed as screening tools for hepatic steatosis and NAFLD.
Thirdly, ALT within the normal range can be viewed as a continuum marker of risk, and it is
therefore conceivable that it could be used in combination with other clinical markers,
perhaps as part of a scoring system, to define "at risk" persons who might then go on to have
confirmatory tests. Future research might examine this further.
In conclusion, this study has confirmed the importance of accurate diagnosis of hepatic
steatosis and NAFLD in population studies of prevalence. Further studies examining
prevalence of steatosis and NAFLD in a group with Type 2 diabetes unselected as to age
would be valuable. Moreover, the use of routinely-available clinical parameters to target
people for ultrasound screening should be investigated further. At present a single
biochemical parameter that identifies those with steatosis remains elusive.
9.1.3 Prevalence and markers of advanced liver disease (Chapter 7)
The use of HA as a surrogate marker identified a prevalence of hepatic fibrosis of 5.7% in
this entire population of older people with Type 2 diabetes. Corresponding figures for
prevalence of ultrasound-diagnosed cirrhosis and HCC were 0.4% and 0.2%. When
participants with a secondary cause for liver disease, in whom fibrosis could be assumed to
be secondary to NAFLD, comparable prevalences of fibrosis, cirrhosis and HCC were 6.1%,
0.2% and 0.3% respectively. Once again routine LFTs performed poorly in the detection of
people with markers of advanced liver disease.
This study is one of the first to attempt to investigate the prevalence of advanced liver
disease in a population of people in whom liver biopsy would not be routinely justified. It
might have been anticipated that the prevalence of advanced liver disease would be higher in
this high risk population. However this supposition is based on data from selected patient
populations in which biopsy has been clinically indicated. It is perhaps surprising that the
prevalence of fibrosis appears to be less than that found in biopsy studies in obese
individuals undergoing bariatric surgery (in whom the prevalence was of the order of 10%),
but these patients were morbidly obese often with Type 2 diabetes and this combination is
likely to account for the difference(97;l76). It is of interest that results are comparable to
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those from another study in people with Type 2 diabetes that is contemporaneous to the
present analysis(173).
The significant limitation of this study was the use of surrogate markers to define advanced
liver disease. The gold standard, histological examination of liver tissue, was not considered
to be feasible or ethical in this study population. The use of HA has been justified by
previous reports that examined its diagnostic accuracy in comparison with biopsy; it is,
however, recognised that the PPV of this test will be affected by the prevalence of the
condition in the population under investigation. We attempted to improve specificity of the
test by using a relatively high cut-off to define fibrosis and by excluding people with arthritis
from the diagnosis. Nonetheless, results may be viewed as interesting baseline work to be
confirmed by subsequent investigation. Future studies might utilise a combination of
markers of fibrosis such as the ELF panel (biochemical markers of matrix turnover,
including HA, TIMP 1 and P3NP), along with imaging assessment of hepatic stiffness using
transient elastography or magnetic resonance elastography. In addition, markers of NASH
(as opposed to fibrosis specifically), such as cytokeratin-18 may be examined.
The proportion of people identified as requiring further investigation for advanced liver
disease (ostensibly biopsy) by available clinical risk scores was found to be much higher
than in the original studies performed in the non-diabetic population. Interestingly, the most
complex of the three scoring systems used in the current study (the NAFLD Fibrosis Score)
designated the majority of participants as being at indeterminate rather than high risk; this
was the only model to correlate with HA levels here. Currently there is not enough
information available to formally assess the diagnostic accuracy of the clinical risk scores in
the present Type 2 diabetic population. It would, however, seem reasonable to presume that
the PPV of all three scores will be less in the general Type 2 diabetic population than in a
population of patients that have had clinical features of liver disease significant enough to
justify biopsy, and indeed a previous study has suggested that the utility of the BARD score
is less in a population with Type 2 diabetes than in the general population. In the absence of
a routinely-available biochemical marker of high diagnostic accuracy, a reliable clinical risk
scoring system would be valuable in selecting patients for biopsy, but it is clear that in order
to be clinically useful such a score would have to be developed within the population at
which it is targeted, in this case in a general population of people with Type 2 diabetes. An
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inherent difficulty with future research into this issue is the lack of a concrete gold standard,
assuming that biopsy is ethically unjustifiable. As discussed in Chapter 7, one approach to
this difficulty would be to validate a construct reference standard against clinical outcomes
(including liver failure, complications of cirrhosis and death); the ET2DS provides a
potential forum for this as 5-year (and beyond) data will become available in the near future.
In conclusion, the use of surrogate markers of hepatic fibrosis is justifiable in the current
study population and has resulted in a prevalence of hepatic fibrosis that is in keeping with
the only other known estimate. Future work should focus on refining this estimate with use
of a battery of non-invasive markers, and more generally on validating such markers along
with clinical scoring systems in the Type 2 diabetic population. Longitudinal studies will be
valuable in defining the rate of and risk factors for progression in this population, Clarity on
this point may aid a decision on the usefulness of screening for different stages ofNAFLD.
9.1.4 Relationship of hepatic steatosis and NAFLD with clot formation and
lysis dynamics, and pro-thrombotic mediators (Chapter 8)
The main finding of this analysis was that the presence of hepatic steatosis and NAFLD was
associated with a longer clot lysis time and higher levels of the pro-thrombotic mediators
PAI-1 and C3. Following multivariate adjustment for these mediators and clinical
characteristics, the independent relationship ofNAFLD and clot lysis time was lost.
The principal hypothesis is that hepatic steatosis and NAFLD contribute to a prothrombotic
and inflammatory milieu that in turn contributes to variation in clot lysis time. It is not
possible to say with any certainty whether the steatotic liver is directly responsible for the
increased production of biochemical mediators (i.e. synthesis and release from hepatocytes),
or whether it is a marker of systemic inflammation and visceral obesity, with adipocytes and
mononuclear cells playing a significant role in production. Further investigation of mRNA
and protein synthesis at a tissue level would clarify this.
177
An unexpected finding was the positive association between hepatic steatosis/NAFLD and
lower fibrinogen levels. This has not been fully explained and further work to determine if
this is a reproducible finding and factors behind it would be valuable.
An area of particular interest is whether the increased clot lysis time might moderate the
previously-observed relationship between NAFLD and cardiovascular disease. The present
analysis has not explored this and a further study might focus on elucidating these
associations, perhaps by analysing the effect ofNAFLD and clot lysis dynamics at baseline
on longitudinal outcomes of cardiovascular disease and mortality. As clot formation and
lysis are likely to have most effect on acute events such as myocardial infarction, it would be
constructive to analyse these events separately from the effects of long-term atherosclerosis
such as angina.
9.1.5 Conclusion
The current work adds to our understanding of the prevalence and risk factors for NAFLD
within the Type 2 diabetic population, but several interlinking questions of clinical
importance remain incompletely answered. In particular, it remains debated whether we
should screen for NAFLD, which patients should be routinely screened and how this should
be carried out.
The evidence, both here and in the work of other authors, is persuasive that a significant
percentage of people with NAFLD in the context of Type 2 diabetes and obesity develop
hepatic fibrosis. Despite this, the proportion that go on to display associated morbidity and
mortality in the form of clinically apparent liver disease may be smaller than previously
postulated. Longitudinal follow-up of cohorts such as the ET2DS will be important in
determining what the impact of NAFLD is, particularly as mortality from cardiovascular
disease is reduced. Such data will inform the decision whether to more comprehensively
screen for NAFLD in the Type 2 diabetic population. Other important considerations are the
development of an effective screening strategy and development of treatments that might
slow or halt progression ofNAFLD.
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If screening were to be proposed then it is certainly possible to argue that all people with
Type 2 diabetes should be screened, and the simple clinical scoring systems for fibrosis that
have been outlined highlight the high-risk nature of this population. A more stratified
approach, based on the data presented in the current work, might use markers such as BMI
and glycaemic control to identify those at particularly high risk.
Currently there is no focused screening strategy designed to systematically diagnose
NAFLD. Traditional LFTs are a poorly sensitive screening tool, but a high ALT is a strong
indicator of liver pathology and should be further pursued. One approach would be to
identify all those with hepatic steatosis on ultrasound as an initial step, and the current study
would suggest that such screening can be carried out by an experienced sonographer as well
as by radiologists. More challenging, however, is the identification of those with NASH or
fibrosis (who are at highest risk of morbidity and mortality related to liver disease) as the
available non-invasive tools, such as the ELF panel or cytokeratin-18, are expensive and not
widely available clinically. It is to be hoped that an increasing body of evidence confirming a
clinically important burden of liver disease will drive change in this area.
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AIM: To compare ultrasound gradings of steatosis with fat fraction (FF) on magnetic reso¬
nance spectroscopy (MRS; the non-invasive reference standard for quantification of hepatic
steatosis), and evaluate inter- and intraobserver variability in the ultrasound gradings.
MATERIALS AND METHODS: Triple grading of hepatic ultrasound examination was performed
by three independent graders on 131 people with type 2 diabetes. The stored images of60 of these
individuals were assessed twice by each grader on separate occasions. Fifty-eight patients were
pre-selected on the basis of ultrasound grading (normal, indeterminate/mild steatosis, or severe
steatosis) to undergo ^-MRS. The sensitivity and specificity of the ultrasound gradings were
determined with reference to MRS data, using two cut-offs ofFF to define steatosis, >9% and >6.1 %.
RESULTS: Median (intraquartile range) MRS FF (%) in the participants graded on ultrasound
as normal, indeterminate/mild steatosis, and severe steatosis were 4.2 (1.2—5.7), 4.1 (3.1—8.5)
and 19.4 (12.9-27.5), respectively. Using a liver FF of >6.1% on MRS to denote hepatic steatosis,
the unadjusted sensitivity and specificity of ultrasound gradings (severe versus other grades of
steatosis) were 71 and 100%, respectively. Interobserver agreement within one grade was
observed in 79% of cases. Exact intraobserver agreement ranged from 62 to 87%.
CONCLUSION: Hepatic ultrasound provided a good measure of the presence of significant
hepatic steatosis with good intra- and interobserver agreement. The grading of a mildly
steatotic liver was less secure and, in particular, there was considerable overlap in hepatic FF
with those who had a normal liver on ultrasound.
© 2011 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
* Guarantor and correspondent: R.M.Williamson, Royal Infirmary of Edinburgh, Little France Crescent, Edinburgh EH16 4SA, UK. Tel.: +44 (0) 131 2421466.
E-mail address: rachel_m_williamson@hotmail.com (R.M. Williamson).
0009-9260/$ - see front matter © 2011 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
doi:10.10l6/j.crad.2010.09.02l
R.M. Williamson et al. / Clinical Radiology 66 (2011) 434-439 435
Introduction
Non-alcoholic fatty liver disease (NAFLD), i.e., hepatic
steatosis in the absence of a secondary cause, is a common
cause of chronic liver disease. It is more common in people
with type 2 diabetes than in the general population, and
studies have suggested that it may affect up to 75% of indi¬
viduals in this group.1-3 It is important to detect this condition
as it can result in considerable morbidity and mortality,4-7
and may independently predict the risk of cardiovascular
events.8 Its identification can be used to initiate screening and
target treatment for hepatic cirrhosis.
Ultrasound imaging is an established imaging modality in
the diagnosis ofhepatic steatosis, both clinically and in large-
scale studies. Although several grading systems have been
proposed for the assessment of hepatic steatosis using
ultrasound, no consensus has been achieved.3,9-12 Detection
of hepatic fat is based on well-established characteristics
including an echogenic parenchyma (especially in relation to
the right kidney), posterior attenuation, and areas of focal
fatty sparing.3,11-14 Compared with liver biopsy, it has been
reported to have a sensitivity of 83-100% and specificity of
84-100% in the diagnosis of hepatic steatosis.9,11,13,15 It also
has the advantages over biopsy of safety, ease of acquisition,
and ability to assess the whole liver.
Although a degree of subjectivity is recognized when
diagnosing hepatic steatosis by ultrasound examination,
few studies have examined intra- and interobserver vari¬
ability in making this diagnosis. One study of 25 patients
with biopsy-proven NAFLD (less than a quarter of whom
had diabetes) reported that the interobserver correlation
between two radiologists in determining severity of stea¬
tosis was 0.40 (representing fair agreement), and the
intraobserver correlation was 0.63 (suggesting more
substantial agreement).9 A different study comprising 168
patients who had undergone abdominal ultrasonography
for a variety of abdominal disorders, demonstrated inter¬
observer agreement between three radiologists regarding
the presence and severity of hepatic steatosis of 0.40-0.51
and intraobserver agreement of 0.58 (moderate agree¬
ment).16 In both studies, the assessment of the severity of
steatosis was based on the presence and severity of
increased echogenicity of the hepatic parenchyma and
attenuation of the ultrasound beam.
In comparison with ultrasound imaging, magnetic reso¬
nance spectroscopy (MRS), the non-invasive reference
standard formeasurement ofhepatic fat, is expensive but has
a high correlation with liver fat concentration on biopsy, of
the order of 0.7—O.9.17,18 Different "normal" values for
hepatic fat fraction (FF) on magnetic resonance imaging have
been reported previously.19-21 The Dallas Fleart Study used
MRS to determine hepatic FF in a population of 345 partici¬
pants who had normal body mass index (BMI), glucose
tolerance, and liver function tests, and non-excessive alcohol
use (i.e., a very low risk for developing hepatic steatosis). In
this group the 95th percentile of hepatic triglyceride content
(expressed as grams of triglyceride per 100 gwet liver tissue)
was 5.5%, corresponding to an MRS fat fraction of 6.1 %,17 and
this was taken as the upper limit of normal.20 In an earlier
smaller study, 28 healthy volunteers underwent magnetic
resonance imaging (MRI) using a modified Dixon gradient
echo technique. All had a magnetic resonance hepatic FF
under 9% and this was later considered as being the upper
limit of normal.19,21 In the same study seven patients with
cystic fibrosis underwent both MRI and liver biopsy: two
patients who had no steatosis on biopsy had a FF on MRI of
<9%; five patients who had mild to severe steatosis had a FF
of >9%. A further study found that the geometric mean
intrahepatic lipid content (percentage ratio ofCH2 lipid peak
area relative to the water peak area) in 23 healthy volunteers
to be 2.7 (range 0.2-77.4).22 There is a paucity of data
comparing qualitative ultrasound gradings with FF on MRS.
The aim of the present study was to compare ultrasound
gradings of hepatic steatosis, performed by three graders,
with hepatic FF on MRS, and also to examine inter- and
intraobserver variability in these ultrasound gradings.
Materials and methods
The selection of participants for the Edinburgh Type 2
Diabetes Study has been previously described in detail.
Briefly, patients recorded as having type 2 diabetes, aged
60—74 years, were selected at random into sex and 5 year
age bands from the Lothian Diabetes Register, a computer¬
ized database that contains details of over 20,000 patients
with type 2 diabetes living in Lothian, Scotland. Invitations
to participate in an initial clinic were sent to 5454 people
and, of these, 1077 (19%) attended a baseline clinic (for
a study investigating cognitive function). Of these, 939
participants re-attended for liver assessment by liver
ultrasound examination (ultrasoundi) at a specially set up
research clinic. Ethical approval for the study had been
gained from the local ethics committee and written
informed consent was given by each participant. All ultra¬
sound examinations were performed after a 4 h fast by
a single ultrasonographer (grader 1), using a Sonoline Ele-
gra Ultrasound Imaging System (Siemans Medical Systems,
Washington, USA), software version 6, with a 3.5 MHz
transducer. The appropriate pre-set ("medium" or "large"
abdomen) was chosen for each subject according to the
ultrasonographer's judgement — these pre-sets remained
constant throughout the study. Participants were scanned
raised at an angle of 30-40° onto their left side. Right lobe
images were subcostal or intercostal depending on the body
habitus of the participant; left lobe images were obtained in
the midline of the abdomen. The following images were
obtained: longitudinal images of the right lobe and caudate
lobe with inferior vena cava, right lobe with the portal vein,
right lobe in the mid-clavicular line, right lobe of liver with
kidney (at least two images) for comparison, right lobe close
to the diaphragm and left lobe in its midline; transverse
images of the right lobe at the level of the hepatic veins
entering the inferior vena cava and at the level of the main
portal vein, the right lobe close to the diaphragm, the right
lobe at the level of the right portal vein and /or right hepatic
vein, the right lobe of liver with kidney for comparison and
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the left lobe at the level of the left hepatic vein and/or left
portal vein. The liver was graded for evidence of hepatic
steatosis using accepted criteria including a bright hepatic
echo pattern (compared with the right kidney), increased
attenuation of the echo beam (impaired visualization of the
diaphragm or intrahepatic vessels) and the presence of focal
fatty sparing.3,9-12 Participants were given an overall liver
grading based on a subjective measurement of the severity
of steatosis: normal; indeterminate (i.e., possible slight
increase in echogenicity or slightly impaired visualization of
the diaphragm or intrahepatic vessels, or difficulty in
grading as a result of a diseased or absent right kidney):
mild steatosis (i.e., definite increase in echogenicity and/or
definite impaired visualization of the intrahepatic vessels
and diaphragm, no or little evidence of focal fatty sparing):
severe steatosis (i.e., marked increase in echogenicity and/
or poor or no visualization of the diaphragm and intra¬
hepatic vessels, with or without focal fatty sparing).
MRS subgroup
A subgroup of participants from the cohort described
above were selected to undergo MRS. Twenty participants
were selected at random into each of three groups on the
basis of their ultrasoundi grading: normal (with normal
biochemical tests of liver function): indeterminate or mild
steatosis (a pre-determined merging of these two gradings
into one group); and severe steatosis. In addition, those
with steatosis were selected following exclusion of
a secondary cause (excess alcohol intake, hepatotoxic
medication use, viral hepatitis, or autoimmune hepatitis)
and, therefore, had NAFLD. Other exclusion criteria were
maximal diameter over 60 cm (in order to fit the dimen¬
sions of the scanner) and contraindications to MR1. One
participant who did not tolerate the procedure was
replaced by another participant who had the same grading
classification. MRS measurements were unsuccessful in two
participants and, therefore, 58 participants who attended
for imaging had successful FF measurements.
At the MRS visit, participants underwent a repeat ultra¬
sound examination (ultrasound2), using the above protocol,
2 h prior to MRS. This measurement was made to ensure
that the ultrasound grading reflected the presence or
absence of steatosis in the liver at the time of MRS.
The MRS examination was performed using a 1.5 T F1DX
scanner (GE Healthcare, Amersham, UK) and consisted of
a PRESS-localized volume of interest (V01) of dimensions
30 x 30 x 30 mm, placed away from vascular structures. The
system's body coil was used for transmission and reception.
A repetition time (TR) of 5 s allowed substantial T1 relaxa¬
tion of the signals, and a short (40 ms) echo time (TE) was
used to minimize T2 decay. Automatic shimming achieved
a water line width of typically 11 Hz. Sixteen acquisitions
were averaged. Water-suppressed spectra (64 acquisitions)
were also collected but are not reported here. The MRS data
files were transferred from the scanner to a computer
workstation for analysis. Quantification consisted of
normalization for scanner transmit and receive gains and
actual VOl volume, followed by modelling of the water and
fat peaks using the MRU1 package (www.mrui.uab.es). FF
was defined as the ratio of the area under the fat peak to the
combined areas under the water and fat peaks.
Intra- and interobserver variability
Sixty participants from the MRS subgroup had
ultrasound2, and 71 participants from the initial cohort had
ultrasoundi, graded by three independent graders using the
four-point grading system outlined above (normal, indeter¬
minate, mild steatosis, and severe steatosis). The 71 partici¬
pants from the initial cohort represented all who were
scanned during a particular calendar month. The three graders
comprised the sonographer who performed the examinations
(grader 1,15 years experience), a consultant radiologist (grader
2, 12 years experience), and a medical trainee in radiology
(grader 3,2.5 years experience). Grader 1 scored images at the
time of acquisition; still images from the examinations were
recorded and saved for examination by graders 2 and 3. The
three graders were blinded to each others' gradings and to the
MRS result. All graders were unaware of the clinical and
laboratory results of the participants.
After an interval of at least 2 months, each of the three
graders re graded the still images from the 60 ultrasound2
examinations, in a blinded fashion, to allow assessment of
intraobserver variability.
Statistical analysis
The median and interquartile ranges of FF on MRS were
calculated in each group according to ultrasound gradings.
The Kruskal—Wallis test was used to compare FF between
all three groups, and the Mann-Whitney test was used for
post-hoc comparisons between pairs of groups. Sensitivity
and specificity of the ultrasound2 gradings were deter¬
mined with reference to MRS data, using two separate cut¬
offs of FF to define "normality", 9% and 6.1 %.17,20,21 The
results for grader 1 were later adjusted to take into account
the proportion of participants in the entire cohort receiving
each grading. Inter- and intraobserver variability were
analysed using the marginal homogeneity test. Data were
analysed using SPSS version 14.0.
Results
MRS subgroup
All 58 participants with spectroscopy measurements
underwent the repeat ultrasound examination (ultra-
sound2) and this was graded by three graders; the number
of participants put into each category for each grader is
listed in Table 1. For grader 1, median MRS FF was 4.2% (1Q
range 1.2-5.7%) in the group graded normal, 4.1% (1Q range
3.1—8.5%) in the group graded indeterminate/mildly stea-
totic, and 19.4% (1Q range 12.9-27.5%) in the group graded
severely steatotic (Fig 1). There was a significant difference
in median FF between the three groups (p < 0.001). The
group with severe steatosis had significantly higher FF than
either the normal (p< 0.001) or the indeterminate/mild
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Table 1
Fat fraction on magnetic resonance spectroscopy for each of three groups of gradings on ultrasound (normal, indeterminate/mildly steatotic, severely steatotic)
as performed by three graders.
Normal Indeterminate/mild Severe
Grader 1 4.2 (1.2—5.7) [n = 17) 4.1 (3.1-8.5) [n = 19] 19.4 (12.9—2.75)a [n = 22]
Grader 2 4.2 (1.3-5.7) [n = 16] 4.1 (2.6-7.9) [n = 20] 19.4 (12.9—27.5)a [n = 22]
Grader 3 4.2 (1.8-6.3) In = 26] 6.0 (3.0-12.5) [n = 14] 20.1 (12.9—28.4)a ]n= 18]
Data are median (interquartile range) [number of participants].
a Significant difference in the fat fraction between the normal, indeterminate/mild, and severe groups (p< 0.001).
steatosis groups (p < 0.001). There was no significant
difference in FF between the normal and indeterminate/
mild steatosis groups. Results were similar for the gradings
of the other two graders (Table 1).
For grader 1, all 17 participants in the group who were
graded as normal had a FF less than 9%, and 14 of these
participants had a FF less than 6.1%. In the indeterminate/
mildly steatotic ultrasound group, 16 participants had a FF
less than 9% and, of these participants, 10 had a FF under
6.1%. In the severely steatotic group, all but one participant
had a FF of greater than 9%, with the remaining participant
having a FF of 8.45%. Results for the other two graders were
similar and are listed in Table 2.
Sensitivity and specificity were calculated with both MRS
FF cut-offs and results, with 95% confidence intervals, are
presented in Table 3. For grader 1 using a liver FF of >9% on
MRS to denote hepatic steatosis, the sensitivity of ultra¬
sound in detecting indeterminate/mild/severe steatosis was
100% and specificity was 50%. If those graded indetermi¬
nate/mild steatosis were instead grouped with those graded
normal (in view of the similar median MRS FF in these
groups) sensitivity was 87.5% and specificity 97.1%. When
a liver FF of >6.1% was used to define hepatic steatosis, the
sensitivity of ultrasound in detecting indeterminate/mild/
normal indeterminate/mild severe
Gradings on USS
Figure 1 Boxplot showing median percentage fat on MRS in each of
the three groups of ultrasound gradings by grader 1 (normal, inde¬
terminate/mild steatosis, severe steatosis). Upper and lower ends of
rectangles correspond to 75th and 25th centiles, respectively. Whis¬
kers represent maximum and minimum values. Outliers in the
indeterminate/mild steatosis group are marked by an asterisk. The
group with severe steatosis had a significantly higher median FF than
those with normal or indeterminate/mild steatosis (p < 0.001).
severe steatosis was 90.3% and specificity was 51.9%. When
those with indeterminate/mild steatosis were grouped with
those graded normal, the sensitivity was 71 % and specificity
100%. Results were extremely similar for grader 2. For
grader 3, the sensitivity in detecting indeterminate/mild/
severe steatosis was lower (87% and 78.1% for the 9% and
6.1% cut-offs, respectively) but specificity was higher (65.7
and 57.6% for the 9% and 6.1% cut-offs, respectively).
As the sensitivity and specificity of a test can be affected
by the prevalence of the underlying condition (and in the
present study, participants were selected according to
presence of the condition on ultrasound, thereby pre¬
determining the prevalence), the results of grader 1 were
adjusted to take account of the proportion of participants in
the entire cohort of 939 participants who received each
grading (24% normal, 19% indeterminate/mild steatosis, 57%
severe steatosis). The results were not substantially
different from the unadjusted data (Table 3).
Inter- and intraobserver variability
Calculation of interobserver agreement between the
three graders revealed exact consensus in 51% (67/131 given
the same grade). Interobserver agreement within one grade
was seen in 79% of cases (104/131). Interobserver variation
of two grades was seen in 17% (22/131), and variation of
three grades was seen in 4% (5/131). On pairwise analysis,
there was no significant variation in the gradings of graders
1 and 2 (68% exact consensus), or between those of graders
2 and 3 (65% exact consensus). When the gradings of
graders 1 and 3 were compared, however, there was found
to be significant variation (disparity in 41% of results,
p = 0.024). When the 71 participants from the original
cohort were examined separately, there was no significant
variation between gradings from different graders. In
contrast, there was significant variation between the grad¬
ings of the 60 participants in the MRS subgroup between
graders 1 and 3 (p = 0.005), and graders 2 and 3 (p = 0.011).
Intraobserver variation was minimal for graders 1 and 2
(87 and 77% exact concordance between the first and second
readings, respectively), but statistically significant for grader
3, with 38% disparity between readings, (p = 0.039).
Discussion
To the authors' knowledge this is the first study to
examine both the relationship between ultrasound gradings
of steatosis and MRS, and the inter- and intraobserver
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Table 2
Comparison of ultrasound gradings with proposed cut-offs of "normality" (<6.1% and 9%) of the fat fraction on magnetic resonance spectroscopy.19,20
MRS cut-off Grading
Normal Indeterminate/mild Severe
Grader 1 Grader 2 Grader 3 Grader 1 Grader 2 Grader 3 Grader 1 Grader 2 Grader 3
(n = 17) (n 16) (n = 26) (n^l9) (n = 20) (n = 14) (n = 22) (n = 22) (n = 18)
9% < 9% 17 16 23 16 17 10 1 2 2
> 9% 0 0 3 3 3 4 21 20 16
6.1% <6.1% 14 14 19 13 13 7 0 0 1
> 6.1% 3 2 7 6 7 7 22 22 18
agreement in ultrasound grading. The present study was
broad in its scope, including both participants who were
likely to have a normal liver and those considered to have
varying degrees of hepatic steatosis, mainly NAFLD. In addi¬
tion, the use of ultrasound has been examined in diagnosing
hepatic steatosis in people with type 2 diabetes, a population
who are at high risk of developing hepatic steatosis and in
whom screening for the condition should be considered.
When compared to MRS, a normal ultrasound grading
was an excellent predictor of a normal hepatic FF, and
a severe steatosis grading was an excellent predictor of the
presence of hepatic steatosis. The grading of a mildly stea-
totic liver was less reliable, and in particular, considerable
overlap in hepatic FF was evident compared with those who
had a normal liver on ultrasound. Therefore, it is reasonable
to suppose that those graded indeterminate/mild steatosis
had subtle changes on ultrasound that were within the
limits of normality. In clinical practice, a grading of inde¬
terminate/mild steatosis should be interpreted in conjunc¬
tion with clinical and biochemical factors, and it may be
appropriate to repeat the ultrasound examination after an
interval of time. The performance of the three graders was
similar when gradings were compared to MRS. It should be
emphasized that ultrasound images were obtained within
hours of MRS measurements to ensure that they were truly
comparable, as hepatic steatosis can vary over time.
Individuals were pre-selected into the MRS subgroup
based on their ultrasound! gradings, with the intention of
having broadly equal numbers of participants in each of
three groups. It was acknowledged that the proportion in
each group was different to the proportion of each grade in
the entire cohort, as graded by grader 1. Therefore, adjusted
figures were provided for comparison, with the assumption
that if the number of participants in each ultrasound
grading group had been selected according to overall
proportion in the total cohort, then the proportion of
participants in each group testing below and above the cut¬
offs of MRS FF would have stayed the same.
No accepted definition of "normal" FF on MRS currently
exists. Biopsy data from normal livers and MRS FF have
rarely been compared. Furthermore, studies investigating
"healthy" volunteers may be skewed by the presence of
overweight individuals or those who drink alcohol in
amounts greater than 14 units/week — both of which are
known to predispose to hepatic steatosis. It seems likely
that the proposed figure of 6.1% (corresponding to 5.5%
hepatic triglyceride content, if expressed as grams of
triglyceride per 100 g wet liver tissue) for the upper limit of
normal is the most accurate available, as this was calculated
using a population from which those with risk factors for
steatosis, such as BMI >25 kg/m2, glucose intolerance, and
excessive alcohol use had been excluded.20
It is acknowledged that MRS gives information regarding
FF within a portion of the liver rather than in the liver as
a whole, and that it was theoretically possible that partici¬
pants with focal fatty change could be misclassified as
a result. In this study, however, the volume of interest for
MRS was fairly large in order to minimize any effects of local
heterogeneity. Indeed, examination ofMRS data from the 15
participants with focal fatty sparing on ultrasound revealed
FFs that were in keeping with their overall ultrasound
grading (data not shown).
Table 3
Sensitivity and specificity of ultrasound in identifying presence of hepatic steatosis, using two cut-offs of hepatic fat fraction (<9% and <6.1%) on magnetic
resonance spectroscopy.
Cut-off Sensitivity (unadjusted) Specificity (unadjusted) Sensitivity (adjusted) Specificity (adjusted)
9% Cut-off
Normalversus indet/mild/severe steatosis
Normal/indet/mild steatosis versus severe
steatosis
6.1% Cut-off
Normal versus indet/mild/severe steatosis 90.3(73.1-97.5) 51.9(32.4-70.8) 94.7(80.9—99.1) 60(36.4-80)
Normal/indet/mild steatosis versus severe 71 (51.8-85.1) 100(84.5-100) 86.8(71.1-95.1) 100(80-100)
steatosis
Data are shown for the grouping of the indeterminate/mild steatosis group with either the normal or the severe steatosis groups. Both unadjusted values and
those that have been adjusted to take account of the proportion of each grading in the entire study cohort are presented. Ultrasound gradings are from grader 1.
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Comparison of the gradings by three experienced
graders revealed some variation, but exact concordance in
a majority of cases, with most differences being small (one-
point only); intraobserver concordance was high in two of
three graders, but was lower for the grader with the least
experience (a medical trainee in radiology). Of the two
previous studies to examine inter- and intraobserver vari¬
ability, one was a small study whose scope was limited to
patients with abnormal biochemical liver function tests and
biopsy-proven NAFLD.9 The other was more comparable in
size and scope to the present study, but results cannot be
directly compared due to different statistical methods used.
The present study compared gradings from graders with
different training (a sonographer, a senior consultant radi¬
ologist, and a medical trainee in radiology). This reflects
clinical practice, and is particularly relevant at a time when
increasing numbers of ultrasound examinations are being
performed by experienced sonographers.
Participants in the MRS substudy were necessarily less
than 60 cm in maximal diameter so excluding people with
very severe obesity. It is widely acknowledged that ultra¬
sound is more difficult in the most obese patients, and it
could be anticipated that accuracy (compared to MRS) and
inter-/intraobserver concordance would be less in this
population. It is, however, important to note that interob-
server variation in the MRS subgroup was not superior to
that of the essentially randomly selected group from this
general study population.
In conclusion, hepatic ultrasound provides a good
measure of the presence of hepatic steatosis, and in partic¬
ular, a normal grading and severe steatosis grading were
excellent predictors of a normal and high MRS FF, respec¬
tively. Hepatic ultrasound has advantages over other
measures of hepatic fat in its ease of use and lack of adverse
side-effects, and is likely to remain a mainstay of investiga¬
tion, both in research and clinical situations.
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OBJECTIVE—Type 2 diabetes is an established risk factor for development of hepatic steatosis
and nonalcoholic fatty liver disease (NAFLD).We aimed to determine the prevalence and clinical
correlates of these conditions in a large cohort of people with type 2 diabetes.
RESEARCH DESIGN AND METHODS—A total of 939 participants, aged 61-76 years,
from the Edinburgh Type 2 Diabetes Study (ET2DS)—a large, randomly selected population of
people with type 2 diabetes—underwent liver ultrasonography. Ultrasound gradings of steatosis
were compared with magnetic resonance spectroscopy in a subgroup. NAFLD was defined as
hepatic steatosis in the absence of a secondary cause (screened by questionnaire assessing alcohol
and hepatotoxic medication use, plasma hepatitis serology, autoantibodies and ferritin, and
record linkage to determine prior diagnoses of liver disease). Binary logistic regression was used
to analyze independent associations of characteristics with NAFLD.
RESULTS—1 iepatic steatosis was present in 56.9% of participants. After excluding those
with a secondary cause for steatosis, the prevalence of NAFLD in the study population was
42.6%. Independent predictors of NAFLD were BM1, lesser duration of diabetes, HbA]c, tri¬
glycerides, and metformin use. These remained unchanged after exclusion of participants with
evidence of hepatic fibrosis from the group with no hepatic steatosis.
CONCLUSIONS—Prevalences of hepatic steatosis and NAFLD were high in this unselected
population of older people with type 2 diabetes, but lower than in studies in which ultrasound
gradings were not compared with a gold standard. Associations with features of the metabolic
syndrome could be used to target screening for this condition.
Nonalcoholic fatty liver disease(NAFLD), defined as hepatic steatosisin the absence of a secondary cause,
is the commonest cause of liver disease
in westernized countries, affecting up to
Diabetes Care 34:1139-1144, 2011
33% of the general population (1,2) and
up to 75% in some subgroups such
as obese patients (3). An association
between NAFLD and type 2 diabetes is
well established. Diabetes has been
shown to be a risk factor for the develop¬
ment of NAFLD and its progression to
more advanced liver disease including fi¬
brosis, cirrhosis, and hepatocellular carci¬
noma (4,5). Furthermore, data suggest
that some classes of antidiabetic agents
(6,7) may be used as treatments in
NAFLD.
Despite the recognized association
between type 2 diabetes and NAFLD,
few large-scale studies of the prevalence
of NAFLD in unselected populations of
people with type 2 diabetes are available.
Studies estimating the prevalence using
liver ultrasound have been performed in
secondary care rather than community
setting and have generally examined small
numbers of patients (8). A large study in
Italian outpatients with type 2 diabetes
reported that 85% had hepatic steatosis
and that 70% met the criteria for NAFLD
(defined in that study as hepatic steatosis
without evidence of excess alcohol con¬
sumption, viral hepatitis, or causative
medications) (9). This study, however,
was confined to patients attending a hos¬
pital clinic and also failed to systemati¬
cally identify and exclude participants
with less common causes of liver disease
such as autoimmune hepatitis. Further¬
more, ultrasound measurements were
not compared with a gold standard in
the population studied—an important
factor given the variable sensitivity and
specificity of ultrasound assessment for
hepatic steatosis (10).
Given the rising incidence and prev¬
alence of type 2 diabetes, an accurate
estimate of the prevalence of NAFLD, as
well as its clinical correlates, is important
to predict the number ofpatients who will
require to be monitored for more ad¬
vanced liver disease or who may benefit
from future disease-modifying agents.
The aim of the current study was to
determine the prevalence of NAFLD in a
large, randomly selected population of
older people with type 2 diabetes, using
magnetic resonance spectroscopy (MRS)
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Hepatic steatosis and NAFLD in ET2DS
to confirm ultrasound grading classifica¬
tions and thorough screening for second¬
ary causes of liver disease, and to examine




baseline examination of subjects for the
Edinburgh Type 2 Diabetes Study
(ET2DS) have been described previously
(11). Briefly, subjects recorded as having
type 2 diabetes and aged 60-74 years
were selected at random by sex and 5-
year age bands in years 2006-2007 from
the Lothian Diabetes Register. This is a
comprehensive database of people with
type 2 diabetes living in Lothian, a region
in the south-east ofScotland that includes
the city of Edinburgh and its surrounding
towns and countryside, including both
patients attending a hospital clinic and
those managed solely in primary care.
Study participants (n = 1,066) have been
shown previously to be representative, in
terms of age, HbAic, duration of diabetes,
insulin treatment, and total cholesterol, of
all those randomly selected to participate
(n = 5,454) and therefore of the target
population of older men and women
with type 2 diabetes living in the gen¬
eral population (12). At the time of re¬
cruitment into the study, participants
attended a baseline examination that in¬
cluded measurement of demographic and
anthropometric variables (age, sex, BMI,
and waist circumference), plasma HbAlc,
total cholesterol, platelets, and hyaluronic
acid. One year after baseline examination,
1,054 participants were invited to attend
a year 1 clinic for assessment of liver
structure and function. A total of 12 par¬
ticipants were not invited due to with¬
drawal (n = 2), refusal of consent for
contact (n = 5), unsuitable for contact
(n = 3), or death (n = 2). A total of 939
subjects (88% of the original cohort) par¬
ticipated in the year 1 clinic. Of those sub¬
jects invited but who did not attend the
year 1 clinics (n = 114), 19 were uncon-
tactable, 61 unable or unwilling to attend,
21 repeatedly cancelled or failed to attend
appointments, and 13 had died.
The ET2DS was approved by the local
research ethics committee, and all partic¬
ipants gave written informed consent for
baseline and year 1 examinations.
Ultrasound examination and
comparison with MRS
Subjects attended the year 1 research
clinic after a 4-h fast for an ultrasound
examination of abdomen. All ultrasound
examinations were performed by a single
ultrasonographer, who was unaware of
the clinical and laboratory results of the
participants, using a Sonoline Elegra Ul¬
trasound Imaging System (Siemens Med¬
ical Systems, Issaquah, WA), software
version 6, with a 3.5-MHz transducer.
The liver was graded for markers of he¬
patic steatosis using established criteria
(13—15) including a bright hepatic echo
pattern (compared with the echo re¬
sponse of the right kidney), increased at¬
tenuation of the echo beam, and the
presence of focal fatty sparing. Partici¬
pants were given an overall liver grading
based on a subjective measurement of the
severity of steatosis: grade 0, normal ap¬
pearance of liver on ultrasound and ini¬
tially graded as a "normal ultrasound";
grade 1, possible slight increase in echo¬
genicity or slightly impaired visualization
of the diaphragm or intrahepatic vessels,
or difficulty in grading as a result of a dis¬
eased or absent right kidney—initially
termed an "indeterminate ultrasound";
grade 2, definite increase in echogenicity
and/or definite impaired visualization of
the intrahepatic vessels and diaphragm,
no or little evidence of focal fatty sparing,
initially graded as "evidence ofmild steatosis
on ultrasound"; grade 3, marked increase
in echogenicity and/or poor or no visu¬
alization of the diaphragm and intrahe¬
patic vessels, with or without focal fatty
sparing, initially graded as "evidence of
severe steatosis on ultrasound." Evidence
of hepatic cirrhosis was also sought sys¬
tematically.
Comparison of the ultrasound grad-
ings for hepatic steatosis with 'H MRS,
the noninvasive gold standard for quanti¬
fication of hepatic fat, in a subgroup of 58
participants has previously been de¬
scribed in detail (16). In brief, 17 partic¬
ipants with a grade 0 ultrasound grading,
19 with grade 1 or 2, and 22 with grade 3
underwent MRS. A grade 0 grading on
ultrasound was associated with a "nor¬
mal" hepatic fat fraction on MRS of
<6.1% (17,18) in 14 of 17 cases (and a
fat fraction of <9% [19,20] in all cases)
and was accepted as "no steatosis." A
grading of grade 3 on ultrasound was
associated with and MRS hepatic fat
fraction >6.1% in all cases, and this was
therefore taken as "definite steatosis." The
group with grade 1 or 2 on ultrasound
had an MRS fat fraction of <6.1% in 13
of 19 cases, and a fat fraction of < 9%
in 16 of 19 cases, thus displaying consid¬
erable overlap with those regarded as
normal. In view of this, the group with
grade 1 or 2 on ultrasound scan was con¬
sidered to have a "probable normal" scan.
If a liver FF of 5:6.1% on MRS was used to
denote hepatic steatosis, sensitivity, spec¬
ificity, and positive and negative predic¬
tive values (adjusted for the portion of the
whole study cohort receiving each grad¬
ing) of ultrasound in detecting "definite
steatosis" were 86.8%, 100%, 100%,
and 80.0%, respectively.
Clinical examination
Average alcohol intake per week over the
previous year, a history of alcohol excess,
and use of hepatotoxic medications
within the previous 6 months were de¬
termined by questionnaire. Average alco¬
hol intake was determined using two
questions adapted from the AUDIT-C
screening tool (21): "How often did you
have a drink containing alcohol in the
past year? Consider a "drink" to be a can
or a bottle of beer, a glass of wine, or one
cocktail or a measure of spirits (like
scotch, gin, or vodka)" (a drink was con¬
sidered to be the equivalent of one unit of
alcohol); and "How many drinks did you
have on a typical day when you were
drinking in the last year?"
Those participants with evidence of
hepatic steatosis or abnormal blood tests
of liver function had further investiga¬
tions performed including serology for
hepatitis B and C, antinuclear antibody
(ANA), antismooth muscle antibody, an-
timitochondrial antibody, and ferritin. All
participants had brachial blood pressure,
serum triglycerides, and HDL cholesterol
measured.
Information on previous diagnoses of
chronic liver disease was collected from
participants by questionnaire at year 1
and supplemented using data on liver
diagnoses, which had been obtained at
baseline via record linkage to hospital
discharges at the Information and Services
Division (ISD) of NHS Scotland.
Definition of NAFLD
NAFLD was defined as the presence of
definite hepatic steatosis on ultrasound
scan (i.e., grade 3) in the absence of a
secondary cause for hepatic steatosis.
Secondary causes were defined as alcohol
consumption >14 units/week (22) or
participant report of current/previous al¬
cohol excess; use of hepatotoxic medica¬
tion (2) (glucocorticoids, isoniazid,
methotrexate, amiodarone, and tamoxi¬
fen) within the 6 months prior to the
year 1 clinic; positive hepatitis B or C
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serology; ferritin concentration >1,000
|xg/L (milder hyperferritinemia can be as¬
sociated with obesity, insulin resistance,
and NAFLD [2,23]); clinically significant
positive immunology titers (antismooth
muscle antibody titer ^1:160 [24] or an-
timitochondrial antibody titer >1:40
[25]); or a previous diagnosis of a persis¬
tent secondary cause for chronic liver dis¬
ease. Subjects were considered to have a
previous diagnosis of a secondary cause
for chronic liver disease if ISD linkage re¬
vealed such a diagnosis, or if a participant
report of a diagnosis was confirmed by
their medical records. Subjects were ex¬
cluded from calculations on the preva¬
lence of NAFLD if data on the above
measures were missing such that a sec¬
ondary cause could not be excluded.
Definition of metabolic syndrome
As per Adult Treatment Panel III criteria,
subjects were considered to have the
metabolic syndrome if, in addition to
type 2 diabetes, they had at least two of
the following: blood pressure si30/85 or
on antihypertensive treatment; triglycer¬
ides si.7 mmol/L or taking a fibrate;
HDL cholesterol < 1.04 mmol/L (men) or
1.29 mmol/L (women); waist circumfer¬
ence >102 cm (men) or 88 cm (women).
Statistical analysis
Analysis was performed using SPSS soft¬
ware version 14.0. Data that did not
conform to the normal distribution (du¬
ration of diabetes and triglycerides) were
log-transformed prior to parametric anal¬
ysis. Statistical analysis included the in¬
dependent t test and y2 tests to compare
characteristics between groups. Binary lo¬
gistic regression analysis was used to as¬
sess the independence ofvariables in their
association with hepatic steatosis and
NAFLD. Variables included in this model
were age, sex, BM1, duration of diabetes,
HbA)c, systolic blood pressure, HDL and
LDL cholesterol, triglycerides, and the use
ofmetformin, sulfonylureas, thiazolidine-
diones, incretinmimetics, and insulin. Al¬
cohol use S14 units/week or previous
alcohol misuse was used as a categorical
variable in the model examining hepatic
steatosis, but not that examining NAFLD.
Results were reported as estimated odds
ratios (ORs) and 95% CI.
RESULTS
Subject characteristics
The characteristics of 939 participants
(aged 61-76 years) attending the year 1
clinic are shown in Table 1. Baseline char¬
acteristics of subjects attending the year 1
clinical examination were similar to those
of the total ET2DS population suggesting
that the study population attending for
liver assessment remained representative
of the target general population with type
2 diabetes.
Prevalence of hepatic steatosis
and NAFLD
Of the 939 subjects undergoing abdom¬
inal ultrasound, data on steatosis grading
was incomplete for 2 subjects, and these
were excluded from the analysis. Hepatic
steatosis was graded as definite (grade 3)
on ultrasound examination in 56.9% (n =
533) of the remaining participants. The
appearance of the liver was normal (grade
0) in 23.5% (n = 220) of participants.
Twenty-two subjects (2.3%) were graded
as grade 1 (in three of these cases, it was
commented that the liver was difficult to
scan as it was located high up under the
costal margin) and a further 16.9% (n =
158) were graded as grade 2, giving a total
of 180 subjects (19.2%) who were classi¬
fied as "probable normal." In addition,
0.4% subjects (n = 4) had a liver in which
ultrasound identified cirrhosis—steatosis
gradings in these subjects were grade 0 in
two participants, grade 1 in one partici¬
pant, and grade 2 in one participant.
Among those with evidence of defi¬
nite hepatic steatosis (grade 3), 123 sub¬
jects had evidence of one or more
secondary causes for steatosis: 78 had
alcohol intake SI4 units/week or a his¬
tory of excess; 40 had used a hepatotoxic
medication, as outlined above, in the
previous 6 months; 1 each had serological
evidence of hepatitis B and C; 3 had ferritin
levels SI,000 p-g/L; 1 had antismooth
muscle antibody titer Si: 160; 1 had
antimitochondrial antibody titer Sl:40;
and 7 had previously diagnosed liver
disease (2 had alcoholic liver disease, 1
hemochromatosis, 1 autoimmune hepa¬
titis, 1 recurrent cholangitis, 1 biliary
cirrhosis, and 1 hepatic carcinoid metas¬
tases). In a further 19 subjects data were
missing such that a secondary cause
could not be excluded. In addition, a
further 160 participants had at least
one positive immunology titer Sl:40,
which was not considered significant.
Of these, most had borderline ANA
or antismooth muscle titers (£1:80; n =
120); 40 participants had ANA titer
>1:160.
Using the predefined criteria, 391 out
of 918 participants with a full dataset had
definite hepatic steatosis on ultrasound
grading with no secondary cause, giving a
prevalence of NAFLD of 42.6% in this
study population.
Table 1—Characteristics of subjects at year 1 clinic
Characteristic Year 1
n 939
Age (years) 68.9 ± 4.2
Sex, % (n) male 52.0 (488)
Race, % (n) Caucasian 98.3 (923)
BM1 measured at baseline clinic (kg/m2) 31.3 ± 5.7
Waist circumference measured at baseline clinic (cm) 106.7 ± 12.8
Duration of diabetes (years) 9.0 ± 6.4
HbA,c (%) 7.19 ± 1.06
Diet controlled, % (n) 19.4(182)
Oral antidiabetic agent users, % (n) 74.4 (699)
Insulin users, % (n) 15.8(148)
Systolic blood pressure (mmHg) 138.1 ± 18.5
Diastolic blood pressure (mmHg) 74.1 ± 9.6
Total cholesterol (mmol/L) 4.15 ± 0.81
HDL cholesterol (mmol/L) 1.23 ± 0.34
LDL cholesterol (mmol/L) 2.17 ± 0.68
Triglyceride (mmol/L) 1.66 ± 0.90
Statin users, % (n) 81.6 (767)
Aspirin users, % (n) 67.7 (636)
ACE inhibitor users, % (n) 52.0 (488)
Current or ex-smokers, % (n) 60.0 (563)
Data are mean ± SD or proportions in whole cohort of participants unless otherwise indicated.
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Physical and biochemical characteristics
of study participants according to steatosis
groups are shown in Table 2. In univariate
analysis, participants in the group with
definite steatosis (grade 3) were signifi¬
cantly younger and had lesser duration
of diabetes than the combined normal/
probably normal groups (grades 0, 1,
and 2) (P < 0.05). BMI, waist circumfer¬
ence, HbAic, diastolic blood pressure, tri¬
glycerides, and prevalence of alcohol
intake over 14 units/week were signifi¬
cantly higher, and HDL cholesterol signif¬
icantly lower, in the definite steatosis
group. Metformin use was more common
in the definite steatosis group. No signif¬
icant differences in the use of other
antidiabetic agents (sulfonylureas, glita-
zones, incretin mimetics, or insulin)
were found.
In multivariate analysis, independent
predictors of definite hepatic steatosis
(compared with those classed as normal/
probable normal) on ultrasound scan
were BMI (OR 1.07 [95% CI 1.04-
1.10]), lesser duration of diabetes (OR
for log duration diabetes 0.53 [0.30-
0.92]), HbAJc (OR 1.35 [1.15-1.59]), tri¬
glycerides (OR for log triglycerides 20.76
[0.85-50.85]), alcohol intake ^14 units/
week (OR 3.13 [1.80-5.43]), and use of
metformin (OR 2.19 [1.59-3.00]).
Similar results were obtained when
those with secondary causes for liver
disease were excluded from analysis.
Independent predictors of NAFLD were
BMI (OR 1.07 [95% CI 1.03-1.10]),
lesser duration of diabetes (OR for log
duration diabetes 0.46 [0.25-0.83]),
HbAlc(OR 1.29 [1.08-1.54]), triglycerides
(OR for log triglycerides 17.57 [6.68—
46.18]), and use of metformin (OR 2.25
[1.60-3.17]).
Of the 400 participants who had
gradings of normal/probable normal liver
parenchyma on ultrasound scan, 74 had
at least one of the following features
suggestive of possible hepatic fibrosis or
cirrhosis: spleen size ^13 cm (16 partic¬
ipants); hyaluronic acid >75 ng/mL (the
upper end of normal on the laboratory
reference range) in the absence of joint
disease (54 participants); or platelet count
<150 X 109/L (20 participants). If these
participants were excluded from regres¬
sion analysis, independent predictors of
definite steatosis and NAFLD were un¬
changed (data not shown).
CONCLUSIONS—This is the first
study to examine the prevalence of he¬
patic steatosis and NAFLD in a popula¬
tion of people with type 2 diabetes using
an ultrasound classification that has been
refined by comparison with MRS and with
detailed exclusion of secondary causes of
steatosis. The study population included
the full clinical spectrum of type 2 diabetes
and included people who were being
managed in the community as well as in
hospital clinics.
Previous studies have estimated that
a hepatic fat fraction on MRS of under
6.1-9% is consistent with a normal liver,
whereas hepatic steatosis is associated
with higher fat fractions (17-20). Com¬
parison of our ultrasound gradings with
MRS suggested that the "definite steato¬
sis" grading was an excellent predictor for
the presence of hepatic steatosis (16). In
contrast, considerable overlap was ob¬
served between those graded initially as
having "indeterminate" or "mild" steatosis
(grade 1 or 2) and the normal group, and
it was considered that these participants
probably had a normal liver. Our preva¬
lence of hepatic steatosis, at 56.9%, was
therefore considerably lower than in pre¬
vious studies including that of a large Ital¬
ian population of patients with type 2
diabetes, in which 85.3% were consid¬
ered to have hepatic steatosis (9). In
view of these findings, caution should
be used with regard to the prevalences
reported by previous studies that have
used ultrasound measurements that
have been less rigorously corroborated
for a diagnosis of hepatic steatosis.
NAFLD was the most common cause
for steatosis, accounting for 76% of all
cases. In comparison with previous stud¬
ies, our analysis had the advantage of a
more systematic identification and exclu¬
sion of secondary causes of liver disease in
those with steatosis, both by the use of
ISD linkage to identify previously diag¬
nosed chronic liver disease and by the
routine measurement of autoantibody
Table 2—Comparison of participant characteristics across gradings of steatosis
Steatosis grade
Grade 0 Grade 1 Grade 2 Grade 3
Characteristic (n = 220) (n = 22) (n = 158) (n = 533)
Age (years) 69.4 ± 4.2 68.5 ± 4.8 69.5 ± 4.4 68.5 ± 4.0*
Sex, % (n) male 59.9(132) 40.9 (9) 49.4 (78) 50.1 (267)
BMI measured at baseline clinic (kg/m2) 28.8 ± 5.18 35.1 ± 8.4 30.7 ± 4.9 32.4 ± 5.5*
Waist circumference (cm) 102.4 ± 13.5 112.6 ± 18.7 104.7 ± 11.6 108.9 ± 12.0*
Duration of diabetes (years) 9.6 ± 7.6 10.5 ± 6.0 9.8 ± 6.5 8.4 ± 5.8*
HbA,c (%) 7.02 ± 0.97 7.15 ± 0.93 6.99 ± 0.98 7.33 ± 1.12*
Systolic blood pressure (mmHg) 140.1 ± 21.5 141.2 ± 22.4 135.9 ± 18.6 137.9 ± 16.7
Diastolic blood pressure (mmHg) 73.4 ± 9.5 76.3 ± 11.2 72.1 ± 9.5 74.9 ± 9.4*
Total cholesterol (mmol/L) 4.14 ± 0.81 4.53 ± 0.81 4.01 ± 0.75 4.17 ± 0.82
HDL cholesterol (mmol/L) 1.28 ± 0.69 1.16 ± 0.27 1.30 ± 0.35 1.19 ± 0.32*
LDL cholesterol (mmol/L) 2.24 ± 0.70 2.57 ± 0.72 2.08 ± 0.65 2.14 ± 0.67
Triglyceride (mmol/L) 1.37 ± 0.69 1.76 ± 0.67 1.37 ± 0.63 1.86 ± 1.00*
Metabolic syndrome, % (n) present 70.2 (153) 86.4(19) 78.3 (123) 91.2 (485)*
Alcohol intake, % (n) over 14 units/week 6.4 (14) 0.0 (0) 7.6(12) 12.9 (69)*
Metformin use, % (n) 48.2 (106) 50.0(11) 63.3 (100) 70.9 (378)*
Data are mean ± SD unless otherwise indicated. 'Significant difference grade 3 vs. grade 0/1/2 by 1 lest or x test, P < 0.05.
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titers and ferritin in all participants with
steatosis. The use of these additional
measures within the group with steatosis
identified four patients with likely
hemochromatosis, two with likely auto¬
immune hepatitis, two with primary
biliary cirrhosis, one with recurrent
cholangitis, and one with hepatic carci¬
noid metastases; these accounted for
1.9% of this group. The systemic iden¬
tification and exclusion of subjects with
any possible secondary cause of steatosis
from the diagnosis of NAFLD may have
caused an underestimation of the prev¬
alence of NAFLD, which may in some
cases have been a coexistent pathology.
It is recognized that the cutoffs used to
define exclusions to the diagnosis of
NAFLD are, to some extent, arbitrary
and the prevalence will depend upon the
precise definition used.
The majority of exclusions from the
diagnosis of NAFLD were on the basis of
excess alcohol intake. It is recognized that
estimation of alcohol consumption can be
unreliable, and in particular that subjects
and investigators may underestimate in¬
take. This, in turn, can lead to overesti-
mation of the prevalence of NAFLD. The
prevalence of alcohol intake 5:14 units/
week as a secondary cause for steatosis
was relatively low in our study population
(14.6%) when compared with a similar
age band in the general population of
England, in which the prevalence of alco¬
hol intake &21 units/week for men and
S14 units/week for women has been
quoted as 23% and 10%, respectively
(26). While this may represent an under¬
estimation of intake, it is also possible that
it reflects genuinely lower alcohol con¬
sumption in a frailer population in which
use of multiple prescription medications
is not uncommon.
Subjects in this study were all aged
61-76 years at the time of examination
and were predominantly Caucasian. Pre¬
vious studies have shown that the preva¬
lence of NAFLD increases with age
(although we did not find evidence of
that within our age range), and therefore
it is possible that the prevalence of
NAFLD in our study population was
greater than that of the general diabetic
population. The results may be less appli¬
cable to populations in other countries,
particularly those in which the prevalence
of other causes of liver disease (such as
alcoholic liver disease and viral hepatitis)
is markedly different to that in the U.K.
It has previously been shown that
NAFLD is associated with features of the
metabolic syndrome within the general
population, and the same was true in this
population of people with type 2 diabetes.
The association of a shorter duration of
diabetes with liver disease has been de¬
scribed before. One possible explanation
is that the greater degree of hyperinsuli-
nemia in early type 2 diabetes drives
uptake of free fatty acids by hepatocytes.
Unexpectedly, the use of metformin was
associated with the presence of NAFLD,
independently of BMI and glycemic con¬
trol. Previous studies of the use of met¬
formin in NAFLD have shown a positive
or neutral effect in individuals (6), and it
therefore seems unlikely that there is a
causative link between metformin use
and NAFLD here. It is possible that those
participants who were on metformin had
other risk factors forNAFLD that were not
accounted for in the present analysis,
such as inflammatory markers. Further¬
more, it is possible that results were con¬
founded by indication, i.e., participants
may have been previously prescribed
metformin in an attempt to treat hepatic
steatosis. Finally, it is possible that the
significant association between metfor¬
min and steatosis was a consequence
of a type 1 statistical error.
It is acknowledged that while data on
most variables were gathered concomi¬
tantly with hepatic ultrasound examina¬
tion, BMI was calculated 1 year previously
during the baseline examination. It is
therefore possible that the results of the
regression analysis are less robust than
they would have been with fully contem¬
poraneous data collection. However,
changes in BMI over 1 year would in
most cases have been small and randomly
distributed throughout the study popu¬
lation, and this should not have substan¬
tially affected the results of analysis.
Another limitation of this study is that
subjects did not have a liver biopsy and
histological examination, the gold stan¬
dard technique for identifying steatosis;
performance of this invasive procedure
would have been neither feasible nor
ethical in a population study of this
magnitude. It was recognized that some
participants with a normal ultrasound
scan could have undiagnosed hepatic
fibrosis and thus be at the severe end of
the spectrum of NAFLD. Of note, any
misclassified cases would tend to under¬
estimate the prevalence of NAFLD and
reduce rather than magnify any differ¬
ences in clinical associations between
groups. Furthermore, reanalysis exclud¬
ing those participants with a normal liver
ultrasound scan but other evidence of
possible fibrosis revealed similar results to
the main analysis. A further limitation is
that only approximately one-fifth of
patients invited to attend the baseline
clinic from the Lothian Diabetes Register
did so. Significantly, however, analysis
revealed that this population was repre¬
sentative of that invited in terms of dura¬
tion of diabetes, HbAic, and treatment
with insulin.
In conclusion, in assessing the prev¬
alence of NAFLD in people with type 2
diabetes, this study has advantages of
robust ultrasound gradings, systematic
exclusion of other causes for liver disease,
and a relatively large, unselected popula¬
tion of older individuals. In the future, it
is possible that the association of liver
disease with other features of the meta¬
bolic syndrome could be used to target
screening for NAFLD. Further research is
required to ascertain whether the risk of
progression of NAFLD to cirrhosis in
patients with type 2 diabetes in the clinical
setting is as high as that predicted—if so,
this would provide further impetus to¬
ward early diagnosis so that they might
be eligible for entry into clinical trials,
screening for complications, and ultimately
new therapies.
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Summary
Background: Type 2 diabetes is a risk factor for
progression of non-alcoholic fatty liver disease
(NAFLD) to fibrosis and cirrhosis. We examined
the prevalence of advanced liver disease in
people with type 2 diabetes and analysed the effect¬
iveness of liver function tests (LFTs) as a screening
tool.
Methods: Participants (n = 939, aged 61-76 years)
from the Edinburgh Type 2 Diabetes Study, a ran¬
domly selected population of people with type 2
diabetes, underwent abdominal ultrasonography.
Hyaluronic acid (HA) and platelet count/spleen
diameter ratio (PSR) were used as non-invasive mark¬
ers of hepatic fibrosis and portal hypertension.
Subjects were screened for secondary causes
of liver disease that excluded them from a diag¬
nosis of NAFLD. The efficacy of LFTs [alanine
aminotransferase (ALT) and gamma-glutamytrans¬
ferase (GGT)] in screening for liver disease was
determined.
Results: Cirrhosis was identified by ultrasound in
four participants (0.4%). Ten (1.1%) had evidence
of portal hypertension (PSR <909), and two (0.2%)
had hepatocellular carcinoma. Fifty-three partici¬
pants (5.7%) had evidence of hepatic fibrosis
(HA>100ng/nil in the absence of joint disease); a
further 169 had HA>50ng/ml. In participants with
NAFLD-related fibrosis (HA> 100ng/ml), 12.5%
had an elevated ALT level and 17.5% had an ele¬
vated GGT level.
Conclusions: The prevalence of hepatic fibrosis
and cirrhosis were lower than expected. The use
of LFTs to screen for liver disease missed most
cases of fibrosis predicted by raised HA levels.
Introduction
Non-alcoholic fatty liver disease (NAFLD) refers
to hepatic steatosis in the absence of a defined
secondary cause. NAFLD is associated with type 2
diabetes and estimates of prevalence of NAFLD
in this group have varied, the highest being 70%.1
Using a validated ultrasound measure and detailed
exclusion of secondary causes of liver disease,
we recently reported a prevalence of NAFLD of
42.6% in over 900 older people with type 2
diabetes.2
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NAFLD encompasses a spectrum of liver disease
from simple steatosis to steatohepatitis, fibrosis
and ultimately cirrhosis. In the general population
of people with simple steatosis secondary to
NAFLD, an estimated 8% progress to advanced
fibrosis and cirrhosis, and this figure is higher
when steatohepatitis is evident at presentation.3
Although type 2 diabetes is considered a risk
factor for the progression of NAFLD,4'5 few studies
have examined the prevalence of advanced liver
disease in this population. Existing evidence is
either indirect or has originated from small studies
or those undertaken in highly selected populations.
In one population-based study, the risk of death
from liver cirrhosis was 2.5 times higher in people
with type 2 diabetes compared with the general
population.6 In another study of 132 patients with
NAFLD (44 of whom had diabetes) who had under¬
gone liver biopsy in a tertiary referral centre, 25% of
those with diabetes had cirrhosis, compared to 10%
of the non-diabetic cohort.7
Screening for liver disease in Type 2 diabetes gen¬
erally involves the measurement of standard liver
function tests (LFTs) alone. Previous studies, how¬
ever, suggest that LFTs may be poorly sensitive in
differentiating patients with steatosis and NAFLD
from those with normal livers.8,9 Furthermore, it is
known that NAFLD can progress to fibrosis without
significant elevation of LFTs.5'9 It has been suggested
that lowering the upper limit of normal of alanine
aminotransferase (ALT) to 30U/I in men and 19U/I
in women may improve sensitivity of this measure in
detecting NAFLD,10 but this has not been widely
adopted. It is therefore likely that many cases of
NAFLD in the people with diabetes are not identi¬
fied and progressive liver disease is often missed.
Flowever, few data are available on the applicability
of LFTs to diagnose hepatic fibrosis in people with
diabetes.
Other approaches have been taken in the pursuit
of a reliable non-invasive method of distinguishing
those patients who have significant fibrosis.
Hyaluronic acid (HA) is a component of the extra¬
cellular matrix, whose production is increased, and
degradation by the liver decreased, in hepatic fibro¬
sis. Several small studies have suggested that cut-off
values of 42-50 ng/ml give optimal sensitivity and
specificity in determining the presence of significant
fibrosis.11-14 Higher levels may be associated with
increasing severity of liver disease and increased
specificity in diagnosing fibrosis and cirrhosis. One
study suggested that a level >100 ng/ml had a 78%
specificity and 83% sensitivity for predicting cirrho¬
sis, with specificity being raised to 96% if a cut-off of
300ng/ml was used.'5 One potential confounder is
that levels of HA can also be raised in patients with
active joint disease.
Other routinely available markers that are predict¬
ive of fibrosis have been combined into scoring sys¬
tems. The BAAT score assigned one point for each of
increased age, BMI, ALT and triglycerides, and
while a score of two gave 71% sensitivity and
80% specificity in detecting septal fibrosis, a score
of three gave 14% sensitivity but 100% specificity.16
The BARD score allocated one point for each of
increased BMI and the presence of diabetes, and
two points for aspartate aminotransferase (AST):
ALT ratio >0.8 - with a cut-off of two points, the
positive predictive value (PPV) and negative predict¬
ive value (NPV) of determining severe fibrosis were
43% and 96%, respectively.17 The NAFLD fibrosis
score, using a formula combining age, BMI, the
presence of diabetes, AST:ALT ratio, albumin and
platelet levels, classified 75% of participants low-
or high-risk groups for severe fibrosis, with a low
cut-off (below —1.455) giving a NPV of 93% and a
high cut-off (above 0.676) a PPV of 90%.18
Ultrasound scanning has diagnostic accuracy of
80-86% in the diagnosis of cirrhosis or extensive
fibrosis in chronic liver disease19 and can detect
consequences of portal hypertension such as
increased spleen size. A low platelet count is a
well-established marker of splenomegaly, and the
platelet count/spleen diameter ratio (PSR) has been
shown to be a reliable predictor of oesophageal vari¬
ces in people with cirrhosis20 and can therefore be
used as a surrogate marker of portal hypertension.
Hepatocellular carcinoma (HCC) is a well-
recognized complication of hepatic cirrhosis.
Diabetes is an established risk factor for HCC and
in one population-based study, diabetes was asso¬
ciated with around a 2.5-fold increase in incidence
of HCC,4 independent of alcohol intake and viral
hepatitis. The prevalence of HCC in the general
population of people with type 2 diabetes, however,
remains unclear.
The present study aimed to estimate the preva¬
lence of fibrosis, cirrhosis and HCC, using a range
of different markers and scoring systems, in a ran¬
domly selected population of people with type 2
diabetes [the Edinburgh Type 2 Diabetes Study
(ET2DS)] and to analyse the effectiveness of LFTs
in screening for liver disease in this population.
Methods
Participants
The selection of subjects for the ET2DS has been
described previously in detail.2,21 Briefly, subjects
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recorded as having type 2 diabetes mellitus, aged
60-74 years, were selected at random into sex and
5-year age bands from the Lothian Diabetes
Register, a computerized database, which contains
details of >20 000 patients with type 2 diabetes
living in Lothian, Scotland, and includes both pa¬
tients attending hospital and those seen only in pri¬
mary care. Invitations to participate were sent to
5454 people and, of these, 1066 (20%) attended a
baseline clinic. The clinical characteristics upon
which the diagnosis of type 2 diabetes mellitus
was confirmed has previously been described in de¬
tail.21 In brief, a diagnosis of diabetes was accepted
in any individual treated with oral antidiabetic
agents and/or insulin, and in any individual treated
with dietary modification alone whose HbAlc was
>6.5%. The clinical records of all subjects treated
with dietary modification alone and with an
HbA1 c ^ 6.5% at the research clinic were reviewed
by a consultant diabetologist (MWJS) to ensure that
the diagnosis of diabetes was accurate. With regard
to the classification of 'type 2' diabetes, the clinical
records of individuals who either (i) started on insu¬
lin within one year of diagnosis of diabetes, (ii) re¬
ported evidence of pancreatic surgery or disease at
the research clinic or (iii) were treated with insulin
and were aged <35 years at diagnosis were also re¬
viewed. Such individuals were considered to be at
greatest risk of mis-classification. Any subject in
whom it was not possible to confirm a clinical diag¬
nosis of type 2 diabetes by review of hospital or
general practitioner records was excluded. Study
participants have been shown previously to be rep¬
resentative of all those randomly selected to partici¬
pate and therefore of the target population of older
men and women with type 2 diabetes living in the
general population.2 A total of 939 subjects partici¬
pated in the Year 1 clinic, a re-attendance rate of
88%. Baseline characteristics of those attending the
Year 1 clinic have been shown to be similar to
the full study population, suggesting that they re¬
mained representative of the target population.2 All
participants gave written informed consent. The
local ethics committee gave ethical approval for
the study.
Procedures
Subjects attended a specially established research
clinic, based in the Wellcome Trust Clinical
Research Facility, Western General Hospital,
Edinburgh, at baseline and after one year (Year 1).
At Year 1, participants attended, after a 4-h fast, for
an ultrasound examination of abdomen and venous
blood sampling.
All ultrasound examinations were performed by a
single ultrasonographer as previously described.2,21
Participants were given an overall liver grading
based on a subjective measurement of the severity
of steatosis. Validation of the ultrasound gradings for
hepatic steatosis with 1H magnetic resonance
spectroscopy, the non-invasive gold standard for
quantification of hepatic fat, in a subgroup of 58
participants has previously been described in de¬
tail.22 Evidence of cirrhosis was sought systemically
and spleen length was measured.
Alcohol intake, use of hepatotoxic medications
(amiodarone, isoniazid, methotrexate, tamoxifen
and glucocorticoids) within the previous 6 months
and history of joint disease were determined by
questionnaire. Those participants with evidence of
hepatic steatosis or abnormal blood tests of liver
function had further tests performed for liver disease
performed including serology for Llepatitis B and C,
anti-nuclear antibody (ANA), anti-smooth muscle
antibody, anti-mitochondrial antibody, ferritin and
alpha fetoprotein (AFP). In addition, all participants
(including those with normal liver and LFTs) seen
after a certain date had these same screening
blood tests performed (n=644). Triglycerides and
HDL cholesterol were measured at Year 1. BMI,
platelets and HA had been previously measured at
the baseline clinic.
Participants who had significant abnormalities on
hepatic USS or blood tests were referred for standard
follow-up within the National Health Service. Those
with focal lesions on USS had these reviewed by a
consultant radiologist and received further imaging
as necessary, and those with raised AFP>20kU/l
were referred for review in a liver clinic.
Data on previous diagnoses of chronic liver dis¬
ease were collected from participants by question¬
naire at Year 1. In addition, data on liver diagnoses
were obtained at baseline from discharge summaries
via record linkage at the Information and Services
Division of NHS Scotland (ISD linkage).
Upper limits of normal on the laboratory refer¬
ence range of bilirubin (Bi), ALT, AST and gamma-
glutamyl transferase (GGT) were 18 pimol/l, 50U/I,
45 U/l and 55 U/l respectively. Analysis was also
carried out using lower upper limits of normal for
ALT—30 U/l for men and 19 U/l for women.10
Definition of NAFLD, PSR, hepatic
fibrosis and HCC
NAFLD was defined as the presence of hepatic stea¬
tosis on ultrasound scan in the absence of a second¬
ary cause for hepatic steatosis. In addition, for this
study, the definition was widened to include people
with markers of fibrosis but no evidence of hepatic
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steatosis on ultrasound, in acknowledgement of the
fact that steatosis can regress in patients with signifi¬
cant fibrosis. Secondary causes were defined as
alcohol consumption ^14U/week or participant
report of a current or previous problem with alcohol
excess, use of hepatotoxic medication (glucocortic¬
oids, isoniazid, methotrexate, amiodarone and tam¬
oxifen) within the 6 months prior to the Year 1 clinic,
positive hepatitis B or C serology, ferritin > 1000 gg/l,
clinically significant positive immunology titres
(anti-smooth muscle antibody titre ^ 1:160 or anti-
mitochondrial antibody titre ^ 1:40) or a previous
diagnosis of a secondary cause for chronic liver dis¬
ease (alcoholic liver disease, autoimmune hepatitis,
primary biliary cirrhosis, cholangitis or liver
metastases).2 Subjects were considered to have a pre¬
vious diagnosis of a secondary cause for chronic liver
disease if ISD linkage revealed such a diagnosis, or if
a participant report of a diagnosis was confirmed by
their medical records.
PCR was defined as the ratio of platelet count (per
cubic millimetre) to spleen diameter (millimetre).20
Hepatic fibrosis was defined on the basis of HA
levels—values of >100 ng/ml, in the absence of arth¬
ritis, were taken as evidence of definite fibrosis and
possible cirrhosis.15 A cut-off of 50 ng/ml was taken
to indicate possible fibrosis;11"14 values >75 ng/ml
are also reported as this is the upper limit of
normal on our laboratory reference range.
HCC was defined, in accordance with accepted
guidelines,23 by one of the following: two imaging
techniques showing a focal lesion over 2 cm in
diameter with arterial hypervascularisation; one
imaging technique showing a focal lesion >2 cm in
diameter in association with AFP levels>400 ng/ml
(484 kU/l); suggestive histology following biopsy of
a lesion.
Fibrosis clinical scoring systems
Participant scores on established scoring systems
(BAAT, BARD and NAFLD fibrosis scores) were cal¬
culated. The BAAT16 and BARD17 scoring systems
are outlined above. NAFLD fibrosis score was
calculated as previously published.16 Scores of 2-4
on both the BAAT and BARD scores were con¬
sidered to be predictive of hepatic fibrosis. On the
NAFLD fibrosis score, a score of >0.676 was con¬
sidered to be predictive of fibrosis, and a score
of -1.455-0.676 was indeterminate for fibrosis.
In view of the fact that these systems have been
developed to assess the severity of NAFLD alone,
they were used only in those participants in whom
another secondary cause for liver disease had been
excluded.
Statistical analyses
Statistical analysis was performed using SPSS soft¬
ware version 14.0 (SPSS Inc., Illinois, USA). Data
not conforming to a normal distribution (in this
study GCT measurments) were log-transformed
prior to parametric analysis. Statistical analysis
included the one-way analysis of variance and
chi-squared test to compare biochemical character¬
istics between groups. PPV and NPV were used
to analyse the utility of LFTs in predicting hepatic
fibrosis.
Results
Prevalence of markers of fibrosis, cirrhosis
and HCC
Baseline characteristics of the 939 participants, aged
61-75 years, who attended the Year 1 clinic are
shown in Table 1. Hepatic cirrhosis on ultrasound
scan was found in four members of the study popu¬
lation, a prevalence of 0.4%. Portal hypertension,
Table 1 Characteristics of subjects at Year 1 clinic
Characteristic Year 1
(n = 939)
Age (years) 68.9 ±4.2
Sex [% (n) male] 52.0 (488)
Race [% (n) Caucasian] 98.3 (923)
BMI- measured at baseline clinic (kg/m2) 31.3 ±5.7
Duration of diabetes (years) 9.0±6.4
HbA1c (%) 7.2 ±1.1
Diet-controlled [% (n)] 19.4 (182)
Oral anti-diabetic agent users ]% (n)] 74.4 (699)
Metformin users [% (n)] 63.7 (598)
Thiazolidinedione users [% (n)] 17.5 (164)
Insulin users [% (n)] 15.8(148)
Systolic blood pressure (mmHg) 138.1 ± 18.5
Diastolic blood pressure (mmHg) 74.1 ±9.6
Total cholesterol (mmol/l) 4.2 ±0.8
High-density lipoprotein 1.2 ±0.3
cholesterol (mmol/l)
Low-density lipoprotein 2.2 ±0.7
cholesterol (mmol/l)
Triglyceride (mmol/l) 1.7 ±0.9
Statin users [% (n)] 81.6 (767)
Aspirin users [% (n)] 67.7 (636)
Angiotensin converting enzyme 52.0 (488)
inhibitor users [% (n)]
Current or ex-smokers [% (n)] 60.0 (563)
Data are mean ± standard deviation or proportions, in
whole cohort of participants unless stated (number of
participants in brackets)
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defined as a platelet count/spleen diameter ratio
<909, was present in 10 participants (1.1%), includ¬
ing one participant who had cirrhosis on ultrasound
scan. A total of 876 participants were fully assessed
for secondary causes of liver disease. Of these, 663
participants had no secondary cause identified, and
in this subgroup findings suggestive of fibrosis
or cirrhosis would be presumed secondary to
NAFLD. Hepatic cirrhosis on ultrasound scan was
found in one person (0.2%) in this subgroup and low
platelet count/spleen diameter in four other people
(0.6%).
The prevalence of definite hepatic fibrosis,
defined as HA level > 100 ng/ml in the absence of
joint disease, was 5.7% in the entire study popula¬
tion of 939 participants. The corresponding figures
for HA level > 50 ng/ml and >75 ng/ml were 23.6%
and 12.2%, respectively. Of the population, 0.5%
had HA level > 300 ng/ml. An additional 20.6% of
participants had HA levels>50 ng/ml but also had
evidence of arthritis. Of the 13 participants with evi¬
dence of cirrhosis on ultrasound scan or a low plate¬
let count/spleen diameter ratio, four (30.8%) had HA
levels 50-100 ng/ml and a further six (46.2%) had
HA levels> 100 ng/ml.
In the subgroup of participants with no secondary
cause for liver disease, 40 participants (6.1%) had
FIA> 100 ng/ml in the absence of joint disease, 166
participants (25.2%) had HA> 50 ng/ml, 86 partici¬
pants (13.0%) had HA>75 ng/ml and 4 participants
(0.6%) had HA>300 ng/ml.
Two participants had definite HCC, a prevalence
in the study population of 0.2%. In one case, this
was confirmed on histology following biopsy of a
3.7cm liver mass on a background of cirrhosis
seen on USS, in association with raised AFP levels
of 40 kU/l. A second participant had a very high AFP
(2712 kU/l); no mass was seen on USS, but appear¬
ances on magnetic resonance imaging were sup¬
portive of a diagnosis of HCC. Neither participant
had a secondary cause for liver disease, giving a
prevalence of 0.3% in the group with possible
NAFLD.
Comparison of clinical fibrosis scoring
systems with radiological and
biochemical markers
The three clinical scoring systems for prediction of
fibrosis secondary to NAFLD were used as alterna¬
tive means of calculating prevalence of fibrosis in
the subgroup with no secondary cause for liver dis¬
ease. The BARD score was positive in 92.6% com¬
pared to 79.3% for the BAAT score, while 16.4% of
the subgroup had a positive NAFLD Fibrosis Score,
and in a further 66.8% this score was indeterminate.
The only participant in this subgroup to have cir¬
rhosis on ultrasound scan had positive BARD, BAAT
and NAFLD Fibrosis scores. When the prevalence of
positive fibrosis scores were compared across three
groups based on HA measurements [HA<50 ng/ml
(or arthritis present); HA 50-100 ng/ml in the ab¬
sence of arthritis; and HA > 100 ng/ml in the absence
of arthritis], the only positive correlation was with
the NAFLD fibrosis score with the prevalence of a
positive score rising from 13.7% to 21.3% to 42.5%
in the three HA groups respectively (P<0.001).
Conversely, 72.5% of those with a positive NAFLD
fibrosis score had a HA measurement >50 ng/ml.
Comparison of tests of liver function with
markers of fibrosis
Standard tests of liver function were compared be¬
tween three groups according to the HA level in
Table 2 Comparison of standard tests of liver function between participants with no secondary cause for liver disease,










ALT > 50 U/l, n (%) 34(6.9)
AST (U/l) 30.1 (9.9)
AST > 45 U/l, n (%) 29(5.9)
CGT (U/l, mean logGGT) 1.2 (0.3)





















*Significant differences between the groups stratified according to HA level by one-way ANOVA or chi-squared test
(P< 0.05).
Data are mean ± standard deviation unless stated otherwise.
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Table 3 Positive and negative predictive values of standard LFTs [ALT (using standard and alternative upper limits of
normal) and GCT] in the diagnosis of fibrosis secondary to NAFLD, as defined using HA levels or the NAFLD Fibrosis Score
ALT (cut-off 50 U/l) ALT (alternative cut-offsa) GGT (cut-off 55 U/l)
PPV (%) NPV (%) PPV (%) NPV (%) PPV (%) NPV (%)
HAb (cut-off 50 ng/ml) 29.2 75.1 25.1 74.8 28.0 75.1
HAb (cut-off 100 ng/ml) 10.4 94.3 6.0 93.7 14.0 94.6
NAFLD Fibrosis Scorec 15.9 13.6 20.5 10.3 22.9 14.6
aUpper limit of normal taken as 30U/I for men and 19U/1 for women.
bParticipants with arthritis were grouped with those with a HA level below the cut-off
cPPVs are predictive of a NAFLD fibrosis score >0.676; NPVs are predictive of a NAFLD fibrosis score less than —1.455.
participants with no secondary cause for liver dis¬
ease (Table 2). Mean levels of ALT, AST and GGT
remained within the laboratory normal reference
range in all three groups. Similarly, mean levels of
ALT, AST and GGT remained within the normal
range in all three groups when participants were
divided according to NAFLD fibrosis score (less
than —1.455; —1.455 to 0.676; and >0.676: data
not shown). The PPV and NPV of ALT and GGT in
predicting fibrosis as diagnosed using HA levels and
the NAFLD fibrosis score are presented in Table 3.
The PPV and NPV of proposed new upper limits
of normal of ALT (>30 U/l for men; >19 U/l for
women) are also shown in Table 3.
Conclusions
Detection of advanced liver disease using
non-invasive methods is challenging. This study
examines the prevalence of markers of hepatic fibro¬
sis and cirrhosis, and their relationship to standard
tests of liver function, in a large randomly selected
cohort of older people with Type 2 diabetes. The
prevalence of hepatic fibrosis was 5.7% and that
of ultrasound-diagnosed cirrhosis under 1%. The
use of LFTs as a screening tool missed the majority
of cases of fibrosis predicted by raised HA levels.
Previous reports have estimated the prevalence
of hepatic fibrosis, cirrhosis and HCC secondary
to NAFLD in this group to be higher than in the
non-diabetic population—but results have often
either been extrapolated from other data or based
on results from relatively highly selected patient
populations. The present study has the advantage
that participants were selected at random from a
register of all people in the South-East of Scotland
who had type 2 diabetes and therefore represented
the entire spectrum of this condition. It is the first
study to include people with diabetes who are
receiving their routine review in the community as
well as those in the secondary care setting, it is pos¬
sible that the high rate of use of anti-diabetic agents
in the population, particularly metformin, may have
had a disease modifying effect on NAFLD and con¬
tributed to the lower than expected rates of fibrosis
and cirrhosis.
Subjects in this study were all aged 61-76 years at
the time of examination and were predominantly
Caucasian. Previous studies have shown that the
prevalence of NAFLD and its progression to fibrosis
and cirrhosis increases with age. It is therefore
possible that the results from our study population
may not be representative of those from other age
ranges. At baseline, approximately one-fifth of
people invited to attend from the Lothian Diabetes
Register did so—analysis suggested that this popula¬
tion was representative of that invited, most import¬
antly in terms of duration of diabetes, HbA1c and
treatment with insulin.
HA was the main marker of fibrosis used in this
study, with cut-offs for fibrosis and cirrhosis defined
as in previous reports.11"15 Liver biopsy, the gold
standard, would have been neither feasible nor eth¬
ical, and in contrast HA measurement is relatively
non-invasive. We attempted to improve specificity
by excluding participants with arthritis (another
cause of raised HA) from the fibrosis categories,
and also by using a high cut-off (100ng/ml) for our
definition of definite evidence of fibrosis. While we
can be reasonably confident that the proportion of
the study population with fibrosis is >5.7% (those
with HA levels > 100 ng/ml, without joint disease),
it is possible that the prevalence of fibrosis was
lower than the 26% predicted by HA levels
>50 ng/ml.
A low platelet count is a well-established conse¬
quence of hypersplenism, and the platelet count/
spleen diameter has previously been validated as a
marker of portal hypertension.20 This validation was,
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however, carried out in patients with known cirrho¬
sis, and it is possible that its use is less applicable in
our study population. In particular, it is possible an
alternative diagnosis may have underpinned the
finding of hypersplenism in some of our participants,
and this may have contributed to the lack of overlap
seen in our measures of cirrhosis and platelet count/
spleen diameter ratio.
The prevalence of HCC in our cohort was 0.2%, a
figure which is comparable to that previously found
on screening both a general population in Italy
(prevalence of 0.7%).24 It is also in keeping with
the only previous large-scale study, carried out in
Taiwan,25 that has looked at prevalence of HCC in
a subgroup of people with type 2 diabetes, in which
the prevalence was 0.1%. This population, unlike
ours, had a high prevalence of viral hepatitis. In
contrast, prevalence of HCC is higher in populations
with known cirrhosis, and in one small-scale study
the prevalence in an obese group with cryptogenic
cirrhosis was 30%.26
Although significant increases were noted in the
values of some conventional LFTs through the
groups with increasing evidence of liver damage,
mean values remained within normal limits. This is
consistent with previous studies which have shown
that progression to cirrhosis can occur without major
perturbation in the LFT values.5 Although the NPVs
for ALT and CGT were high in predicting lower HA
levels, these values are affected by the very low
population prevalence of fibrosis. The use of lower
values for the upper limit of normal of ALT did not
materially change the results. Currently, liver screen¬
ing in type 2 diabetes is carried out using conven¬
tional LFTs alone, and our data suggest that such an
approach misses the majority of cases of hepatic
fibrosis.
The only clinical scoring system to positively
correlate with HA measurements was the NAFLD
fibrosis score, which predicted definite fibrosis in
16.4% of participants with no secondary cause for
liver disease. A further 66.8% of subjects had an
indeterminate score. This is a much higher propor¬
tion than in the original article, which suggested that
such patients should be considered for liver bi¬
opsy.18 The BARD and BAAT scores both estimated
that a very high percentage of participants in this
study had fibrosis but in view of the emphasis on
age, BMI and diabetes in these scoring systems, this
could have been anticipated. Interestingly, when the
BARD score was validated in a subgroup with type 2
diabetes in the initial study, the AUC was lower than
in the group as a whole (0.53 vs. 0.80). This supports
the concept that these more simple scoring systems,
while useful in the general population of patients
with NAFLD, may be less applicable to populations
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of people with type 2 diabetes. The risk of their in¬
discriminate use is that they may identify large num¬
bers of patients for biopsy without any definitive
evidence of a high prevalence of advanced liver
disease.
In conclusion, this study provides an estimate
of prevalence of hepatic fibrosis in a large popula¬
tion of older people with type 2 diabetes. There
are challenges in detecting advancing liver disease,
and current screening methods using conventional
LFTs are almost certainly inadequate. Further
work is required to refine identification of these
patients, particularly in those in whom liver biopsy
would be difficult to justify. This may require a
panel of biochemical markers, for example, the
Enhanced Liver Fibrosis panel or cytokeratin-18,
or a radiological method such as transient
elastography.
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